id	sid	tid	token	lemma	pos
dpc-1882	1	1	melanoma	melanoma	NOUN
dpc-1882	1	2	today	today	NOUN
dpc-1882	1	3	dpc	dpc	PROPN
dpc-1882	1	4	journal	journal	PROPN
dpc-1882	1	5	special	special	ADJ
dpc-1882	1	6	issue	issue	NOUN
dpc-1882	1	7	table	table	NOUN
dpc-1882	1	8	of	of	ADP
dpc-1882	1	9	contents	content	NOUN
dpc-1882	1	10	epidemiology	epidemiology	NOUN
dpc-1882	1	11	and	and	CCONJ
dpc-1882	1	12	risk	risk	NOUN
dpc-1882	1	13	factors	factor	NOUN
dpc-1882	1	14	of	of	ADP
dpc-1882	1	15	melanoma	melanoma	NOUN
dpc-1882	1	16	:	:	PUNCT
dpc-1882	1	17	a	a	DET
dpc-1882	1	18	review	review	NOUN
dpc-1882	1	19	claudio	claudio	PROPN
dpc-1882	1	20	conforti	conforti	PROPN
dpc-1882	1	21	,	,	PUNCT
dpc-1882	1	22	iris	iris	NOUN
dpc-1882	1	23	zalaudek	zalaudek	PROPN
dpc-1882	1	24	evolution	evolution	NOUN
dpc-1882	1	25	of	of	ADP
dpc-1882	1	26	the	the	DET
dpc-1882	1	27	clinical	clinical	ADJ
dpc-1882	1	28	,	,	PUNCT
dpc-1882	1	29	dermoscopic	dermoscopic	ADJ
dpc-1882	1	30	and	and	CCONJ
dpc-1882	1	31	pathologic	pathologic	ADJ
dpc-1882	1	32	diagnosis	diagnosis	NOUN
dpc-1882	1	33	of	of	ADP
dpc-1882	1	34	melanoma	melanoma	NOUN
dpc-1882	1	35	harald	harald	PROPN
dpc-1882	1	36	kittler	kittler	PROPN
dpc-1882	1	37	melanoma	melanoma	NOUN
dpc-1882	1	38	:	:	PUNCT
dpc-1882	1	39	staging	staging	NOUN
dpc-1882	1	40	and	and	CCONJ
dpc-1882	1	41	follow	follow	VERB
dpc-1882	1	42	-	-	PUNCT
dpc-1882	1	43	up	up	ADP
dpc-1882	1	44	chryssoula	chryssoula	PROPN
dpc-1882	1	45	papageorgiou	papageorgiou	NOUN
dpc-1882	1	46	,	,	PUNCT
dpc-1882	1	47	zoe	zoe	PROPN
dpc-1882	1	48	apalla	apalla	PROPN
dpc-1882	1	49	,	,	PUNCT
dpc-1882	1	50	sofia	sofia	NOUN
dpc-1882	1	51	-	-	PUNCT
dpc-1882	1	52	magdalini	magdalini	PROPN
dpc-1882	1	53	manoli	manoli	PROPN
dpc-1882	1	54	,	,	PUNCT
dpc-1882	1	55	konstantinos	konstantinos	PROPN
dpc-1882	1	56	lallas	lallas	PROPN
dpc-1882	1	57	,	,	PUNCT
dpc-1882	1	58	efstratios	efstratio	NOUN
dpc-1882	1	59	vakirlis	vakirli	NOUN
dpc-1882	1	60	,	,	PUNCT
dpc-1882	1	61	aimilios	aimilios	PROPN
dpc-1882	1	62	lallas	lalla	NOUN
dpc-1882	1	63	current	current	ADJ
dpc-1882	1	64	landscape	landscape	NOUN
dpc-1882	1	65	and	and	CCONJ
dpc-1882	1	66	open	open	ADJ
dpc-1882	1	67	questions	question	NOUN
dpc-1882	1	68	on	on	ADP
dpc-1882	1	69	adjuvant	adjuvant	ADJ
dpc-1882	1	70	therapies	therapy	NOUN
dpc-1882	1	71	in	in	ADP
dpc-1882	1	72	melanoma	melanoma	PROPN
dpc-1882	1	73	vincenzo	vincenzo	PROPN
dpc-1882	1	74	de	de	PROPN
dpc-1882	1	75	falco	falco	PROPN
dpc-1882	1	76	,	,	PUNCT
dpc-1882	1	77	stefania	stefania	PROPN
dpc-1882	1	78	napolitano	napolitano	PROPN
dpc-1882	1	79	,	,	PUNCT
dpc-1882	1	80	luigi	luigi	PROPN
dpc-1882	1	81	pio	pio	PROPN
dpc-1882	1	82	guerrera	guerrera	PROPN
dpc-1882	1	83	,	,	PUNCT
dpc-1882	1	84	teresa	teresa	PROPN
dpc-1882	1	85	troiani	troiani	ADJ
dpc-1882	1	86	treatment	treatment	NOUN
dpc-1882	1	87	of	of	ADP
dpc-1882	1	88	advanced	advanced	ADJ
dpc-1882	1	89	metastatic	metastatic	ADJ
dpc-1882	1	90	melanoma	melanoma	NOUN
dpc-1882	1	91	pietro	pietro	NOUN
dpc-1882	1	92	quaglino	quaglino	PROPN
dpc-1882	1	93	,	,	PUNCT
dpc-1882	1	94	paolo	paolo	PROPN
dpc-1882	1	95	fava	fava	NOUN
dpc-1882	1	96	,	,	PUNCT
dpc-1882	1	97	luca	luca	PROPN
dpc-1882	1	98	tonella	tonella	PROPN
dpc-1882	1	99	,	,	PUNCT
dpc-1882	1	100	marco	marco	PROPN
dpc-1882	1	101	rubatto	rubatto	NOUN
dpc-1882	1	102	,	,	PUNCT
dpc-1882	1	103	simone	simone	NOUN
dpc-1882	1	104	ribero	ribero	PROPN
dpc-1882	1	105	,	,	PUNCT
dpc-1882	1	106	maria	maria	PROPN
dpc-1882	1	107	teresa	teresa	PROPN
dpc-1882	1	108	fierro	fierro	PROPN
dpc-1882	1	109	mattioli	mattioli	PROPN
dpc-1882	1	110	1885	1885	NUM
dpc-1882	1	111	www.mattioli1885.com	www.mattioli1885.com	NOUN
dpc-1882	1	112	chief	chief	ADJ
dpc-1882	1	113	editor	editor	NOUN
dpc-1882	1	114	prof	prof	NOUN
dpc-1882	1	115	.	.	PUNCT
dpc-1882	2	1	giuseppe	giuseppe	PROPN
dpc-1882	2	2	argenziano	argenziano	PROPN
dpc-1882	2	3	,	,	PUNCT
dpc-1882	2	4	md	md	PROPN
dpc-1882	2	5	dermatology	dermatology	NOUN
dpc-1882	2	6	unit	unit	NOUN
dpc-1882	2	7	,	,	PUNCT
dpc-1882	2	8	university	university	PROPN
dpc-1882	2	9	of	of	ADP
dpc-1882	2	10	campania	campania	PROPN
dpc-1882	2	11	luigi	luigi	PROPN
dpc-1882	2	12	vanvitelli	vanvitelli	PROPN
dpc-1882	2	13	,	,	PUNCT
dpc-1882	2	14	naples	naples	PROPN
dpc-1882	2	15	guest	guest	PROPN
dpc-1882	2	16	editors	editor	NOUN
dpc-1882	2	17	prof	prof	PROPN
dpc-1882	2	18	.	.	PUNCT
dpc-1882	3	1	h.	h.	PROPN
dpc-1882	3	2	peter	peter	PROPN
dpc-1882	3	3	soyer	soyer	PROPN
dpc-1882	3	4	,	,	PUNCT
dpc-1882	3	5	md	md	PROPN
dpc-1882	3	6	,	,	PUNCT
dpc-1882	3	7	facd	facd	NOUN
dpc-1882	3	8	,	,	PUNCT
dpc-1882	3	9	fahms	fahm	NOUN
dpc-1882	3	10	chair	chair	NOUN
dpc-1882	3	11	in	in	ADP
dpc-1882	3	12	dermatology	dermatology	NOUN
dpc-1882	3	13	.	.	PUNCT
dpc-1882	4	1	director	director	NOUN
dpc-1882	4	2	,	,	PUNCT
dpc-1882	4	3	dermatology	dermatology	NOUN
dpc-1882	4	4	research	research	NOUN
dpc-1882	4	5	centre	centre	NOUN
dpc-1882	4	6	,	,	PUNCT
dpc-1882	4	7	the	the	DET
dpc-1882	4	8	university	university	PROPN
dpc-1882	4	9	of	of	ADP
dpc-1882	4	10	queensland	queensland	PROPN
dpc-1882	4	11	diamantina	diamantina	PROPN
dpc-1882	4	12	institute	institute	PROPN
dpc-1882	4	13	;	;	PUNCT
dpc-1882	4	14	director	director	NOUN
dpc-1882	4	15	,	,	PUNCT
dpc-1882	4	16	dermatology	dermatology	NOUN
dpc-1882	4	17	department	department	NOUN
dpc-1882	4	18	,	,	PUNCT
dpc-1882	4	19	princess	princess	NOUN
dpc-1882	4	20	alexandra	alexandra	PROPN
dpc-1882	4	21	hospital	hospital	PROPN
dpc-1882	4	22	prof	prof	PROPN
dpc-1882	4	23	.	.	PUNCT
dpc-1882	5	1	paola	paola	PROPN
dpc-1882	5	2	queirolo	queirolo	PROPN
dpc-1882	5	3	,	,	PUNCT
dpc-1882	5	4	md	md	PROPN
dpc-1882	5	5	director	director	NOUN
dpc-1882	5	6	of	of	ADP
dpc-1882	5	7	the	the	DET
dpc-1882	5	8	“	"	PUNCT
dpc-1882	5	9	divisione	divisione	X
dpc-1882	5	10	di	di	X
dpc-1882	5	11	oncologia	oncologia	PROPN
dpc-1882	5	12	medica	medica	PROPN
dpc-1882	5	13	del	del	PROPN
dpc-1882	5	14	melanoma	melanoma	PROPN
dpc-1882	5	15	,	,	PUNCT
dpc-1882	5	16	sarcoma	sarcoma	PROPN
dpc-1882	5	17	e	e	PROPN
dpc-1882	5	18	tumori	tumori	PROPN
dpc-1882	5	19	rari	rari	PROPN
dpc-1882	5	20	”	"	PUNCT
dpc-1882	5	21	istituto	istituto	PROPN
dpc-1882	5	22	europeo	europeo	PROPN
dpc-1882	5	23	di	di	PROPN
dpc-1882	5	24	oncologia	oncologia	PROPN
dpc-1882	5	25	,	,	PUNCT
dpc-1882	5	26	ieo	ieo	PROPN
dpc-1882	5	27	grazie	grazie	PROPN
dpc-1882	5	28	al	al	PROPN
dpc-1882	5	29	contributo	contributo	PROPN
dpc-1882	5	30	di	di	X
dpc-1882	5	31	melanoma	melanoma	PROPN
dpc-1882	5	32	today	today	NOUN
dpc-1882	5	33	dpc	dpc	PROPN
dpc-1882	5	34	journal	journal	PROPN
dpc-1882	5	35	special	special	ADJ
dpc-1882	5	36	issue	issue	NOUN
dpc-1882	5	37	table	table	NOUN
dpc-1882	5	38	of	of	ADP
dpc-1882	5	39	contents	content	NOUN
dpc-1882	5	40	epidemiology	epidemiology	NOUN
dpc-1882	5	41	and	and	CCONJ
dpc-1882	5	42	risk	risk	NOUN
dpc-1882	5	43	factors	factor	NOUN
dpc-1882	5	44	of	of	ADP
dpc-1882	5	45	melanoma	melanoma	NOUN
dpc-1882	5	46	:	:	PUNCT
dpc-1882	5	47	a	a	DET
dpc-1882	5	48	review	review	NOUN
dpc-1882	5	49	claudio	claudio	PROPN
dpc-1882	5	50	conforti	conforti	PROPN
dpc-1882	5	51	,	,	PUNCT
dpc-1882	5	52	iris	iris	NOUN
dpc-1882	5	53	zalaudek	zalaudek	PROPN
dpc-1882	5	54	the	the	DET
dpc-1882	5	55	evolution	evolution	NOUN
dpc-1882	5	56	of	of	ADP
dpc-1882	5	57	the	the	DET
dpc-1882	5	58	clinical	clinical	ADJ
dpc-1882	5	59	,	,	PUNCT
dpc-1882	5	60	dermoscopic	dermoscopic	ADJ
dpc-1882	5	61	and	and	CCONJ
dpc-1882	5	62	pathologic	pathologic	ADJ
dpc-1882	5	63	diagnosis	diagnosis	NOUN
dpc-1882	5	64	of	of	ADP
dpc-1882	5	65	melanoma	melanoma	NOUN
dpc-1882	5	66	harald	harald	PROPN
dpc-1882	5	67	kittler	kittler	PROPN
dpc-1882	5	68	melanoma	melanoma	NOUN
dpc-1882	5	69	:	:	PUNCT
dpc-1882	5	70	staging	staging	NOUN
dpc-1882	5	71	and	and	CCONJ
dpc-1882	5	72	follow	follow	VERB
dpc-1882	5	73	-	-	PUNCT
dpc-1882	5	74	up	up	ADP
dpc-1882	5	75	chryssoula	chryssoula	PROPN
dpc-1882	5	76	papageorgiou	papageorgiou	NOUN
dpc-1882	5	77	,	,	PUNCT
dpc-1882	5	78	zoe	zoe	PROPN
dpc-1882	5	79	apalla	apalla	PROPN
dpc-1882	5	80	,	,	PUNCT
dpc-1882	5	81	sofia	sofia	NOUN
dpc-1882	5	82	-	-	PUNCT
dpc-1882	5	83	magdalini	magdalini	PROPN
dpc-1882	5	84	manoli	manoli	PROPN
dpc-1882	5	85	,	,	PUNCT
dpc-1882	5	86	konstantinos	konstantinos	PROPN
dpc-1882	5	87	lallas	lallas	PROPN
dpc-1882	5	88	,	,	PUNCT
dpc-1882	5	89	efstratios	efstratio	NOUN
dpc-1882	5	90	vakirlis	vakirli	NOUN
dpc-1882	5	91	,	,	PUNCT
dpc-1882	5	92	aimilios	aimilios	PROPN
dpc-1882	5	93	lallas	lalla	NOUN
dpc-1882	5	94	current	current	ADJ
dpc-1882	5	95	landscape	landscape	NOUN
dpc-1882	5	96	and	and	CCONJ
dpc-1882	5	97	open	open	ADJ
dpc-1882	5	98	questions	question	NOUN
dpc-1882	5	99	on	on	ADP
dpc-1882	5	100	adjuvant	adjuvant	ADJ
dpc-1882	5	101	therapies	therapy	NOUN
dpc-1882	5	102	in	in	ADP
dpc-1882	5	103	melanoma	melanoma	PROPN
dpc-1882	5	104	vincenzo	vincenzo	PROPN
dpc-1882	5	105	de	de	PROPN
dpc-1882	5	106	falco	falco	PROPN
dpc-1882	5	107	,	,	PUNCT
dpc-1882	5	108	stefania	stefania	PROPN
dpc-1882	5	109	napolitano	napolitano	PROPN
dpc-1882	5	110	,	,	PUNCT
dpc-1882	5	111	luigi	luigi	PROPN
dpc-1882	5	112	pio	pio	PROPN
dpc-1882	5	113	guerrera	guerrera	PROPN
dpc-1882	5	114	,	,	PUNCT
dpc-1882	5	115	teresa	teresa	PROPN
dpc-1882	5	116	troiani	troiani	ADJ
dpc-1882	5	117	treatment	treatment	NOUN
dpc-1882	5	118	of	of	ADP
dpc-1882	5	119	advanced	advanced	ADJ
dpc-1882	5	120	metastatic	metastatic	ADJ
dpc-1882	5	121	melanoma	melanoma	NOUN
dpc-1882	5	122	pietro	pietro	NOUN
dpc-1882	5	123	quaglino	quaglino	PROPN
dpc-1882	5	124	,	,	PUNCT
dpc-1882	5	125	paolo	paolo	PROPN
dpc-1882	5	126	fava	fava	NOUN
dpc-1882	5	127	,	,	PUNCT
dpc-1882	5	128	luca	luca	PROPN
dpc-1882	5	129	tonella	tonella	PROPN
dpc-1882	5	130	,	,	PUNCT
dpc-1882	5	131	marco	marco	PROPN
dpc-1882	5	132	rubatto	rubatto	NOUN
dpc-1882	5	133	,	,	PUNCT
dpc-1882	5	134	simone	simone	NOUN
dpc-1882	5	135	ribero	ribero	PROPN
dpc-1882	5	136	,	,	PUNCT
dpc-1882	5	137	maria	maria	PROPN
dpc-1882	5	138	teresa	teresa	PROPN
dpc-1882	5	139	fierro	fierro	PROPN
dpc-1882	5	140	mattioli	mattioli	PROPN
dpc-1882	5	141	1885	1885	NUM
dpc-1882	5	142	www.mattioli1885.com	www.mattioli1885.com	NOUN
dpc-1882	5	143	chief	chief	ADJ
dpc-1882	5	144	editor	editor	NOUN
dpc-1882	5	145	prof	prof	NOUN
dpc-1882	5	146	.	.	PUNCT
dpc-1882	6	1	giuseppe	giuseppe	PROPN
dpc-1882	6	2	argenziano	argenziano	PROPN
dpc-1882	6	3	,	,	PUNCT
dpc-1882	6	4	md	md	PROPN
dpc-1882	6	5	dermatology	dermatology	NOUN
dpc-1882	6	6	unit	unit	NOUN
dpc-1882	6	7	,	,	PUNCT
dpc-1882	6	8	university	university	PROPN
dpc-1882	6	9	of	of	ADP
dpc-1882	6	10	campania	campania	PROPN
dpc-1882	6	11	luigi	luigi	PROPN
dpc-1882	6	12	vanvitelli	vanvitelli	PROPN
dpc-1882	6	13	,	,	PUNCT
dpc-1882	6	14	naples	naples	PROPN
dpc-1882	6	15	guest	guest	PROPN
dpc-1882	6	16	editors	editor	NOUN
dpc-1882	6	17	prof	prof	PROPN
dpc-1882	6	18	.	.	PUNCT
dpc-1882	7	1	h.	h.	PROPN
dpc-1882	7	2	peter	peter	PROPN
dpc-1882	7	3	soyer	soyer	PROPN
dpc-1882	7	4	,	,	PUNCT
dpc-1882	7	5	md	md	PROPN
dpc-1882	7	6	,	,	PUNCT
dpc-1882	7	7	facd	facd	NOUN
dpc-1882	7	8	,	,	PUNCT
dpc-1882	7	9	fahms	fahm	NOUN
dpc-1882	7	10	chair	chair	NOUN
dpc-1882	7	11	in	in	ADP
dpc-1882	7	12	dermatology	dermatology	NOUN
dpc-1882	7	13	.	.	PUNCT
dpc-1882	8	1	director	director	NOUN
dpc-1882	8	2	,	,	PUNCT
dpc-1882	8	3	dermatology	dermatology	NOUN
dpc-1882	8	4	research	research	NOUN
dpc-1882	8	5	centre	centre	NOUN
dpc-1882	8	6	,	,	PUNCT
dpc-1882	8	7	the	the	DET
dpc-1882	8	8	university	university	PROPN
dpc-1882	8	9	of	of	ADP
dpc-1882	8	10	queensland	queensland	PROPN
dpc-1882	8	11	diamantina	diamantina	PROPN
dpc-1882	8	12	institute	institute	PROPN
dpc-1882	8	13	;	;	PUNCT
dpc-1882	8	14	director	director	NOUN
dpc-1882	8	15	,	,	PUNCT
dpc-1882	8	16	dermatology	dermatology	NOUN
dpc-1882	8	17	department	department	NOUN
dpc-1882	8	18	,	,	PUNCT
dpc-1882	8	19	princess	princess	NOUN
dpc-1882	8	20	alexandra	alexandra	PROPN
dpc-1882	8	21	hospital	hospital	PROPN
dpc-1882	8	22	prof	prof	PROPN
dpc-1882	8	23	.	.	PUNCT
dpc-1882	9	1	paola	paola	PROPN
dpc-1882	9	2	queirolo	queirolo	PROPN
dpc-1882	9	3	,	,	PUNCT
dpc-1882	9	4	md	md	PROPN
dpc-1882	9	5	director	director	NOUN
dpc-1882	9	6	of	of	ADP
dpc-1882	9	7	the	the	DET
dpc-1882	9	8	“	"	PUNCT
dpc-1882	9	9	divisione	divisione	X
dpc-1882	9	10	di	di	X
dpc-1882	9	11	oncologia	oncologia	PROPN
dpc-1882	9	12	medica	medica	PROPN
dpc-1882	9	13	del	del	PROPN
dpc-1882	9	14	melanoma	melanoma	PROPN
dpc-1882	9	15	,	,	PUNCT
dpc-1882	9	16	sarcoma	sarcoma	PROPN
dpc-1882	9	17	e	e	PROPN
dpc-1882	9	18	tumori	tumori	PROPN
dpc-1882	9	19	rari	rari	PROPN
dpc-1882	9	20	”	"	PUNCT
dpc-1882	9	21	istituto	istituto	PROPN
dpc-1882	9	22	europeo	europeo	PROPN
dpc-1882	9	23	di	di	PROPN
dpc-1882	9	24	oncologia	oncologia	PROPN
dpc-1882	9	25	,	,	PUNCT
dpc-1882	9	26	ieo	ieo	PROPN
dpc-1882	9	27	grazie	grazie	PROPN
dpc-1882	9	28	al	al	PROPN
dpc-1882	9	29	contributo	contributo	PROPN
dpc-1882	9	30	di	di	X
dpc-1882	9	31	melanoma	melanoma	PROPN
dpc-1882	9	32	today	today	NOUN
dpc-1882	9	33	dpc	dpc	PROPN
dpc-1882	9	34	journal	journal	PROPN
dpc-1882	9	35	special	special	ADJ
dpc-1882	9	36	issue	issue	NOUN
dpc-1882	9	37	table	table	NOUN
dpc-1882	9	38	of	of	ADP
dpc-1882	9	39	contents	content	NOUN
dpc-1882	9	40	epidemiology	epidemiology	NOUN
dpc-1882	9	41	and	and	CCONJ
dpc-1882	9	42	risk	risk	NOUN
dpc-1882	9	43	factors	factor	NOUN
dpc-1882	9	44	of	of	ADP
dpc-1882	9	45	melanoma	melanoma	NOUN
dpc-1882	9	46	:	:	PUNCT
dpc-1882	9	47	a	a	DET
dpc-1882	9	48	review	review	NOUN
dpc-1882	9	49	claudio	claudio	PROPN
dpc-1882	9	50	conforti	conforti	PROPN
dpc-1882	9	51	,	,	PUNCT
dpc-1882	9	52	iris	iris	NOUN
dpc-1882	9	53	zalaudek	zalaudek	PROPN
dpc-1882	9	54	the	the	DET
dpc-1882	9	55	evolution	evolution	NOUN
dpc-1882	9	56	of	of	ADP
dpc-1882	9	57	the	the	DET
dpc-1882	9	58	clinical	clinical	ADJ
dpc-1882	9	59	,	,	PUNCT
dpc-1882	9	60	dermoscopic	dermoscopic	ADJ
dpc-1882	9	61	and	and	CCONJ
dpc-1882	9	62	pathologic	pathologic	ADJ
dpc-1882	9	63	diagnosis	diagnosis	NOUN
dpc-1882	9	64	of	of	ADP
dpc-1882	9	65	melanoma	melanoma	NOUN
dpc-1882	9	66	harald	harald	PROPN
dpc-1882	9	67	kittler	kittler	PROPN
dpc-1882	9	68	melanoma	melanoma	NOUN
dpc-1882	9	69	:	:	PUNCT
dpc-1882	9	70	staging	staging	NOUN
dpc-1882	9	71	and	and	CCONJ
dpc-1882	9	72	follow	follow	VERB
dpc-1882	9	73	-	-	PUNCT
dpc-1882	9	74	up	up	ADP
dpc-1882	9	75	chryssoula	chryssoula	PROPN
dpc-1882	9	76	papageorgiou	papageorgiou	NOUN
dpc-1882	9	77	,	,	PUNCT
dpc-1882	9	78	zoe	zoe	PROPN
dpc-1882	9	79	apalla	apalla	PROPN
dpc-1882	9	80	,	,	PUNCT
dpc-1882	9	81	sofia	sofia	NOUN
dpc-1882	9	82	-	-	PUNCT
dpc-1882	9	83	magdalini	magdalini	PROPN
dpc-1882	9	84	manoli	manoli	PROPN
dpc-1882	9	85	,	,	PUNCT
dpc-1882	9	86	konstantinos	konstantinos	PROPN
dpc-1882	9	87	lallas	lallas	PROPN
dpc-1882	9	88	,	,	PUNCT
dpc-1882	9	89	efstratios	efstratio	NOUN
dpc-1882	9	90	vakirlis	vakirli	NOUN
dpc-1882	9	91	,	,	PUNCT
dpc-1882	9	92	aimilios	aimilios	PROPN
dpc-1882	9	93	lallas	lalla	NOUN
dpc-1882	9	94	current	current	ADJ
dpc-1882	9	95	landscape	landscape	NOUN
dpc-1882	9	96	and	and	CCONJ
dpc-1882	9	97	open	open	ADJ
dpc-1882	9	98	questions	question	NOUN
dpc-1882	9	99	on	on	ADP
dpc-1882	9	100	adjuvant	adjuvant	ADJ
dpc-1882	9	101	therapies	therapy	NOUN
dpc-1882	9	102	in	in	ADP
dpc-1882	9	103	melanoma	melanoma	PROPN
dpc-1882	9	104	vincenzo	vincenzo	PROPN
dpc-1882	9	105	de	de	PROPN
dpc-1882	9	106	falco	falco	PROPN
dpc-1882	9	107	,	,	PUNCT
dpc-1882	9	108	stefania	stefania	PROPN
dpc-1882	9	109	napolitano	napolitano	PROPN
dpc-1882	9	110	,	,	PUNCT
dpc-1882	9	111	luigi	luigi	PROPN
dpc-1882	9	112	pio	pio	PROPN
dpc-1882	9	113	guerrera	guerrera	PROPN
dpc-1882	9	114	,	,	PUNCT
dpc-1882	9	115	teresa	teresa	PROPN
dpc-1882	9	116	troiani	troiani	ADJ
dpc-1882	9	117	treatment	treatment	NOUN
dpc-1882	9	118	of	of	ADP
dpc-1882	9	119	advanced	advanced	ADJ
dpc-1882	9	120	metastatic	metastatic	ADJ
dpc-1882	9	121	melanoma	melanoma	NOUN
dpc-1882	9	122	pietro	pietro	NOUN
dpc-1882	9	123	quaglino	quaglino	PROPN
dpc-1882	9	124	,	,	PUNCT
dpc-1882	9	125	paolo	paolo	PROPN
dpc-1882	9	126	fava	fava	NOUN
dpc-1882	9	127	,	,	PUNCT
dpc-1882	9	128	luca	luca	PROPN
dpc-1882	9	129	tonella	tonella	PROPN
dpc-1882	9	130	,	,	PUNCT
dpc-1882	9	131	marco	marco	PROPN
dpc-1882	9	132	rubatto	rubatto	NOUN
dpc-1882	9	133	,	,	PUNCT
dpc-1882	9	134	simone	simone	NOUN
dpc-1882	9	135	ribero	ribero	PROPN
dpc-1882	9	136	,	,	PUNCT
dpc-1882	9	137	maria	maria	PROPN
dpc-1882	9	138	teresa	teresa	PROPN
dpc-1882	9	139	fierro	fierro	PROPN
dpc-1882	9	140	guest	guest	PROPN
dpc-1882	9	141	editors	editor	NOUN
dpc-1882	9	142	prof	prof	PROPN
dpc-1882	9	143	.	.	PUNCT
dpc-1882	10	1	h.	h.	PROPN
dpc-1882	10	2	peter	peter	PROPN
dpc-1882	10	3	soyer	soyer	PROPN
dpc-1882	10	4	,	,	PUNCT
dpc-1882	10	5	md	md	PROPN
dpc-1882	10	6	,	,	PUNCT
dpc-1882	10	7	facd	facd	NOUN
dpc-1882	10	8	,	,	PUNCT
dpc-1882	10	9	fahms	fahm	NOUN
dpc-1882	10	10	chair	chair	NOUN
dpc-1882	10	11	in	in	ADP
dpc-1882	10	12	dermatology	dermatology	NOUN
dpc-1882	10	13	.	.	PUNCT
dpc-1882	11	1	director	director	NOUN
dpc-1882	11	2	,	,	PUNCT
dpc-1882	11	3	dermatology	dermatology	NOUN
dpc-1882	11	4	research	research	NOUN
dpc-1882	11	5	centre	centre	NOUN
dpc-1882	11	6	,	,	PUNCT
dpc-1882	11	7	the	the	DET
dpc-1882	11	8	university	university	PROPN
dpc-1882	11	9	of	of	ADP
dpc-1882	11	10	queensland	queensland	PROPN
dpc-1882	11	11	diamantina	diamantina	PROPN
dpc-1882	11	12	institute	institute	PROPN
dpc-1882	11	13	;	;	PUNCT
dpc-1882	11	14	director	director	NOUN
dpc-1882	11	15	,	,	PUNCT
dpc-1882	11	16	dermatology	dermatology	NOUN
dpc-1882	11	17	department	department	NOUN
dpc-1882	11	18	,	,	PUNCT
dpc-1882	11	19	princess	princess	NOUN
dpc-1882	11	20	alexandra	alexandra	PROPN
dpc-1882	11	21	hospital	hospital	PROPN
dpc-1882	11	22	prof	prof	PROPN
dpc-1882	11	23	.	.	PUNCT
dpc-1882	12	1	paola	paola	PROPN
dpc-1882	12	2	queirolo	queirolo	PROPN
dpc-1882	12	3	,	,	PUNCT
dpc-1882	12	4	md	md	PROPN
dpc-1882	12	5	director	director	NOUN
dpc-1882	12	6	of	of	ADP
dpc-1882	12	7	the	the	DET
dpc-1882	12	8	“	"	PUNCT
dpc-1882	12	9	divisione	divisione	X
dpc-1882	12	10	di	di	X
dpc-1882	12	11	oncologia	oncologia	PROPN
dpc-1882	12	12	medica	medica	PROPN
dpc-1882	12	13	del	del	PROPN
dpc-1882	12	14	melanoma	melanoma	PROPN
dpc-1882	12	15	,	,	PUNCT
dpc-1882	12	16	sarcoma	sarcoma	PROPN
dpc-1882	12	17	e	e	PROPN
dpc-1882	12	18	tumori	tumori	PROPN
dpc-1882	12	19	rari	rari	PROPN
dpc-1882	12	20	”	"	PUNCT
dpc-1882	12	21	istituto	istituto	PROPN
dpc-1882	12	22	europeo	europeo	PROPN
dpc-1882	12	23	di	di	PROPN
dpc-1882	12	24	oncologia	oncologia	PROPN
dpc-1882	12	25	,	,	PUNCT
dpc-1882	12	26	ieo	ieo	NOUN
dpc-1882	12	27	.	.	PROPN
dpc-1882	13	1	thanks	thank	NOUN
dpc-1882	13	2	to	to	ADP
dpc-1882	13	3	dermatology	dermatology	NOUN
dpc-1882	13	4	practical	practical	ADJ
dpc-1882	13	5	&	&	CCONJ
dpc-1882	13	6	conceptual	conceptual	ADJ
dpc-1882	13	7	review	review	NOUN
dpc-1882	13	8	|	|	ADV
dpc-1882	13	9	dermatol	dermatol	ADJ
dpc-1882	13	10	pract	pract	NOUN
dpc-1882	13	11	concept	concept	NOUN
dpc-1882	13	12	.	.	PUNCT
dpc-1882	14	1	2021;11(s1	2021;11(s1	NUM
dpc-1882	14	2	):	):	PUNCT
dpc-1882	14	3	e2021165s	e2021165s	X
dpc-1882	14	4	1	1	NUM
dpc-1882	14	5	current	current	ADJ
dpc-1882	14	6	landscape	landscape	NOUN
dpc-1882	14	7	and	and	CCONJ
dpc-1882	14	8	open	open	ADJ
dpc-1882	14	9	questions	question	NOUN
dpc-1882	14	10	on	on	ADP
dpc-1882	14	11	adjuvant	adjuvant	ADJ
dpc-1882	14	12	therapies	therapy	NOUN
dpc-1882	14	13	in	in	ADP
dpc-1882	14	14	melanoma	melanoma	PROPN
dpc-1882	14	15	vincenzo	vincenzo	PROPN
dpc-1882	14	16	de	de	X
dpc-1882	14	17	falco1	falco1	PROPN
dpc-1882	14	18	,	,	PUNCT
dpc-1882	14	19	stefania	stefania	NOUN
dpc-1882	14	20	napolitano1	napolitano1	PROPN
dpc-1882	14	21	,	,	PUNCT
dpc-1882	14	22	luigi	luigi	PROPN
dpc-1882	14	23	pio	pio	PROPN
dpc-1882	14	24	guerrera1	guerrera1	PROPN
dpc-1882	14	25	,	,	PUNCT
dpc-1882	14	26	teresa	teresa	PROPN
dpc-1882	14	27	troiani1	troiani1	PROPN
dpc-1882	14	28	medical	medical	ADJ
dpc-1882	14	29	oncology	oncology	NOUN
dpc-1882	14	30	,	,	PUNCT
dpc-1882	14	31	department	department	NOUN
dpc-1882	14	32	of	of	ADP
dpc-1882	14	33	precision	precision	NOUN
dpc-1882	14	34	medicine	medicine	NOUN
dpc-1882	14	35	,	,	PUNCT
dpc-1882	14	36	università	università	PROPN
dpc-1882	14	37	degli	degli	PROPN
dpc-1882	14	38	studi	studi	PROPN
dpc-1882	14	39	della	della	PROPN
dpc-1882	14	40	campania	campania	PROPN
dpc-1882	14	41	“	"	PUNCT
dpc-1882	14	42	luigi	luigi	PROPN
dpc-1882	14	43	vanvitelli	vanvitelli	PROPN
dpc-1882	14	44	”	"	PUNCT
dpc-1882	14	45	,	,	PUNCT
dpc-1882	14	46	napoli	napoli	PROPN
dpc-1882	14	47	,	,	PUNCT
dpc-1882	14	48	italy	italy	PROPN
dpc-1882	14	49	key	key	ADJ
dpc-1882	14	50	words	word	NOUN
dpc-1882	14	51	:	:	PUNCT
dpc-1882	14	52	locoregional	locoregional	ADJ
dpc-1882	14	53	melanoma	melanoma	NOUN
dpc-1882	14	54	,	,	PUNCT
dpc-1882	14	55	stage	stage	NOUN
dpc-1882	14	56	iii	iii	NUM
dpc-1882	14	57	melanoma	melanoma	NOUN
dpc-1882	14	58	,	,	PUNCT
dpc-1882	14	59	adjuvant	adjuvant	ADJ
dpc-1882	14	60	therapy	therapy	NOUN
dpc-1882	14	61	citation	citation	NOUN
dpc-1882	14	62	:	:	PUNCT
dpc-1882	14	63	de	de	PROPN
dpc-1882	14	64	falco	falco	PROPN
dpc-1882	14	65	v	v	PROPN
dpc-1882	14	66	,	,	PUNCT
dpc-1882	14	67	napolitano	napolitano	PROPN
dpc-1882	14	68	s	s	PROPN
dpc-1882	14	69	,	,	PUNCT
dpc-1882	14	70	guerrera	guerrera	PROPN
dpc-1882	14	71	lp	lp	PROPN
dpc-1882	14	72	,	,	PUNCT
dpc-1882	14	73	troiani	troiani	ADJ
dpc-1882	14	74	t.	t.	PROPN
dpc-1882	14	75	current	current	ADJ
dpc-1882	14	76	landscape	landscape	NOUN
dpc-1882	14	77	and	and	CCONJ
dpc-1882	14	78	open	open	ADJ
dpc-1882	14	79	questions	question	NOUN
dpc-1882	14	80	on	on	ADP
dpc-1882	14	81	adjuvant	adjuvant	ADJ
dpc-1882	14	82	therapies	therapy	NOUN
dpc-1882	14	83	in	in	ADP
dpc-1882	14	84	melanoma	melanoma	NOUN
dpc-1882	14	85	.	.	PUNCT
dpc-1882	15	1	dermatol	dermatol	NOUN
dpc-1882	15	2	pract	pract	PROPN
dpc-1882	15	3	concept	concept	NOUN
dpc-1882	15	4	.	.	PUNCT
dpc-1882	16	1	2021;11(s1	2021;11(s1	NUM
dpc-1882	16	2	):	):	PUNCT
dpc-1882	16	3	e2021165s	e2021165s	PROPN
dpc-1882	16	4	.	.	NOUN
dpc-1882	16	5	doi	doi	PROPN
dpc-1882	16	6	:	:	PUNCT
dpc-1882	16	7	https://doi.org/10.5826/dpc.11s1a165s	https://doi.org/10.5826/dpc.11s1a165s	PROPN
dpc-1882	16	8	accepted	accept	VERB
dpc-1882	16	9	:	:	PUNCT
dpc-1882	16	10	july	july	PROPN
dpc-1882	16	11	14	14	NUM
dpc-1882	16	12	,	,	PUNCT
dpc-1882	16	13	2021	2021	NUM
dpc-1882	16	14	;	;	PUNCT
dpc-1882	16	15	published	publish	VERB
dpc-1882	16	16	:	:	PUNCT
dpc-1882	17	1	july	july	PROPN
dpc-1882	17	2	2021	2021	NUM
dpc-1882	17	3	copyright	copyright	NOUN
dpc-1882	17	4	:	:	PUNCT
dpc-1882	17	5	©	©	PROPN
dpc-1882	17	6	2021	2021	NUM
dpc-1882	17	7	de	de	SYM
dpc-1882	17	8	falco	falco	PROPN
dpc-1882	17	9	et	et	PROPN
dpc-1882	17	10	al	al	PROPN
dpc-1882	17	11	.	.	PUNCT
dpc-1882	18	1	this	this	PRON
dpc-1882	18	2	is	be	AUX
dpc-1882	18	3	an	an	DET
dpc-1882	18	4	open	open	ADJ
dpc-1882	18	5	-	-	PUNCT
dpc-1882	18	6	access	access	NOUN
dpc-1882	18	7	article	article	NOUN
dpc-1882	18	8	distributed	distribute	VERB
dpc-1882	18	9	under	under	ADP
dpc-1882	18	10	the	the	DET
dpc-1882	18	11	terms	term	NOUN
dpc-1882	18	12	of	of	ADP
dpc-1882	18	13	the	the	DET
dpc-1882	18	14	creative	creative	ADJ
dpc-1882	18	15	commons	common	NOUN
dpc-1882	18	16	attribution	attribution	NOUN
dpc-1882	18	17	license	license	NOUN
dpc-1882	18	18	by	by	ADP
dpc-1882	18	19	-	-	PUNCT
dpc-1882	18	20	nc-4.0	nc-4.0	NOUN
dpc-1882	18	21	,	,	PUNCT
dpc-1882	18	22	which	which	PRON
dpc-1882	18	23	permits	permit	VERB
dpc-1882	18	24	unrestricted	unrestricted	ADJ
dpc-1882	18	25	noncommercial	noncommercial	ADJ
dpc-1882	18	26	use	use	NOUN
dpc-1882	18	27	,	,	PUNCT
dpc-1882	18	28	distribution	distribution	NOUN
dpc-1882	18	29	,	,	PUNCT
dpc-1882	18	30	and	and	CCONJ
dpc-1882	18	31	reproduction	reproduction	NOUN
dpc-1882	18	32	in	in	ADP
dpc-1882	18	33	any	any	DET
dpc-1882	18	34	medium	medium	NOUN
dpc-1882	18	35	,	,	PUNCT
dpc-1882	18	36	provided	provide	VERB
dpc-1882	18	37	the	the	DET
dpc-1882	18	38	original	original	ADJ
dpc-1882	18	39	authors	author	NOUN
dpc-1882	18	40	and	and	CCONJ
dpc-1882	18	41	source	source	NOUN
dpc-1882	18	42	are	be	AUX
dpc-1882	18	43	credited	credit	VERB
dpc-1882	18	44	.	.	PUNCT
dpc-1882	19	1	funding	funding	NOUN
dpc-1882	19	2	:	:	PUNCT
dpc-1882	19	3	none	none	NOUN
dpc-1882	19	4	.	.	PUNCT
dpc-1882	20	1	competing	compete	VERB
dpc-1882	20	2	interests	interest	NOUN
dpc-1882	20	3	:	:	PUNCT
dpc-1882	20	4	the	the	DET
dpc-1882	20	5	authors	author	NOUN
dpc-1882	20	6	have	have	VERB
dpc-1882	20	7	no	no	DET
dpc-1882	20	8	conflicts	conflict	NOUN
dpc-1882	20	9	of	of	ADP
dpc-1882	20	10	interest	interest	NOUN
dpc-1882	20	11	to	to	PART
dpc-1882	20	12	disclose	disclose	VERB
dpc-1882	20	13	.	.	PUNCT
dpc-1882	21	1	authorship	authorship	NOUN
dpc-1882	21	2	:	:	PUNCT
dpc-1882	21	3	all	all	DET
dpc-1882	21	4	authors	author	NOUN
dpc-1882	21	5	have	have	AUX
dpc-1882	21	6	contributed	contribute	VERB
dpc-1882	21	7	significantly	significantly	ADV
dpc-1882	21	8	to	to	ADP
dpc-1882	21	9	this	this	DET
dpc-1882	21	10	publication	publication	NOUN
dpc-1882	21	11	.	.	PUNCT
dpc-1882	22	1	corresponding	correspond	VERB
dpc-1882	22	2	author	author	NOUN
dpc-1882	22	3	:	:	PUNCT
dpc-1882	22	4	teresa	teresa	PROPN
dpc-1882	22	5	troiani	troiani	PROPN
dpc-1882	22	6	,	,	PUNCT
dpc-1882	22	7	md	md	PROPN
dpc-1882	22	8	,	,	PUNCT
dpc-1882	22	9	phd	phd	PROPN
dpc-1882	22	10	,	,	PUNCT
dpc-1882	22	11	department	department	NOUN
dpc-1882	22	12	of	of	ADP
dpc-1882	22	13	precision	precision	NOUN
dpc-1882	22	14	medicine	medicine	NOUN
dpc-1882	22	15	,	,	PUNCT
dpc-1882	22	16	università	università	PROPN
dpc-1882	22	17	della	della	PROPN
dpc-1882	22	18	campania	campania	PROPN
dpc-1882	22	19	“	"	PUNCT
dpc-1882	22	20	luigi	luigi	PROPN
dpc-1882	22	21	vanvitelli	vanvitelli	PROPN
dpc-1882	22	22	”	"	PUNCT
dpc-1882	22	23	,	,	PUNCT
dpc-1882	22	24	via	via	ADP
dpc-1882	22	25	s.	s.	PROPN
dpc-1882	22	26	pansini	pansini	PROPN
dpc-1882	22	27	5	5	NUM
dpc-1882	22	28	,	,	PUNCT
dpc-1882	22	29	80131	80131	NUM
dpc-1882	22	30	,	,	PUNCT
dpc-1882	22	31	napoli	napoli	PROPN
dpc-1882	22	32	,	,	PUNCT
dpc-1882	22	33	italy	italy	PROPN
dpc-1882	22	34	.	.	PUNCT
dpc-1882	23	1	email	email	NOUN
dpc-1882	23	2	:	:	PUNCT
dpc-1882	23	3	teresa.troiani@unicampania.it	teresa.troiani@unicampania.it	PROPN
dpc-1882	23	4	phone	phone	NOUN
dpc-1882	23	5	:	:	PUNCT
dpc-1882	23	6	00390815666728	00390815666728	NUM
dpc-1882	23	7	melanoma	melanoma	NOUN
dpc-1882	23	8	is	be	AUX
dpc-1882	23	9	a	a	DET
dpc-1882	23	10	form	form	NOUN
dpc-1882	23	11	of	of	ADP
dpc-1882	23	12	skin	skin	NOUN
dpc-1882	23	13	cancer	cancer	NOUN
dpc-1882	23	14	that	that	PRON
dpc-1882	23	15	is	be	AUX
dpc-1882	23	16	frequently	frequently	ADV
dpc-1882	23	17	diagnosed	diagnose	VERB
dpc-1882	23	18	at	at	ADP
dpc-1882	23	19	early	early	ADJ
dpc-1882	23	20	stages	stage	NOUN
dpc-1882	23	21	.	.	PUNCT
dpc-1882	24	1	in	in	ADP
dpc-1882	24	2	most	most	ADJ
dpc-1882	24	3	cases	case	NOUN
dpc-1882	24	4	,	,	PUNCT
dpc-1882	24	5	surgical	surgical	ADJ
dpc-1882	24	6	resection	resection	NOUN
dpc-1882	24	7	is	be	AUX
dpc-1882	24	8	curative	curative	ADJ
dpc-1882	24	9	.	.	PUNCT
dpc-1882	25	1	in	in	ADP
dpc-1882	25	2	case	case	NOUN
dpc-1882	25	3	of	of	ADP
dpc-1882	25	4	thicker	thick	ADJ
dpc-1882	25	5	melanomas	melanomas	NOUN
dpc-1882	25	6	(	(	PUNCT
dpc-1882	25	7	>	>	X
dpc-1882	25	8	pt1b	pt1b	NOUN
dpc-1882	25	9	)	)	PUNCT
dpc-1882	25	10	without	without	ADP
dpc-1882	25	11	clinical	clinical	ADJ
dpc-1882	25	12	or	or	CCONJ
dpc-1882	25	13	instrumental	instrumental	ADJ
dpc-1882	25	14	evidence	evidence	NOUN
dpc-1882	25	15	of	of	ADP
dpc-1882	25	16	metastasis	metastasis	NOUN
dpc-1882	25	17	,	,	PUNCT
dpc-1882	25	18	a	a	DET
dpc-1882	25	19	sentinel	sentinel	ADJ
dpc-1882	25	20	lymph	lymph	NOUN
dpc-1882	25	21	node	node	ADJ
dpc-1882	25	22	biopsy	biopsy	NOUN
dpc-1882	25	23	is	be	AUX
dpc-1882	25	24	recommended	recommend	VERB
dpc-1882	25	25	for	for	ADP
dpc-1882	25	26	staging	stage	VERB
dpc-1882	25	27	purposes	purpose	NOUN
dpc-1882	25	28	.	.	PUNCT
dpc-1882	26	1	if	if	SCONJ
dpc-1882	26	2	the	the	DET
dpc-1882	26	3	lymph	lymph	NOUN
dpc-1882	26	4	nodes	node	NOUN
dpc-1882	26	5	are	be	AUX
dpc-1882	26	6	the	the	DET
dpc-1882	26	7	only	only	ADJ
dpc-1882	26	8	site	site	NOUN
dpc-1882	26	9	of	of	ADP
dpc-1882	26	10	disease	disease	NOUN
dpc-1882	26	11	(	(	PUNCT
dpc-1882	26	12	macroscopic	macroscopic	ADJ
dpc-1882	26	13	or	or	CCONJ
dpc-1882	26	14	microscopic	microscopic	ADJ
dpc-1882	26	15	>	>	X
dpc-1882	26	16	1	1	NUM
dpc-1882	26	17	mm	mm	NOUN
dpc-1882	26	18	)	)	PUNCT
dpc-1882	26	19	,	,	PUNCT
dpc-1882	26	20	configuring	configuring	NOUN
dpc-1882	26	21	stage	stage	PROPN
dpc-1882	26	22	iii	iii	PROPN
dpc-1882	26	23	,	,	PUNCT
dpc-1882	26	24	the	the	DET
dpc-1882	26	25	international	international	ADJ
dpc-1882	26	26	guidelines	guideline	NOUN
dpc-1882	26	27	recommend	recommend	VERB
dpc-1882	26	28	the	the	DET
dpc-1882	26	29	use	use	NOUN
dpc-1882	26	30	of	of	ADP
dpc-1882	26	31	adjuvant	adjuvant	ADJ
dpc-1882	26	32	therapy	therapy	NOUN
dpc-1882	26	33	with	with	ADP
dpc-1882	26	34	checkpoint	checkpoint	NOUN
dpc-1882	26	35	inhibitors	inhibitor	NOUN
dpc-1882	26	36	(	(	PUNCT
dpc-1882	26	37	nivolumab	nivolumab	NOUN
dpc-1882	26	38	or	or	CCONJ
dpc-1882	26	39	pembrolizumab	pembrolizumab	NOUN
dpc-1882	26	40	)	)	PUNCT
dpc-1882	26	41	or	or	CCONJ
dpc-1882	26	42	targeted	target	VERB
dpc-1882	26	43	therapies	therapy	NOUN
dpc-1882	26	44	(	(	PUNCT
dpc-1882	26	45	dabrafenib	dabrafenib	NOUN
dpc-1882	26	46	plus	plus	CCONJ
dpc-1882	26	47	trametinib	trametinib	NOUN
dpc-1882	26	48	)	)	PUNCT
dpc-1882	26	49	.	.	PUNCT
dpc-1882	27	1	these	these	DET
dpc-1882	27	2	drugs	drug	NOUN
dpc-1882	27	3	have	have	AUX
dpc-1882	27	4	shown	show	VERB
dpc-1882	27	5	a	a	DET
dpc-1882	27	6	significant	significant	ADJ
dpc-1882	27	7	increase	increase	NOUN
dpc-1882	27	8	in	in	ADP
dpc-1882	27	9	recurrence	recurrence	NOUN
dpc-1882	27	10	-	-	PUNCT
dpc-1882	27	11	free	free	ADJ
dpc-1882	27	12	survival	survival	NOUN
dpc-1882	27	13	,	,	PUNCT
dpc-1882	27	14	although	although	SCONJ
dpc-1882	27	15	some	some	DET
dpc-1882	27	16	doubts	doubt	NOUN
dpc-1882	27	17	and	and	CCONJ
dpc-1882	27	18	open	open	ADJ
dpc-1882	27	19	questions	question	NOUN
dpc-1882	27	20	remain	remain	VERB
dpc-1882	27	21	.	.	PUNCT
dpc-1882	28	1	specifically	specifically	ADV
dpc-1882	28	2	,	,	PUNCT
dpc-1882	28	3	none	none	NOUN
dpc-1882	28	4	of	of	ADP
dpc-1882	28	5	the	the	DET
dpc-1882	28	6	available	available	ADJ
dpc-1882	28	7	treatments	treatment	NOUN
dpc-1882	28	8	has	have	AUX
dpc-1882	28	9	shown	show	VERB
dpc-1882	28	10	a	a	DET
dpc-1882	28	11	clear	clear	ADJ
dpc-1882	28	12	benefit	benefit	NOUN
dpc-1882	28	13	in	in	ADP
dpc-1882	28	14	the	the	DET
dpc-1882	28	15	overall	overall	ADJ
dpc-1882	28	16	survival	survival	NOUN
dpc-1882	28	17	rates	rate	NOUN
dpc-1882	28	18	,	,	PUNCT
dpc-1882	28	19	the	the	DET
dpc-1882	28	20	advantages	advantage	NOUN
dpc-1882	28	21	they	they	PRON
dpc-1882	28	22	give	give	VERB
dpc-1882	28	23	in	in	ADP
dpc-1882	28	24	stage	stage	NOUN
dpc-1882	28	25	iiia	iiia	NOUN
dpc-1882	28	26	are	be	AUX
dpc-1882	28	27	not	not	PART
dpc-1882	28	28	well	well	ADV
dpc-1882	28	29	known	know	VERB
dpc-1882	28	30	,	,	PUNCT
dpc-1882	28	31	and	and	CCONJ
dpc-1882	28	32	finally	finally	ADV
dpc-1882	28	33	there	there	PRON
dpc-1882	28	34	are	be	VERB
dpc-1882	28	35	still	still	ADV
dpc-1882	28	36	no	no	DET
dpc-1882	28	37	prospective	prospective	ADJ
dpc-1882	28	38	clinical	clinical	ADJ
dpc-1882	28	39	studies	study	NOUN
dpc-1882	28	40	abstract	abstract	ADV
dpc-1882	28	41	this	this	DET
dpc-1882	28	42	article	article	NOUN
dpc-1882	28	43	is	be	AUX
dpc-1882	28	44	part	part	NOUN
dpc-1882	28	45	of	of	ADP
dpc-1882	28	46	the	the	DET
dpc-1882	28	47	dpc	dpc	PROPN
dpc-1882	28	48	journal	journal	PROPN
dpc-1882	28	49	special	special	ADJ
dpc-1882	28	50	issue	issue	NOUN
dpc-1882	28	51	melanoma	melanoma	NOUN
dpc-1882	28	52	today	today	NOUN
dpc-1882	28	53	guest	guest	PROPN
dpc-1882	28	54	editors	editor	NOUN
dpc-1882	28	55	prof	prof	PROPN
dpc-1882	28	56	.	.	PUNCT
dpc-1882	29	1	h.	h.	PROPN
dpc-1882	29	2	peter	peter	PROPN
dpc-1882	29	3	soyer	soyer	PROPN
dpc-1882	29	4	,	,	PUNCT
dpc-1882	29	5	md	md	PROPN
dpc-1882	29	6	,	,	PUNCT
dpc-1882	29	7	facd	facd	NOUN
dpc-1882	29	8	,	,	PUNCT
dpc-1882	29	9	fahms	fahm	NOUN
dpc-1882	29	10	chair	chair	NOUN
dpc-1882	29	11	in	in	ADP
dpc-1882	29	12	dermatology	dermatology	NOUN
dpc-1882	29	13	.	.	PUNCT
dpc-1882	30	1	director	director	NOUN
dpc-1882	30	2	,	,	PUNCT
dpc-1882	30	3	dermatology	dermatology	NOUN
dpc-1882	30	4	research	research	NOUN
dpc-1882	30	5	centre	centre	NOUN
dpc-1882	30	6	,	,	PUNCT
dpc-1882	30	7	the	the	DET
dpc-1882	30	8	university	university	PROPN
dpc-1882	30	9	of	of	ADP
dpc-1882	30	10	queensland	queensland	PROPN
dpc-1882	30	11	diamantina	diamantina	PROPN
dpc-1882	30	12	institute	institute	PROPN
dpc-1882	30	13	;	;	PUNCT
dpc-1882	30	14	director	director	NOUN
dpc-1882	30	15	,	,	PUNCT
dpc-1882	30	16	dermatology	dermatology	NOUN
dpc-1882	30	17	department	department	NOUN
dpc-1882	30	18	,	,	PUNCT
dpc-1882	30	19	princess	princess	NOUN
dpc-1882	30	20	alexandra	alexandra	PROPN
dpc-1882	30	21	hospital	hospital	PROPN
dpc-1882	30	22	prof	prof	PROPN
dpc-1882	30	23	.	.	PUNCT
dpc-1882	31	1	paola	paola	PROPN
dpc-1882	31	2	queirolo	queirolo	PROPN
dpc-1882	31	3	,	,	PUNCT
dpc-1882	31	4	md	md	PROPN
dpc-1882	31	5	director	director	NOUN
dpc-1882	31	6	of	of	ADP
dpc-1882	31	7	the	the	DET
dpc-1882	31	8	“	"	PUNCT
dpc-1882	31	9	divisione	divisione	X
dpc-1882	31	10	di	di	X
dpc-1882	31	11	oncologia	oncologia	PROPN
dpc-1882	31	12	medica	medica	PROPN
dpc-1882	31	13	del	del	PROPN
dpc-1882	31	14	melanoma	melanoma	PROPN
dpc-1882	31	15	,	,	PUNCT
dpc-1882	31	16	sarcoma	sarcoma	PROPN
dpc-1882	31	17	e	e	PROPN
dpc-1882	31	18	tumori	tumori	PROPN
dpc-1882	31	19	rari	rari	PROPN
dpc-1882	31	20	”	"	PUNCT
dpc-1882	31	21	istituto	istituto	PROPN
dpc-1882	31	22	europeo	europeo	PROPN
dpc-1882	31	23	di	di	PROPN
dpc-1882	31	24	oncologia	oncologia	PROPN
dpc-1882	31	25	,	,	PUNCT
dpc-1882	31	26	ieo	ieo	NOUN
dpc-1882	31	27	.	.	PROPN
dpc-1882	31	28	2	2	NUM
dpc-1882	31	29	review	review	NOUN
dpc-1882	31	30	|	|	ADV
dpc-1882	31	31	dermatol	dermatol	ADJ
dpc-1882	31	32	pract	pract	NOUN
dpc-1882	31	33	concept	concept	NOUN
dpc-1882	31	34	.	.	PUNCT
dpc-1882	32	1	2021;11(s1	2021;11(s1	NUM
dpc-1882	32	2	):	):	PUNCT
dpc-1882	32	3	e2021165s	e2021165s	PUNCT
dpc-1882	32	4	introduction	introduction	NOUN
dpc-1882	32	5	melanoma	melanoma	NOUN
dpc-1882	32	6	is	be	AUX
dpc-1882	32	7	the	the	DET
dpc-1882	32	8	deadliest	deadly	ADJ
dpc-1882	32	9	of	of	ADP
dpc-1882	32	10	skin	skin	NOUN
dpc-1882	32	11	cancers	cancer	NOUN
dpc-1882	32	12	and	and	CCONJ
dpc-1882	32	13	occurs	occur	VERB
dpc-1882	32	14	primarily	primarily	ADV
dpc-1882	32	15	the	the	DET
dpc-1882	32	16	elderly	elderly	ADJ
dpc-1882	32	17	,	,	PUNCT
dpc-1882	32	18	still	still	ADV
dpc-1882	32	19	,	,	PUNCT
dpc-1882	32	20	it	it	PRON
dpc-1882	32	21	is	be	AUX
dpc-1882	32	22	one	one	NUM
dpc-1882	32	23	of	of	ADP
dpc-1882	32	24	the	the	DET
dpc-1882	32	25	most	most	ADV
dpc-1882	32	26	common	common	ADJ
dpc-1882	32	27	cancers	cancer	NOUN
dpc-1882	32	28	diagnosed	diagnose	VERB
dpc-1882	32	29	in	in	ADP
dpc-1882	32	30	young	young	ADJ
dpc-1882	32	31	adults	adult	NOUN
dpc-1882	32	32	,	,	PUNCT
dpc-1882	32	33	particularly	particularly	ADV
dpc-1882	32	34	in	in	ADP
dpc-1882	32	35	women	woman	NOUN
dpc-1882	32	36	[	[	X
dpc-1882	32	37	1	1	NUM
dpc-1882	32	38	]	]	PUNCT
dpc-1882	32	39	.	.	PUNCT
dpc-1882	33	1	about	about	ADV
dpc-1882	33	2	50	50	NUM
dpc-1882	33	3	%	%	NOUN
dpc-1882	33	4	of	of	ADP
dpc-1882	33	5	patients	patient	NOUN
dpc-1882	33	6	with	with	ADP
dpc-1882	33	7	cutaneous	cutaneous	ADJ
dpc-1882	33	8	melanoma	melanoma	NOUN
dpc-1882	33	9	harbor	harbor	VERB
dpc-1882	33	10	a	a	DET
dpc-1882	33	11	mutation	mutation	NOUN
dpc-1882	33	12	in	in	ADP
dpc-1882	33	13	exon	exon	PROPN
dpc-1882	33	14	15	15	NUM
dpc-1882	33	15	(	(	PUNCT
dpc-1882	33	16	codon	codon	NOUN
dpc-1882	33	17	600	600	NUM
dpc-1882	33	18	)	)	PUNCT
dpc-1882	33	19	of	of	ADP
dpc-1882	33	20	braf	braf	NOUN
dpc-1882	33	21	proto	proto	NOUN
dpc-1882	33	22	-	-	PUNCT
dpc-1882	33	23	oncogene	oncogene	ADJ
dpc-1882	33	24	,	,	PUNCT
dpc-1882	33	25	conferring	confer	VERB
dpc-1882	33	26	a	a	DET
dpc-1882	33	27	worse	bad	ADJ
dpc-1882	33	28	prognosis	prognosis	NOUN
dpc-1882	33	29	[	[	X
dpc-1882	33	30	2	2	NUM
dpc-1882	33	31	]	]	PUNCT
dpc-1882	33	32	.	.	PUNCT
dpc-1882	34	1	according	accord	VERB
dpc-1882	34	2	to	to	ADP
dpc-1882	34	3	the	the	DET
dpc-1882	34	4	new	new	ADJ
dpc-1882	34	5	8th	8th	ADJ
dpc-1882	34	6	edition	edition	NOUN
dpc-1882	34	7	of	of	ADP
dpc-1882	34	8	the	the	DET
dpc-1882	34	9	american	american	PROPN
dpc-1882	34	10	joint	joint	PROPN
dpc-1882	34	11	committee	committee	PROPN
dpc-1882	34	12	on	on	ADP
dpc-1882	34	13	cancer	cancer	NOUN
dpc-1882	34	14	(	(	PUNCT
dpc-1882	34	15	ajcc	ajcc	PROPN
dpc-1882	34	16	)	)	PUNCT
dpc-1882	34	17	staging	staging	NOUN
dpc-1882	34	18	,	,	PUNCT
dpc-1882	34	19	patients	patient	NOUN
dpc-1882	34	20	with	with	ADP
dpc-1882	34	21	early	early	ADJ
dpc-1882	34	22	-	-	PUNCT
dpc-1882	34	23	stage	stage	NOUN
dpc-1882	34	24	(	(	PUNCT
dpc-1882	34	25	i	i	PROPN
dpc-1882	34	26	-	-	PUNCT
dpc-1882	34	27	ii	ii	NOUN
dpc-1882	34	28	)	)	PUNCT
dpc-1882	34	29	have	have	VERB
dpc-1882	34	30	an	an	DET
dpc-1882	34	31	overall	overall	ADJ
dpc-1882	34	32	favorable	favorable	ADJ
dpc-1882	34	33	prognosis	prognosis	NOUN
dpc-1882	34	34	,	,	PUNCT
dpc-1882	34	35	whereas	whereas	SCONJ
dpc-1882	34	36	patients	patient	NOUN
dpc-1882	34	37	with	with	ADP
dpc-1882	34	38	stage	stage	NOUN
dpc-1882	34	39	iii	iii	NUM
dpc-1882	34	40	melanoma	melanoma	PROPN
dpc-1882	34	41	have	have	VERB
dpc-1882	34	42	a	a	DET
dpc-1882	34	43	rather	rather	ADV
dpc-1882	34	44	heterogeneous	heterogeneous	ADJ
dpc-1882	34	45	prognosis	prognosis	NOUN
dpc-1882	34	46	[	[	X
dpc-1882	34	47	3	3	NUM
dpc-1882	34	48	]	]	PUNCT
dpc-1882	34	49	.	.	PUNCT
dpc-1882	35	1	the	the	DET
dpc-1882	35	2	discovery	discovery	NOUN
dpc-1882	35	3	of	of	ADP
dpc-1882	35	4	immune	immune	ADJ
dpc-1882	35	5	checkpoint	checkpoint	NOUN
dpc-1882	35	6	inhibitors	inhibitor	NOUN
dpc-1882	35	7	and	and	CCONJ
dpc-1882	35	8	targeted	target	VERB
dpc-1882	35	9	therapies	therapy	NOUN
dpc-1882	35	10	(	(	PUNCT
dpc-1882	35	11	tt	tt	NOUN
dpc-1882	35	12	)	)	PUNCT
dpc-1882	35	13	revolutionized	revolutionize	VERB
dpc-1882	35	14	the	the	DET
dpc-1882	35	15	treatment	treatment	NOUN
dpc-1882	35	16	scenario	scenario	NOUN
dpc-1882	35	17	of	of	ADP
dpc-1882	35	18	metastatic	metastatic	ADJ
dpc-1882	35	19	melanoma	melanoma	NOUN
dpc-1882	35	20	and	and	CCONJ
dpc-1882	35	21	with	with	ADP
dpc-1882	35	22	the	the	DET
dpc-1882	35	23	latest	late	ADJ
dpc-1882	35	24	evidence	evidence	NOUN
dpc-1882	35	25	these	these	DET
dpc-1882	35	26	drugs	drug	NOUN
dpc-1882	35	27	were	be	AUX
dpc-1882	35	28	also	also	ADV
dpc-1882	35	29	added	add	VERB
dpc-1882	35	30	in	in	ADP
dpc-1882	35	31	adjuvant	adjuvant	ADJ
dpc-1882	35	32	setting	setting	NOUN
dpc-1882	35	33	.	.	PUNCT
dpc-1882	36	1	in	in	ADP
dpc-1882	36	2	this	this	DET
dpc-1882	36	3	work	work	NOUN
dpc-1882	36	4	,	,	PUNCT
dpc-1882	36	5	we	we	PRON
dpc-1882	36	6	will	will	AUX
dpc-1882	36	7	review	review	VERB
dpc-1882	36	8	the	the	DET
dpc-1882	36	9	state	state	NOUN
dpc-1882	36	10	of	of	ADP
dpc-1882	36	11	art	art	NOUN
dpc-1882	36	12	and	and	CCONJ
dpc-1882	36	13	the	the	DET
dpc-1882	36	14	unresolved	unresolved	ADJ
dpc-1882	36	15	questions	question	NOUN
dpc-1882	36	16	of	of	ADP
dpc-1882	36	17	adjuvant	adjuvant	ADJ
dpc-1882	36	18	therapy	therapy	NOUN
dpc-1882	36	19	.	.	PUNCT
dpc-1882	37	1	finally	finally	ADV
dpc-1882	37	2	,	,	PUNCT
dpc-1882	37	3	we	we	PRON
dpc-1882	37	4	will	will	AUX
dpc-1882	37	5	examine	examine	VERB
dpc-1882	37	6	future	future	ADJ
dpc-1882	37	7	directions	direction	NOUN
dpc-1882	37	8	for	for	ADP
dpc-1882	37	9	stage	stage	NOUN
dpc-1882	37	10	iii	iii	NUM
dpc-1882	37	11	cutaneous	cutaneous	ADJ
dpc-1882	37	12	melanoma	melanoma	NOUN
dpc-1882	37	13	.	.	PUNCT
dpc-1882	38	1	immunotherapy	immunotherapy	NOUN
dpc-1882	38	2	(	(	PUNCT
dpc-1882	38	3	it	it	PRON
dpc-1882	38	4	)	)	PUNCT
dpc-1882	38	5	until	until	ADP
dpc-1882	38	6	few	few	ADJ
dpc-1882	38	7	years	year	NOUN
dpc-1882	38	8	ago	ago	ADV
dpc-1882	38	9	,	,	PUNCT
dpc-1882	38	10	only	only	ADV
dpc-1882	38	11	interferon	interferon	ADJ
dpc-1882	38	12	-	-	PUNCT
dpc-1882	38	13	α	α	NOUN
dpc-1882	38	14	(	(	PUNCT
dpc-1882	38	15	ifn	ifn	PROPN
dpc-1882	38	16	-	-	PUNCT
dpc-1882	38	17	α	α	NOUN
dpc-1882	38	18	)	)	PUNCT
dpc-1882	38	19	showed	show	VERB
dpc-1882	38	20	a	a	DET
dpc-1882	38	21	survival	survival	NOUN
dpc-1882	38	22	benefit	benefit	NOUN
dpc-1882	38	23	in	in	ADP
dpc-1882	38	24	this	this	DET
dpc-1882	38	25	setting	setting	NOUN
dpc-1882	38	26	,	,	PUNCT
dpc-1882	38	27	although	although	SCONJ
dpc-1882	38	28	it	it	PRON
dpc-1882	38	29	had	have	VERB
dpc-1882	38	30	a	a	DET
dpc-1882	38	31	very	very	ADV
dpc-1882	38	32	modest	modest	ADJ
dpc-1882	38	33	efficacy	efficacy	NOUN
dpc-1882	38	34	and	and	CCONJ
dpc-1882	38	35	was	be	AUX
dpc-1882	38	36	limited	limit	VERB
dpc-1882	38	37	to	to	ADP
dpc-1882	38	38	ulcerated	ulcerated	ADJ
dpc-1882	38	39	melanoma	melanoma	NOUN
dpc-1882	38	40	[	[	X
dpc-1882	38	41	4	4	NUM
dpc-1882	38	42	]	]	PUNCT
dpc-1882	38	43	.	.	PUNCT
dpc-1882	39	1	anti	anti	ADJ
dpc-1882	39	2	-	-	ADJ
dpc-1882	39	3	programmed	programmed	ADJ
dpc-1882	39	4	cell	cell	NOUN
dpc-1882	39	5	death-1	death-1	NUM
dpc-1882	39	6	(	(	PUNCT
dpc-1882	39	7	anti	anti	ADJ
dpc-1882	39	8	-	-	ADJ
dpc-1882	39	9	pd-1	pd-1	ADJ
dpc-1882	39	10	)	)	PUNCT
dpc-1882	39	11	antibodies	antibodie	VERB
dpc-1882	39	12	such	such	ADJ
dpc-1882	39	13	as	as	ADP
dpc-1882	39	14	nivolumab	nivolumab	NOUN
dpc-1882	39	15	and	and	CCONJ
dpc-1882	39	16	pembrolizumab	pembrolizumab	NOUN
dpc-1882	39	17	and	and	CCONJ
dpc-1882	39	18	anticytotoxic	anticytotoxic	ADV
dpc-1882	39	19	t	t	PROPN
dpc-1882	39	20	lymphocyte	lymphocyte	NOUN
dpc-1882	39	21	-	-	PUNCT
dpc-1882	39	22	associated	associate	VERB
dpc-1882	39	23	antigen	antigen	ADJ
dpc-1882	39	24	4	4	NUM
dpc-1882	39	25	(	(	PUNCT
dpc-1882	39	26	anti	anti	ADJ
dpc-1882	39	27	-	-	ADJ
dpc-1882	39	28	ctla-4	ctla-4	NOUN
dpc-1882	39	29	)	)	PUNCT
dpc-1882	39	30	antibodies	antibodie	VERB
dpc-1882	39	31	such	such	ADJ
dpc-1882	39	32	as	as	ADP
dpc-1882	39	33	ipilimumab	ipilimumab	NOUN
dpc-1882	39	34	clearly	clearly	ADV
dpc-1882	39	35	exhibited	exhibit	VERB
dpc-1882	39	36	a	a	DET
dpc-1882	39	37	benefit	benefit	NOUN
dpc-1882	39	38	in	in	ADP
dpc-1882	39	39	terms	term	NOUN
dpc-1882	39	40	of	of	ADP
dpc-1882	39	41	progression	progression	NOUN
dpc-1882	39	42	free	free	ADJ
dpc-1882	39	43	survival	survival	NOUN
dpc-1882	39	44	(	(	PUNCT
dpc-1882	39	45	pfs	pfs	PROPN
dpc-1882	39	46	)	)	PUNCT
dpc-1882	39	47	and	and	CCONJ
dpc-1882	39	48	overall	overall	ADJ
dpc-1882	39	49	survival	survival	NOUN
dpc-1882	39	50	(	(	PUNCT
dpc-1882	39	51	os	os	NOUN
dpc-1882	39	52	)	)	PUNCT
dpc-1882	39	53	in	in	ADP
dpc-1882	39	54	patients	patient	NOUN
dpc-1882	39	55	with	with	ADP
dpc-1882	39	56	metastatic	metastatic	ADJ
dpc-1882	39	57	melanoma	melanoma	NOUN
dpc-1882	40	1	[	[	X
dpc-1882	40	2	5	5	NUM
dpc-1882	40	3	]	]	PUNCT
dpc-1882	40	4	.	.	PUNCT
dpc-1882	41	1	for	for	ADP
dpc-1882	41	2	this	this	DET
dpc-1882	41	3	reason	reason	NOUN
dpc-1882	41	4	,	,	PUNCT
dpc-1882	41	5	several	several	ADJ
dpc-1882	41	6	trials	trial	NOUN
dpc-1882	41	7	have	have	AUX
dpc-1882	41	8	evaluated	evaluate	VERB
dpc-1882	41	9	the	the	DET
dpc-1882	41	10	efficacy	efficacy	NOUN
dpc-1882	41	11	of	of	ADP
dpc-1882	41	12	these	these	DET
dpc-1882	41	13	drugs	drug	NOUN
dpc-1882	41	14	in	in	ADP
dpc-1882	41	15	reducing	reduce	VERB
dpc-1882	41	16	the	the	DET
dpc-1882	41	17	risk	risk	NOUN
dpc-1882	41	18	of	of	ADP
dpc-1882	41	19	relapse	relapse	NOUN
dpc-1882	41	20	in	in	ADP
dpc-1882	41	21	stage	stage	NOUN
dpc-1882	41	22	iii	iii	NUM
dpc-1882	41	23	radically	radically	ADV
dpc-1882	41	24	resected	resect	VERB
dpc-1882	41	25	melanomas	melanoma	NOUN
dpc-1882	41	26	.	.	PUNCT
dpc-1882	42	1	in	in	ADP
dpc-1882	42	2	2015	2015	NUM
dpc-1882	42	3	,	,	PUNCT
dpc-1882	42	4	eortc	eortc	VERB
dpc-1882	42	5	18071	18071	NUM
dpc-1882	42	6	trial	trial	NOUN
dpc-1882	42	7	evaluated	evaluate	VERB
dpc-1882	42	8	ipilimumab	ipilimumab	ADV
dpc-1882	42	9	at	at	ADP
dpc-1882	42	10	a	a	DET
dpc-1882	42	11	dose	dose	NOUN
dpc-1882	42	12	of	of	ADP
dpc-1882	42	13	10mg	10mg	PROPN
dpc-1882	42	14	/	/	SYM
dpc-1882	42	15	kg	kg	X
dpc-1882	42	16	versus	versus	ADP
dpc-1882	42	17	placebo	placebo	NOUN
dpc-1882	42	18	for	for	ADP
dpc-1882	42	19	up	up	ADP
dpc-1882	42	20	to	to	PART
dpc-1882	42	21	3	3	NUM
dpc-1882	42	22	years	year	NOUN
dpc-1882	42	23	in	in	ADP
dpc-1882	42	24	patients	patient	NOUN
dpc-1882	42	25	who	who	PRON
dpc-1882	42	26	had	have	AUX
dpc-1882	42	27	undergone	undergo	VERB
dpc-1882	42	28	complete	complete	ADJ
dpc-1882	42	29	resection	resection	NOUN
dpc-1882	42	30	of	of	ADP
dpc-1882	42	31	stage	stage	NOUN
dpc-1882	42	32	iii	iii	NUM
dpc-1882	42	33	melanoma	melanoma	NOUN
dpc-1882	43	1	[	[	X
dpc-1882	43	2	6	6	NUM
dpc-1882	43	3	]	]	PUNCT
dpc-1882	43	4	.	.	PUNCT
dpc-1882	44	1	both	both	DET
dpc-1882	44	2	recurrence	recurrence	NOUN
dpc-1882	44	3	-	-	PUNCT
dpc-1882	44	4	free	free	ADJ
dpc-1882	44	5	survival	survival	NOUN
dpc-1882	44	6	(	(	PUNCT
dpc-1882	44	7	rfs	rfs	PROPN
dpc-1882	44	8	)	)	PUNCT
dpc-1882	44	9	and	and	CCONJ
dpc-1882	44	10	os	os	NOUN
dpc-1882	44	11	were	be	AUX
dpc-1882	44	12	significantly	significantly	ADV
dpc-1882	44	13	superior	superior	ADJ
dpc-1882	44	14	in	in	ADP
dpc-1882	44	15	the	the	DET
dpc-1882	44	16	ipilimumab	ipilimumab	NOUN
dpc-1882	44	17	group	group	NOUN
dpc-1882	44	18	compared	compare	VERB
dpc-1882	44	19	to	to	ADP
dpc-1882	44	20	placebo	placebo	NOUN
dpc-1882	44	21	group	group	NOUN
dpc-1882	44	22	at	at	ADP
dpc-1882	44	23	the	the	DET
dpc-1882	44	24	cost	cost	NOUN
dpc-1882	44	25	of	of	ADP
dpc-1882	44	26	very	very	ADV
dpc-1882	44	27	high	high	ADJ
dpc-1882	44	28	percentage	percentage	NOUN
dpc-1882	44	29	of	of	ADP
dpc-1882	44	30	serious	serious	ADJ
dpc-1882	44	31	adverse	adverse	ADJ
dpc-1882	44	32	events	event	NOUN
dpc-1882	44	33	(	(	PUNCT
dpc-1882	44	34	5	5	NUM
dpc-1882	44	35	patients	patient	NOUN
dpc-1882	44	36	died	die	VERB
dpc-1882	44	37	for	for	ADP
dpc-1882	44	38	immune	immune	NOUN
dpc-1882	44	39	-	-	PUNCT
dpc-1882	44	40	related	relate	VERB
dpc-1882	44	41	toxicities	toxicity	NOUN
dpc-1882	44	42	)	)	PUNCT
dpc-1882	44	43	.	.	PUNCT
dpc-1882	45	1	ipilimumab	ipilimumab	PROPN
dpc-1882	45	2	was	be	AUX
dpc-1882	45	3	therefore	therefore	ADV
dpc-1882	45	4	considered	consider	VERB
dpc-1882	45	5	too	too	ADV
dpc-1882	45	6	toxic	toxic	ADJ
dpc-1882	45	7	and	and	CCONJ
dpc-1882	45	8	was	be	AUX
dpc-1882	45	9	not	not	PART
dpc-1882	45	10	approved	approve	VERB
dpc-1882	45	11	by	by	ADP
dpc-1882	45	12	the	the	DET
dpc-1882	45	13	european	european	PROPN
dpc-1882	45	14	medicines	medicines	PROPN
dpc-1882	45	15	agency	agency	NOUN
dpc-1882	45	16	(	(	PUNCT
dpc-1882	45	17	ema	ema	PROPN
dpc-1882	45	18	)	)	PUNCT
dpc-1882	45	19	in	in	ADP
dpc-1882	45	20	patient	patient	ADJ
dpc-1882	45	21	populations	population	NOUN
dpc-1882	45	22	who	who	PRON
dpc-1882	45	23	are	be	AUX
dpc-1882	45	24	potentially	potentially	ADV
dpc-1882	45	25	cured	cure	VERB
dpc-1882	45	26	with	with	ADP
dpc-1882	45	27	surgery	surgery	NOUN
dpc-1882	45	28	alone	alone	ADV
dpc-1882	45	29	.	.	PUNCT
dpc-1882	46	1	on	on	ADP
dpc-1882	46	2	the	the	DET
dpc-1882	46	3	other	other	ADJ
dpc-1882	46	4	hand	hand	NOUN
dpc-1882	46	5	,	,	PUNCT
dpc-1882	46	6	checkmate-238	checkmate-238	ADJ
dpc-1882	46	7	trial	trial	NOUN
dpc-1882	46	8	tested	test	VERB
dpc-1882	46	9	nivolumab	nivolumab	ADV
dpc-1882	46	10	3mg	3mg	PROPN
dpc-1882	46	11	/	/	SYM
dpc-1882	46	12	kg	kg	PROPN
dpc-1882	46	13	vs	vs	ADP
dpc-1882	46	14	ipilimumab	ipilimumab	NOUN
dpc-1882	46	15	10mg	10mg	PROPN
dpc-1882	46	16	/	/	SYM
dpc-1882	46	17	kg	kg	NOUN
dpc-1882	46	18	for	for	ADP
dpc-1882	46	19	up	up	ADP
dpc-1882	46	20	to	to	PART
dpc-1882	46	21	1	1	NUM
dpc-1882	46	22	year	year	NOUN
dpc-1882	46	23	in	in	ADP
dpc-1882	46	24	stage	stage	NOUN
dpc-1882	46	25	iiib	iiib	NOUN
dpc-1882	46	26	-	-	PUNCT
dpc-1882	46	27	c	c	NOUN
dpc-1882	46	28	(	(	PUNCT
dpc-1882	46	29	81.3	81.3	NUM
dpc-1882	46	30	%	%	NOUN
dpc-1882	46	31	of	of	ADP
dpc-1882	46	32	study	study	NOUN
dpc-1882	46	33	population	population	NOUN
dpc-1882	46	34	)	)	PUNCT
dpc-1882	46	35	and	and	CCONJ
dpc-1882	46	36	stage	stage	NOUN
dpc-1882	46	37	iv	iv	NUM
dpc-1882	46	38	radically	radically	ADV
dpc-1882	46	39	resected	resect	VERB
dpc-1882	46	40	melanomas	melanomas	NOUN
dpc-1882	47	1	[	[	X
dpc-1882	47	2	7	7	NUM
dpc-1882	47	3	]	]	PUNCT
dpc-1882	47	4	.	.	PUNCT
dpc-1882	48	1	the	the	DET
dpc-1882	48	2	4	4	NUM
dpc-1882	48	3	-	-	PUNCT
dpc-1882	48	4	year	year	NOUN
dpc-1882	48	5	rfs	rfs	NOUN
dpc-1882	48	6	was	be	AUX
dpc-1882	48	7	52.4	52.4	NUM
dpc-1882	48	8	%	%	NOUN
dpc-1882	48	9	for	for	ADP
dpc-1882	48	10	the	the	DET
dpc-1882	48	11	nivolumab	nivolumab	NOUN
dpc-1882	48	12	group	group	NOUN
dpc-1882	48	13	vs	vs	ADP
dpc-1882	48	14	24.1	24.1	NUM
dpc-1882	48	15	%	%	NOUN
dpc-1882	48	16	for	for	ADP
dpc-1882	48	17	the	the	DET
dpc-1882	48	18	ipilimumab	ipilimumab	NOUN
dpc-1882	48	19	group	group	NOUN
dpc-1882	48	20	,	,	PUNCT
dpc-1882	48	21	with	with	ADP
dpc-1882	48	22	a	a	DET
dpc-1882	48	23	hazard	hazard	NOUN
dpc-1882	48	24	ratio	ratio	NOUN
dpc-1882	48	25	(	(	PUNCT
dpc-1882	48	26	hr	hr	NOUN
dpc-1882	48	27	)	)	PUNCT
dpc-1882	48	28	of	of	ADP
dpc-1882	48	29	0.71	0.71	NUM
dpc-1882	48	30	(	(	PUNCT
dpc-1882	48	31	p=.0003	p=.0003	NOUN
dpc-1882	48	32	)	)	PUNCT
dpc-1882	49	1	[	[	X
dpc-1882	49	2	8	8	NUM
dpc-1882	49	3	]	]	PUNCT
dpc-1882	49	4	.	.	PUNCT
dpc-1882	50	1	most	most	ADJ
dpc-1882	50	2	frequent	frequent	ADJ
dpc-1882	50	3	adverse	adverse	ADJ
dpc-1882	50	4	events	event	NOUN
dpc-1882	50	5	were	be	AUX
dpc-1882	50	6	fatigue	fatigue	NOUN
dpc-1882	50	7	,	,	PUNCT
dpc-1882	50	8	diarrhea	diarrhea	PROPN
dpc-1882	50	9	,	,	PUNCT
dpc-1882	50	10	pruritus	pruritus	NOUN
dpc-1882	50	11	,	,	PUNCT
dpc-1882	50	12	and	and	CCONJ
dpc-1882	50	13	rash	rash	ADJ
dpc-1882	50	14	but	but	CCONJ
dpc-1882	50	15	only	only	ADV
dpc-1882	50	16	in	in	ADP
dpc-1882	50	17	14.4	14.4	NUM
dpc-1882	50	18	%	%	NOUN
dpc-1882	50	19	of	of	ADP
dpc-1882	50	20	cases	case	NOUN
dpc-1882	50	21	,	,	PUNCT
dpc-1882	50	22	these	these	PRON
dpc-1882	50	23	were	be	AUX
dpc-1882	50	24	grade	grade	NOUN
dpc-1882	50	25	3	3	NUM
dpc-1882	50	26	-	-	SYM
dpc-1882	50	27	5	5	NUM
dpc-1882	50	28	.	.	PUNCT
dpc-1882	51	1	nonetheless	nonetheless	ADV
dpc-1882	51	2	,	,	PUNCT
dpc-1882	51	3	the	the	DET
dpc-1882	51	4	keynote-054	keynote-054	ADJ
dpc-1882	51	5	trial	trial	NOUN
dpc-1882	51	6	compared	compare	VERB
dpc-1882	51	7	pembrolizumab	pembrolizumab	NOUN
dpc-1882	51	8	200	200	NUM
dpc-1882	51	9	mg	mg	NOUN
dpc-1882	51	10	versus	versus	ADP
dpc-1882	51	11	placebo	placebo	NOUN
dpc-1882	51	12	in	in	ADP
dpc-1882	51	13	stage	stage	NOUN
dpc-1882	51	14	iiia	iiia	NOUN
dpc-1882	51	15	-	-	PUNCT
dpc-1882	51	16	b	b	NOUN
dpc-1882	51	17	-	-	PUNCT
dpc-1882	51	18	c	c	NOUN
dpc-1882	51	19	radically	radically	ADV
dpc-1882	51	20	resected	resect	VERB
dpc-1882	51	21	melanoma	melanoma	NOUN
dpc-1882	51	22	:	:	PUNCT
dpc-1882	51	23	3.5	3.5	NUM
dpc-1882	51	24	-	-	PUNCT
dpc-1882	51	25	year	year	NOUN
dpc-1882	51	26	rfs	rfs	NOUN
dpc-1882	51	27	was	be	AUX
dpc-1882	51	28	59.8	59.8	NUM
dpc-1882	51	29	%	%	NOUN
dpc-1882	51	30	versus	versus	ADP
dpc-1882	51	31	41.4	41.4	NUM
dpc-1882	51	32	%	%	NOUN
dpc-1882	51	33	,	,	PUNCT
dpc-1882	51	34	respectively	respectively	ADV
dpc-1882	51	35	(	(	PUNCT
dpc-1882	51	36	hr	hr	NOUN
dpc-1882	51	37	0.59	0.59	NUM
dpc-1882	51	38	,	,	PUNCT
dpc-1882	51	39	p<.001	p<.001	NOUN
dpc-1882	51	40	)	)	PUNCT
dpc-1882	51	41	.	.	PUNCT
dpc-1882	52	1	adverse	adverse	ADJ
dpc-1882	52	2	events	event	NOUN
dpc-1882	52	3	were	be	AUX
dpc-1882	52	4	similar	similar	ADJ
dpc-1882	52	5	to	to	ADP
dpc-1882	52	6	those	those	PRON
dpc-1882	52	7	reported	report	VERB
dpc-1882	52	8	with	with	ADP
dpc-1882	52	9	other	other	ADJ
dpc-1882	52	10	anti	anti	ADJ
dpc-1882	52	11	-	-	ADJ
dpc-1882	52	12	pd1	pd1	VERB
dpc-1882	52	13	inhibitors	inhibitor	NOUN
dpc-1882	52	14	[	[	X
dpc-1882	52	15	9	9	NUM
dpc-1882	52	16	]	]	PUNCT
dpc-1882	52	17	.	.	PUNCT
dpc-1882	53	1	very	very	ADV
dpc-1882	53	2	recently	recently	ADV
dpc-1882	53	3	,	,	PUNCT
dpc-1882	53	4	the	the	DET
dpc-1882	53	5	last	last	ADJ
dpc-1882	53	6	update	update	NOUN
dpc-1882	53	7	of	of	ADP
dpc-1882	53	8	the	the	DET
dpc-1882	53	9	s1404	s1404	PROPN
dpc-1882	53	10	trial	trial	NOUN
dpc-1882	53	11	was	be	AUX
dpc-1882	53	12	presented	present	VERB
dpc-1882	53	13	,	,	PUNCT
dpc-1882	53	14	in	in	ADP
dpc-1882	53	15	which	which	DET
dpc-1882	53	16	pembrolizumab	pembrolizumab	NOUN
dpc-1882	53	17	was	be	AUX
dpc-1882	53	18	compared	compare	VERB
dpc-1882	53	19	with	with	ADP
dpc-1882	53	20	1	1	NUM
dpc-1882	53	21	year	year	NOUN
dpc-1882	53	22	of	of	ADP
dpc-1882	53	23	high	high	ADJ
dpc-1882	53	24	dose	dose	NOUN
dpc-1882	53	25	interferon	interferon	NOUN
dpc-1882	53	26	or	or	CCONJ
dpc-1882	53	27	up	up	ADP
dpc-1882	53	28	to	to	PART
dpc-1882	53	29	3	3	NUM
dpc-1882	53	30	years	year	NOUN
dpc-1882	53	31	of	of	ADP
dpc-1882	53	32	ipilimumab	ipilimumab	NOUN
dpc-1882	53	33	in	in	ADP
dpc-1882	53	34	radically	radically	ADV
dpc-1882	53	35	resected	resect	VERB
dpc-1882	53	36	stage	stage	NOUN
dpc-1882	53	37	iii	iii	NOUN
dpc-1882	53	38	or	or	CCONJ
dpc-1882	53	39	iv	iv	NUM
dpc-1882	53	40	melanoma	melanoma	NOUN
dpc-1882	53	41	:	:	PUNCT
dpc-1882	53	42	hr	hr	NOUN
dpc-1882	53	43	for	for	ADP
dpc-1882	53	44	rfs	rfs	PROPN
dpc-1882	53	45	was	be	AUX
dpc-1882	53	46	0.74	0.74	NUM
dpc-1882	53	47	(	(	PUNCT
dpc-1882	53	48	p<0.001	p<0.001	X
dpc-1882	53	49	)	)	PUNCT
dpc-1882	54	1	[	[	X
dpc-1882	54	2	10	10	NUM
dpc-1882	54	3	]	]	PUNCT
dpc-1882	54	4	.	.	PUNCT
dpc-1882	55	1	after	after	SCONJ
dpc-1882	55	2	these	these	DET
dpc-1882	55	3	strong	strong	ADJ
dpc-1882	55	4	evidences	evidence	NOUN
dpc-1882	55	5	,	,	PUNCT
dpc-1882	55	6	nivolumab	nivolumab	NOUN
dpc-1882	55	7	and	and	CCONJ
dpc-1882	55	8	pembrolizumab	pembrolizumab	NOUN
dpc-1882	55	9	were	be	AUX
dpc-1882	55	10	approved	approve	VERB
dpc-1882	55	11	by	by	ADP
dpc-1882	55	12	ema	ema	PROPN
dpc-1882	55	13	as	as	ADP
dpc-1882	55	14	adjuvant	adjuvant	ADJ
dpc-1882	55	15	therapy	therapy	NOUN
dpc-1882	55	16	for	for	ADP
dpc-1882	55	17	all	all	DET
dpc-1882	55	18	stage	stage	NOUN
dpc-1882	55	19	iii	iii	NUM
dpc-1882	55	20	melanomas	melanomas	NOUN
dpc-1882	55	21	(	(	PUNCT
dpc-1882	55	22	nivolumab	nivolumab	NOUN
dpc-1882	55	23	also	also	ADV
dpc-1882	55	24	for	for	ADP
dpc-1882	55	25	radically	radically	ADV
dpc-1882	55	26	resected	resect	VERB
dpc-1882	55	27	stage	stage	NOUN
dpc-1882	55	28	iv	iv	NOUN
dpc-1882	55	29	)	)	PUNCT
dpc-1882	55	30	.	.	PUNCT
dpc-1882	56	1	finally	finally	ADV
dpc-1882	56	2	,	,	PUNCT
dpc-1882	56	3	also	also	ADV
dpc-1882	56	4	the	the	DET
dpc-1882	56	5	combination	combination	NOUN
dpc-1882	56	6	of	of	ADP
dpc-1882	56	7	nivolumab	nivolumab	NOUN
dpc-1882	56	8	and	and	CCONJ
dpc-1882	56	9	ipilimumab	ipilimumab	NOUN
dpc-1882	56	10	has	have	AUX
dpc-1882	56	11	been	be	AUX
dpc-1882	56	12	tested	test	VERB
dpc-1882	56	13	in	in	ADP
dpc-1882	56	14	adjuvant	adjuvant	ADJ
dpc-1882	56	15	settings	setting	NOUN
dpc-1882	56	16	in	in	ADP
dpc-1882	56	17	immuned	immuned	ADJ
dpc-1882	56	18	trial	trial	NOUN
dpc-1882	56	19	and	and	CCONJ
dpc-1882	56	20	checkmate-915	checkmate-915	NOUN
dpc-1882	56	21	trial	trial	NOUN
dpc-1882	56	22	with	with	ADP
dpc-1882	56	23	conflicting	conflicting	ADJ
dpc-1882	56	24	results	result	NOUN
dpc-1882	56	25	.	.	PUNCT
dpc-1882	57	1	in	in	ADP
dpc-1882	57	2	the	the	DET
dpc-1882	57	3	first	first	ADJ
dpc-1882	57	4	case	case	NOUN
dpc-1882	57	5	,	,	PUNCT
dpc-1882	57	6	a	a	DET
dpc-1882	57	7	german	german	ADJ
dpc-1882	57	8	phase	phase	NOUN
dpc-1882	57	9	ii	ii	NOUN
dpc-1882	57	10	trial	trial	NOUN
dpc-1882	57	11	,	,	PUNCT
dpc-1882	57	12	patients	patient	NOUN
dpc-1882	57	13	with	with	ADP
dpc-1882	57	14	radically	radically	ADV
dpc-1882	57	15	resected	resect	VERB
dpc-1882	57	16	stage	stage	NOUN
dpc-1882	57	17	iv	iv	NUM
dpc-1882	57	18	melanoma	melanoma	NOUN
dpc-1882	57	19	were	be	AUX
dpc-1882	57	20	randomly	randomly	ADV
dpc-1882	57	21	assigned	assign	VERB
dpc-1882	57	22	to	to	ADP
dpc-1882	57	23	nivolumab+ipilimumab	nivolumab+ipilimumab	PROPN
dpc-1882	57	24	or	or	CCONJ
dpc-1882	57	25	nivolumab	nivolumab	NOUN
dpc-1882	57	26	alone	alone	ADV
dpc-1882	57	27	,	,	PUNCT
dpc-1882	57	28	or	or	CCONJ
dpc-1882	57	29	placebo	placebo	NOUN
dpc-1882	57	30	.	.	PUNCT
dpc-1882	58	1	hr	hr	NOUN
dpc-1882	58	2	for	for	ADP
dpc-1882	58	3	recurrence	recurrence	NOUN
dpc-1882	58	4	for	for	ADP
dpc-1882	58	5	the	the	DET
dpc-1882	58	6	doublet	doublet	ADJ
dpc-1882	58	7	group	group	NOUN
dpc-1882	58	8	vs	vs	ADP
dpc-1882	58	9	placebo	placebo	NOUN
dpc-1882	58	10	was	be	AUX
dpc-1882	58	11	0.23	0.23	NUM
dpc-1882	58	12	and	and	CCONJ
dpc-1882	58	13	median	median	ADJ
dpc-1882	58	14	rfs	rfs	PROPN
dpc-1882	58	15	was	be	AUX
dpc-1882	58	16	not	not	PART
dpc-1882	58	17	reached	reach	VERB
dpc-1882	58	18	after	after	ADP
dpc-1882	58	19	median	median	ADJ
dpc-1882	58	20	follow	follow	NOUN
dpc-1882	58	21	-	-	PUNCT
dpc-1882	58	22	up	up	NOUN
dpc-1882	58	23	of	of	ADP
dpc-1882	58	24	28.4	28.4	NUM
dpc-1882	58	25	months	month	NOUN
dpc-1882	58	26	[	[	X
dpc-1882	58	27	11	11	NUM
dpc-1882	58	28	]	]	PUNCT
dpc-1882	58	29	.	.	PUNCT
dpc-1882	59	1	on	on	ADP
dpc-1882	59	2	the	the	DET
dpc-1882	59	3	contrary	contrary	NOUN
dpc-1882	59	4	,	,	PUNCT
dpc-1882	59	5	phase	phase	NOUN
dpc-1882	59	6	iii	iii	NUM
dpc-1882	59	7	checkmate-915	checkmate-915	NOUN
dpc-1882	59	8	examined	examine	VERB
dpc-1882	59	9	adjuvant	adjuvant	ADJ
dpc-1882	59	10	nivolumab	nivolumab	NOUN
dpc-1882	59	11	vs	vs	ADP
dpc-1882	59	12	combination	combination	NOUN
dpc-1882	59	13	of	of	ADP
dpc-1882	59	14	nivolumab	nivolumab	NOUN
dpc-1882	59	15	and	and	CCONJ
dpc-1882	59	16	ipilimumab	ipilimumab	VERB
dpc-1882	59	17	in	in	ADP
dpc-1882	59	18	resected	resect	VERB
dpc-1882	59	19	stage	stage	NOUN
dpc-1882	59	20	iiib	iiib	NOUN
dpc-1882	59	21	-	-	PUNCT
dpc-1882	59	22	d	d	NOUN
dpc-1882	59	23	or	or	CCONJ
dpc-1882	59	24	iv	iv	NUM
dpc-1882	59	25	melanomas	melanoma	NOUN
dpc-1882	59	26	,	,	PUNCT
dpc-1882	59	27	but	but	CCONJ
dpc-1882	59	28	it	it	PRON
dpc-1882	59	29	did	do	AUX
dpc-1882	59	30	not	not	PART
dpc-1882	59	31	meet	meet	VERB
dpc-1882	59	32	its	its	PRON
dpc-1882	59	33	endpoint	endpoint	NOUN
dpc-1882	59	34	[	[	X
dpc-1882	59	35	12	12	NUM
dpc-1882	59	36	]	]	PUNCT
dpc-1882	59	37	.	.	PUNCT
dpc-1882	60	1	these	these	DET
dpc-1882	60	2	results	result	NOUN
dpc-1882	60	3	might	might	AUX
dpc-1882	60	4	be	be	AUX
dpc-1882	60	5	due	due	ADJ
dpc-1882	60	6	to	to	ADP
dpc-1882	60	7	the	the	DET
dpc-1882	60	8	different	different	ADJ
dpc-1882	60	9	study	study	NOUN
dpc-1882	60	10	population	population	NOUN
dpc-1882	60	11	and	and	CCONJ
dpc-1882	60	12	to	to	ADP
dpc-1882	60	13	the	the	DET
dpc-1882	60	14	different	different	ADJ
dpc-1882	60	15	dose	dose	PROPN
dpc-1882	60	16	/	/	SYM
dpc-1882	60	17	frequency	frequency	NOUN
dpc-1882	60	18	of	of	ADP
dpc-1882	60	19	ipilimumab	ipilimumab	NOUN
dpc-1882	60	20	,	,	PUNCT
dpc-1882	60	21	nonetheless	nonetheless	ADV
dpc-1882	60	22	further	further	ADJ
dpc-1882	60	23	studies	study	NOUN
dpc-1882	60	24	are	be	AUX
dpc-1882	60	25	needed	need	VERB
dpc-1882	60	26	.	.	PUNCT
dpc-1882	61	1	targeted	target	VERB
dpc-1882	61	2	therapy	therapy	NOUN
dpc-1882	61	3	(	(	PUNCT
dpc-1882	61	4	tt	tt	PROPN
dpc-1882	61	5	)	)	PUNCT
dpc-1882	61	6	as	as	ADP
dpc-1882	61	7	immunotherapies	immunotherapy	NOUN
dpc-1882	61	8	,	,	PUNCT
dpc-1882	61	9	braf	braf	NOUN
dpc-1882	61	10	and	and	CCONJ
dpc-1882	61	11	mek	mek	PROPN
dpc-1882	61	12	inhibitors	inhibitor	NOUN
dpc-1882	61	13	represented	represent	VERB
dpc-1882	61	14	a	a	DET
dpc-1882	61	15	turning	turning	NOUN
dpc-1882	61	16	point	point	NOUN
dpc-1882	61	17	for	for	ADP
dpc-1882	61	18	the	the	DET
dpc-1882	61	19	treatment	treatment	NOUN
dpc-1882	61	20	of	of	ADP
dpc-1882	61	21	braf	braf	NOUN
dpc-1882	61	22	mutant	mutant	NOUN
dpc-1882	61	23	metastatic	metastatic	ADJ
dpc-1882	61	24	melanomas	melanoma	NOUN
dpc-1882	61	25	with	with	ADP
dpc-1882	61	26	very	very	ADV
dpc-1882	61	27	high	high	ADJ
dpc-1882	61	28	response	response	NOUN
dpc-1882	61	29	rates	rate	NOUN
dpc-1882	61	30	and	and	CCONJ
dpc-1882	61	31	a	a	DET
dpc-1882	61	32	significant	significant	ADJ
dpc-1882	61	33	benefit	benefit	NOUN
dpc-1882	61	34	in	in	ADP
dpc-1882	61	35	terms	term	NOUN
dpc-1882	61	36	of	of	ADP
dpc-1882	61	37	pfs	pfs	PROPN
dpc-1882	61	38	and	and	CCONJ
dpc-1882	61	39	os	os	NOUN
dpc-1882	61	40	.	.	PUNCT
dpc-1882	62	1	regarding	regard	VERB
dpc-1882	62	2	the	the	DET
dpc-1882	62	3	efficacy	efficacy	NOUN
dpc-1882	62	4	in	in	ADP
dpc-1882	62	5	the	the	DET
dpc-1882	62	6	adjuvant	adjuvant	ADJ
dpc-1882	62	7	setting	setting	NOUN
dpc-1882	62	8	,	,	PUNCT
dpc-1882	62	9	combi	combi	NOUN
dpc-1882	62	10	-	-	PUNCT
dpc-1882	62	11	ad	ad	NOUN
dpc-1882	62	12	trial	trial	NOUN
dpc-1882	62	13	tried	try	VERB
dpc-1882	62	14	to	to	PART
dpc-1882	62	15	show	show	VERB
dpc-1882	62	16	the	the	DET
dpc-1882	62	17	efficacy	efficacy	NOUN
dpc-1882	62	18	of	of	ADP
dpc-1882	62	19	these	these	DET
dpc-1882	62	20	drugs	drug	NOUN
dpc-1882	62	21	also	also	ADV
dpc-1882	62	22	in	in	ADP
dpc-1882	62	23	the	the	DET
dpc-1882	62	24	adjuvant	adjuvant	ADJ
dpc-1882	62	25	setting	setting	NOUN
dpc-1882	62	26	.	.	PUNCT
dpc-1882	63	1	it	it	PRON
dpc-1882	63	2	compared	compare	VERB
dpc-1882	63	3	dabrafenib	dabrafenib	NOUN
dpc-1882	63	4	(	(	PUNCT
dpc-1882	63	5	braf	braf	NOUN
dpc-1882	63	6	inhibitor	inhibitor	NOUN
dpc-1882	63	7	)	)	PUNCT
dpc-1882	63	8	150	150	NUM
dpc-1882	63	9	mg	mg	NOUN
dpc-1882	63	10	twice	twice	ADV
dpc-1882	63	11	daily	daily	ADV
dpc-1882	63	12	plus	plus	CCONJ
dpc-1882	63	13	trametinib	trametinib	NOUN
dpc-1882	63	14	(	(	PUNCT
dpc-1882	63	15	mek	mek	PROPN
dpc-1882	63	16	inhibitor	inhibitor	NOUN
dpc-1882	63	17	)	)	PUNCT
dpc-1882	63	18	at	at	ADP
dpc-1882	63	19	a	a	DET
dpc-1882	63	20	dose	dose	NOUN
dpc-1882	63	21	of	of	ADP
dpc-1882	63	22	2	2	NUM
dpc-1882	63	23	mg	mg	NOUN
dpc-1882	63	24	once	once	ADV
dpc-1882	63	25	daily	daily	ADV
dpc-1882	63	26	,	,	PUNCT
dpc-1882	63	27	versus	versus	ADP
dpc-1882	63	28	placebo	placebo	NOUN
dpc-1882	63	29	in	in	ADP
dpc-1882	63	30	stage	stage	NOUN
dpc-1882	63	31	iiia	iiia	NOUN
dpc-1882	63	32	-	-	PUNCT
dpc-1882	63	33	b	b	NOUN
dpc-1882	63	34	-	-	PUNCT
dpc-1882	63	35	c	c	NOUN
dpc-1882	63	36	melanoma	melanoma	NOUN
dpc-1882	63	37	.	.	PUNCT
dpc-1882	64	1	in	in	ADP
dpc-1882	64	2	the	the	DET
dpc-1882	64	3	last	last	ADJ
dpc-1882	64	4	update	update	NOUN
dpc-1882	64	5	,	,	PUNCT
dpc-1882	64	6	3	3	NUM
dpc-1882	64	7	-	-	PUNCT
dpc-1882	64	8	years	year	NOUN
dpc-1882	64	9	rfs	rfs	NOUN
dpc-1882	64	10	was	be	AUX
dpc-1882	64	11	58	58	NUM
dpc-1882	64	12	%	%	NOUN
dpc-1882	64	13	in	in	ADP
dpc-1882	64	14	the	the	DET
dpc-1882	64	15	experimental	experimental	ADJ
dpc-1882	64	16	arm	arm	NOUN
dpc-1882	64	17	and	and	CCONJ
dpc-1882	64	18	39	39	NUM
dpc-1882	64	19	%	%	NOUN
dpc-1882	64	20	in	in	ADP
dpc-1882	64	21	the	the	DET
dpc-1882	64	22	placebo	placebo	NOUN
dpc-1882	64	23	arm	arm	NOUN
dpc-1882	64	24	(	(	PUNCT
dpc-1882	64	25	hr	hr	NOUN
dpc-1882	64	26	0.47	0.47	NUM
dpc-1882	64	27	p<0.001	p<0.001	X
dpc-1882	64	28	)	)	PUNCT
dpc-1882	65	1	[	[	X
dpc-1882	65	2	13	13	NUM
dpc-1882	65	3	]	]	PUNCT
dpc-1882	65	4	.	.	PUNCT
dpc-1882	66	1	adverse	adverse	ADJ
dpc-1882	66	2	events	event	NOUN
dpc-1882	66	3	were	be	AUX
dpc-1882	66	4	repreidentifying	repreidentifye	VERB
dpc-1882	66	5	the	the	DET
dpc-1882	66	6	best	good	ADJ
dpc-1882	66	7	approach	approach	NOUN
dpc-1882	66	8	to	to	PART
dpc-1882	66	9	continue	continue	VERB
dpc-1882	66	10	the	the	DET
dpc-1882	66	11	therapeutic	therapeutic	ADJ
dpc-1882	66	12	process	process	NOUN
dpc-1882	66	13	in	in	ADP
dpc-1882	66	14	case	case	NOUN
dpc-1882	66	15	of	of	ADP
dpc-1882	66	16	relapse	relapse	NOUN
dpc-1882	66	17	.	.	PUNCT
dpc-1882	67	1	furthermore	furthermore	ADV
dpc-1882	67	2	,	,	PUNCT
dpc-1882	67	3	there	there	PRON
dpc-1882	67	4	are	be	VERB
dpc-1882	67	5	new	new	ADJ
dpc-1882	67	6	opportunities	opportunity	NOUN
dpc-1882	67	7	opening	open	VERB
dpc-1882	67	8	up	up	ADP
dpc-1882	67	9	with	with	ADP
dpc-1882	67	10	the	the	DET
dpc-1882	67	11	upcoming	upcoming	ADJ
dpc-1882	67	12	results	result	NOUN
dpc-1882	67	13	of	of	ADP
dpc-1882	67	14	the	the	DET
dpc-1882	67	15	neoadjuvant	neoadjuvant	ADJ
dpc-1882	67	16	trials	trial	NOUN
dpc-1882	67	17	that	that	PRON
dpc-1882	67	18	could	could	AUX
dpc-1882	67	19	revolutionize	revolutionize	VERB
dpc-1882	67	20	the	the	DET
dpc-1882	67	21	treatment	treatment	NOUN
dpc-1882	67	22	of	of	ADP
dpc-1882	67	23	clinically	clinically	ADV
dpc-1882	67	24	evident	evident	ADJ
dpc-1882	67	25	stage	stage	NOUN
dpc-1882	67	26	iii	iii	NUM
dpc-1882	67	27	melanoma	melanoma	NOUN
dpc-1882	67	28	.	.	PUNCT
dpc-1882	68	1	review	review	VERB
dpc-1882	68	2	|	|	ADV
dpc-1882	68	3	dermatol	dermatol	ADJ
dpc-1882	68	4	pract	pract	NOUN
dpc-1882	68	5	concept	concept	NOUN
dpc-1882	68	6	.	.	PUNCT
dpc-1882	69	1	2021;11(s1	2021;11(s1	NUM
dpc-1882	69	2	):	):	PUNCT
dpc-1882	69	3	e2021165s	e2021165s	X
dpc-1882	69	4	3	3	NUM
dpc-1882	69	5	sented	sente	VERB
dpc-1882	69	6	by	by	ADP
dpc-1882	69	7	pyrexia	pyrexia	NOUN
dpc-1882	69	8	,	,	PUNCT
dpc-1882	69	9	fatigue	fatigue	NOUN
dpc-1882	69	10	,	,	PUNCT
dpc-1882	69	11	nausea	nausea	NOUN
dpc-1882	69	12	,	,	PUNCT
dpc-1882	69	13	headache	headache	NOUN
dpc-1882	69	14	,	,	PUNCT
dpc-1882	69	15	chills	chill	NOUN
dpc-1882	69	16	,	,	PUNCT
dpc-1882	69	17	diarrhea	diarrhea	PROPN
dpc-1882	69	18	,	,	PUNCT
dpc-1882	69	19	arthralgia	arthralgia	NOUN
dpc-1882	69	20	,	,	PUNCT
dpc-1882	69	21	and	and	CCONJ
dpc-1882	69	22	rash	rash	NOUN
dpc-1882	69	23	.	.	PUNCT
dpc-1882	70	1	these	these	PRON
dpc-1882	70	2	were	be	AUX
dpc-1882	70	3	of	of	ADP
dpc-1882	70	4	grade	grade	NOUN
dpc-1882	70	5	3	3	NUM
dpc-1882	70	6	to	to	ADP
dpc-1882	70	7	5	5	NUM
dpc-1882	70	8	in	in	ADP
dpc-1882	70	9	41	41	NUM
dpc-1882	70	10	%	%	NOUN
dpc-1882	70	11	of	of	ADP
dpc-1882	70	12	cases	case	NOUN
dpc-1882	70	13	.	.	PUNCT
dpc-1882	71	1	however	however	ADV
dpc-1882	71	2	,	,	PUNCT
dpc-1882	71	3	also	also	ADV
dpc-1882	71	4	dabrafenib	dabrafenib	NOUN
dpc-1882	71	5	plus	plus	CCONJ
dpc-1882	71	6	trametinib	trametinib	NOUN
dpc-1882	71	7	became	become	VERB
dpc-1882	71	8	a	a	DET
dpc-1882	71	9	valid	valid	ADJ
dpc-1882	71	10	option	option	NOUN
dpc-1882	71	11	as	as	ADP
dpc-1882	71	12	adjuvant	adjuvant	ADJ
dpc-1882	71	13	therapy	therapy	NOUN
dpc-1882	71	14	.	.	PUNCT
dpc-1882	72	1	open	open	ADJ
dpc-1882	72	2	questions	question	NOUN
dpc-1882	72	3	on	on	ADP
dpc-1882	72	4	adjuvant	adjuvant	ADJ
dpc-1882	72	5	therapy	therapy	NOUN
dpc-1882	72	6	and	and	CCONJ
dpc-1882	72	7	how	how	SCONJ
dpc-1882	72	8	to	to	PART
dpc-1882	72	9	manage	manage	VERB
dpc-1882	72	10	recurrences	recurrence	NOUN
dpc-1882	72	11	despite	despite	SCONJ
dpc-1882	72	12	the	the	DET
dpc-1882	72	13	undoubted	undoubted	ADJ
dpc-1882	72	14	effectiveness	effectiveness	NOUN
dpc-1882	72	15	of	of	ADP
dpc-1882	72	16	these	these	DET
dpc-1882	72	17	therapies	therapy	NOUN
dpc-1882	72	18	,	,	PUNCT
dpc-1882	72	19	a	a	DET
dpc-1882	72	20	number	number	NOUN
dpc-1882	72	21	of	of	ADP
dpc-1882	72	22	open	open	ADJ
dpc-1882	72	23	questions	question	NOUN
dpc-1882	72	24	still	still	ADV
dpc-1882	72	25	remain	remain	VERB
dpc-1882	72	26	open	open	ADJ
dpc-1882	72	27	.	.	PUNCT
dpc-1882	73	1	these	these	DET
dpc-1882	73	2	concern	concern	NOUN
dpc-1882	73	3	for	for	ADP
dpc-1882	73	4	instance	instance	NOUN
dpc-1882	73	5	the	the	DET
dpc-1882	73	6	timing	timing	NOUN
dpc-1882	73	7	of	of	ADP
dpc-1882	73	8	their	their	PRON
dpc-1882	73	9	use	use	NOUN
dpc-1882	73	10	and	and	CCONJ
dpc-1882	73	11	the	the	DET
dpc-1882	73	12	risk	risk	NOUN
dpc-1882	73	13	/	/	SYM
dpc-1882	73	14	benefit	benefit	NOUN
dpc-1882	73	15	ratio	ratio	NOUN
dpc-1882	73	16	in	in	ADP
dpc-1882	73	17	some	some	DET
dpc-1882	73	18	subgroups	subgroup	NOUN
dpc-1882	73	19	of	of	ADP
dpc-1882	73	20	patients	patient	NOUN
dpc-1882	73	21	.	.	PUNCT
dpc-1882	74	1	first	first	ADV
dpc-1882	74	2	of	of	ADP
dpc-1882	74	3	all	all	PRON
dpc-1882	74	4	,	,	PUNCT
dpc-1882	74	5	there	there	PRON
dpc-1882	74	6	is	be	VERB
dpc-1882	74	7	still	still	ADV
dpc-1882	74	8	no	no	DET
dpc-1882	74	9	evidence	evidence	NOUN
dpc-1882	74	10	regarding	regard	VERB
dpc-1882	74	11	the	the	DET
dpc-1882	74	12	benefit	benefit	NOUN
dpc-1882	74	13	in	in	ADP
dpc-1882	74	14	survival	survival	NOUN
dpc-1882	74	15	rates	rate	NOUN
dpc-1882	74	16	:	:	PUNCT
dpc-1882	74	17	although	although	SCONJ
dpc-1882	74	18	ipilimumab	ipilimumab	NOUN
dpc-1882	74	19	had	have	AUX
dpc-1882	74	20	already	already	ADV
dpc-1882	74	21	demonstrated	demonstrate	VERB
dpc-1882	74	22	an	an	DET
dpc-1882	74	23	os	os	NOUN
dpc-1882	74	24	advantage	advantage	NOUN
dpc-1882	74	25	vs	vs	ADP
dpc-1882	74	26	placebo	placebo	NOUN
dpc-1882	74	27	,	,	PUNCT
dpc-1882	74	28	in	in	ADP
dpc-1882	74	29	the	the	DET
dpc-1882	74	30	checkmate-238	checkmate-238	NOUN
dpc-1882	74	31	,	,	PUNCT
dpc-1882	74	32	following	follow	VERB
dpc-1882	74	33	a	a	DET
dpc-1882	74	34	48	48	NUM
dpc-1882	74	35	months	month	NOUN
dpc-1882	74	36	follow	follow	VERB
dpc-1882	74	37	-	-	PUNCT
dpc-1882	74	38	up	up	NOUN
dpc-1882	74	39	there	there	PRON
dpc-1882	74	40	are	be	VERB
dpc-1882	74	41	no	no	DET
dpc-1882	74	42	differences	difference	NOUN
dpc-1882	74	43	in	in	ADP
dpc-1882	74	44	os	os	NOUN
dpc-1882	74	45	between	between	ADP
dpc-1882	74	46	nivolumab	nivolumab	NOUN
dpc-1882	74	47	and	and	CCONJ
dpc-1882	74	48	ipilimumab	ipilimumab	NOUN
dpc-1882	74	49	(	(	PUNCT
dpc-1882	74	50	78	78	NUM
dpc-1882	74	51	%	%	NOUN
dpc-1882	74	52	vs	vs	ADP
dpc-1882	74	53	77	77	NUM
dpc-1882	74	54	%	%	NOUN
dpc-1882	74	55	,	,	PUNCT
dpc-1882	74	56	hr	hr	NOUN
dpc-1882	74	57	0.87	0.87	NUM
dpc-1882	74	58	p=0.315)[8	p=0.315)[8	NOUN
dpc-1882	74	59	]	]	PUNCT
dpc-1882	74	60	.	.	PUNCT
dpc-1882	75	1	however	however	ADV
dpc-1882	75	2	,	,	PUNCT
dpc-1882	75	3	fewer	few	ADJ
dpc-1882	75	4	events	event	NOUN
dpc-1882	75	5	than	than	SCONJ
dpc-1882	75	6	expected	expect	VERB
dpc-1882	75	7	occurred	occur	VERB
dpc-1882	75	8	in	in	ADP
dpc-1882	75	9	the	the	DET
dpc-1882	75	10	trials	trial	NOUN
dpc-1882	75	11	,	,	PUNCT
dpc-1882	75	12	so	so	CCONJ
dpc-1882	75	13	it	it	PRON
dpc-1882	75	14	is	be	AUX
dpc-1882	75	15	underpowered	underpowered	ADJ
dpc-1882	75	16	.	.	PUNCT
dpc-1882	76	1	also	also	ADV
dpc-1882	76	2	,	,	PUNCT
dpc-1882	76	3	for	for	ADP
dpc-1882	76	4	pembrolizumab	pembrolizumab	NOUN
dpc-1882	76	5	in	in	ADP
dpc-1882	76	6	s1404	s1404	PROPN
dpc-1882	76	7	no	no	DET
dpc-1882	76	8	benefit	benefit	NOUN
dpc-1882	76	9	in	in	ADP
dpc-1882	76	10	os	os	NOUN
dpc-1882	76	11	was	be	AUX
dpc-1882	76	12	observed	observe	VERB
dpc-1882	76	13	[	[	X
dpc-1882	76	14	10	10	NUM
dpc-1882	76	15	]	]	PUNCT
dpc-1882	76	16	.	.	PUNCT
dpc-1882	77	1	moreover	moreover	ADV
dpc-1882	77	2	,	,	PUNCT
dpc-1882	77	3	in	in	ADP
dpc-1882	77	4	the	the	DET
dpc-1882	77	5	combi	combi	NOUN
dpc-1882	77	6	-	-	PUNCT
dpc-1882	77	7	ad	ad	NOUN
dpc-1882	77	8	trial	trial	NOUN
dpc-1882	77	9	the	the	DET
dpc-1882	77	10	statistical	statistical	ADJ
dpc-1882	77	11	significance	significance	NOUN
dpc-1882	77	12	did	do	AUX
dpc-1882	77	13	not	not	PART
dpc-1882	77	14	reach	reach	VERB
dpc-1882	77	15	the	the	DET
dpc-1882	77	16	prespecified	prespecified	ADJ
dpc-1882	77	17	target	target	NOUN
dpc-1882	77	18	of	of	ADP
dpc-1882	77	19	p=0.000019	p=0.000019	PROPN
dpc-1882	77	20	(	(	PUNCT
dpc-1882	77	21	3	3	NUM
dpc-1882	77	22	-	-	PUNCT
dpc-1882	77	23	years	year	NOUN
dpc-1882	77	24	os	os	NOUN
dpc-1882	77	25	:	:	PUNCT
dpc-1882	77	26	86	86	NUM
dpc-1882	77	27	%	%	NOUN
dpc-1882	77	28	vs	vs	ADP
dpc-1882	77	29	77	77	NUM
dpc-1882	77	30	%	%	NOUN
dpc-1882	77	31	,	,	PUNCT
dpc-1882	77	32	hr	hr	NOUN
dpc-1882	77	33	0.57	0.57	NUM
dpc-1882	77	34	p=0.0006	p=0.0006	NUM
dpc-1882	77	35	)	)	PUNCT
dpc-1882	78	1	[	[	X
dpc-1882	78	2	13	13	NUM
dpc-1882	78	3	]	]	PUNCT
dpc-1882	78	4	.	.	PUNCT
dpc-1882	79	1	definitive	definitive	ADJ
dpc-1882	79	2	data	datum	NOUN
dpc-1882	79	3	of	of	ADP
dpc-1882	79	4	these	these	DET
dpc-1882	79	5	2	2	NUM
dpc-1882	79	6	studies	study	NOUN
dpc-1882	79	7	and	and	CCONJ
dpc-1882	79	8	of	of	ADP
dpc-1882	79	9	keynote-054	keynote-054	NOUN
dpc-1882	79	10	,	,	PUNCT
dpc-1882	79	11	the	the	DET
dpc-1882	79	12	only	only	ADJ
dpc-1882	79	13	study	study	NOUN
dpc-1882	79	14	in	in	ADP
dpc-1882	79	15	which	which	PRON
dpc-1882	79	16	a	a	DET
dpc-1882	79	17	cross	cross	NOUN
dpc-1882	79	18	-	-	ADJ
dpc-1882	79	19	over	over	ADV
dpc-1882	79	20	between	between	ADP
dpc-1882	79	21	treatments	treatment	NOUN
dpc-1882	79	22	was	be	AUX
dpc-1882	79	23	allowed	allow	VERB
dpc-1882	79	24	,	,	PUNCT
dpc-1882	79	25	will	will	AUX
dpc-1882	79	26	clarify	clarify	VERB
dpc-1882	79	27	if	if	SCONJ
dpc-1882	79	28	starting	start	VERB
dpc-1882	79	29	the	the	DET
dpc-1882	79	30	therapy	therapy	NOUN
dpc-1882	79	31	at	at	ADP
dpc-1882	79	32	the	the	DET
dpc-1882	79	33	time	time	NOUN
dpc-1882	79	34	of	of	ADP
dpc-1882	79	35	relapse	relapse	NOUN
dpc-1882	79	36	affects	affect	VERB
dpc-1882	79	37	survival	survival	NOUN
dpc-1882	79	38	rates	rate	NOUN
dpc-1882	79	39	.	.	PUNCT
dpc-1882	80	1	a	a	DET
dpc-1882	80	2	second	second	ADJ
dpc-1882	80	3	important	important	ADJ
dpc-1882	80	4	aspect	aspect	NOUN
dpc-1882	80	5	is	be	AUX
dpc-1882	80	6	that	that	SCONJ
dpc-1882	80	7	all	all	DET
dpc-1882	80	8	these	these	DET
dpc-1882	80	9	studies	study	NOUN
dpc-1882	80	10	started	start	VERB
dpc-1882	80	11	before	before	ADP
dpc-1882	80	12	the	the	DET
dpc-1882	80	13	definitive	definitive	ADJ
dpc-1882	80	14	data	datum	NOUN
dpc-1882	80	15	of	of	ADP
dpc-1882	80	16	multicentre	multicentre	NOUN
dpc-1882	80	17	selective	selective	ADJ
dpc-1882	80	18	lympadenectomy	lympadenectomy	NOUN
dpc-1882	80	19	trial	trial	NOUN
dpc-1882	80	20	ii	ii	NOUN
dpc-1882	81	1	[	[	X
dpc-1882	81	2	14	14	NUM
dpc-1882	81	3	]	]	PUNCT
dpc-1882	81	4	and	and	CCONJ
dpc-1882	81	5	the	the	DET
dpc-1882	81	6	german	german	ADJ
dpc-1882	81	7	dermatologic	dermatologic	ADJ
dpc-1882	81	8	cooperative	cooperative	ADJ
dpc-1882	81	9	oncology	oncology	NOUN
dpc-1882	81	10	group	group	NOUN
dpc-1882	81	11	-	-	PUNCT
dpc-1882	81	12	selective	selective	ADJ
dpc-1882	81	13	lymphadenectomy	lymphadenectomy	NOUN
dpc-1882	81	14	trial	trial	NOUN
dpc-1882	81	15	[	[	X
dpc-1882	81	16	15	15	NUM
dpc-1882	81	17	]	]	PUNCT
dpc-1882	81	18	,	,	PUNCT
dpc-1882	81	19	that	that	PRON
dpc-1882	81	20	did	do	AUX
dpc-1882	81	21	not	not	PART
dpc-1882	81	22	report	report	VERB
dpc-1882	81	23	an	an	DET
dpc-1882	81	24	improvement	improvement	NOUN
dpc-1882	81	25	in	in	ADP
dpc-1882	81	26	melanoma	melanoma	NOUN
dpc-1882	81	27	specific	specific	ADJ
dpc-1882	81	28	survival	survival	NOUN
dpc-1882	81	29	(	(	PUNCT
dpc-1882	81	30	mss	mss	PROPN
dpc-1882	81	31	)	)	PUNCT
dpc-1882	81	32	for	for	ADP
dpc-1882	81	33	complete	complete	ADJ
dpc-1882	81	34	lymph	lymph	NOUN
dpc-1882	81	35	node	node	NOUN
dpc-1882	81	36	dissection	dissection	NOUN
dpc-1882	81	37	versus	versus	ADP
dpc-1882	81	38	periodic	periodic	ADJ
dpc-1882	81	39	ultrasonographic	ultrasonographic	ADJ
dpc-1882	81	40	surveillance	surveillance	NOUN
dpc-1882	81	41	in	in	ADP
dpc-1882	81	42	patients	patient	NOUN
dpc-1882	81	43	with	with	ADP
dpc-1882	81	44	positive	positive	ADJ
dpc-1882	81	45	sentinel	sentinel	NOUN
dpc-1882	81	46	lymph	lymph	NOUN
dpc-1882	81	47	node	node	NOUN
dpc-1882	81	48	.	.	PUNCT
dpc-1882	82	1	this	this	PRON
dpc-1882	82	2	suggests	suggest	VERB
dpc-1882	82	3	that	that	SCONJ
dpc-1882	82	4	the	the	DET
dpc-1882	82	5	study	study	NOUN
dpc-1882	82	6	population	population	NOUN
dpc-1882	82	7	does	do	AUX
dpc-1882	82	8	not	not	PART
dpc-1882	82	9	correspond	correspond	VERB
dpc-1882	82	10	to	to	ADP
dpc-1882	82	11	patients	patient	NOUN
dpc-1882	82	12	treated	treat	VERB
dpc-1882	82	13	in	in	ADP
dpc-1882	82	14	current	current	ADJ
dpc-1882	82	15	clinical	clinical	ADJ
dpc-1882	82	16	practice	practice	NOUN
dpc-1882	82	17	.	.	PUNCT
dpc-1882	83	1	moreover	moreover	ADV
dpc-1882	83	2	,	,	PUNCT
dpc-1882	83	3	the	the	DET
dpc-1882	83	4	new	new	ADJ
dpc-1882	83	5	edition	edition	NOUN
dpc-1882	83	6	of	of	ADP
dpc-1882	83	7	ajcc	ajcc	PROPN
dpc-1882	83	8	staging	staging	NOUN
dpc-1882	83	9	was	be	AUX
dpc-1882	83	10	approved	approve	VERB
dpc-1882	83	11	and	and	CCONJ
dpc-1882	83	12	the	the	DET
dpc-1882	83	13	main	main	ADJ
dpc-1882	83	14	changes	change	NOUN
dpc-1882	83	15	concerned	concerned	ADJ
dpc-1882	83	16	stage	stage	NOUN
dpc-1882	83	17	iii	iii	NOUN
dpc-1882	83	18	:	:	PUNCT
dpc-1882	83	19	stage	stage	NOUN
dpc-1882	83	20	iiid	iiid	NOUN
dpc-1882	83	21	was	be	AUX
dpc-1882	83	22	added	add	VERB
dpc-1882	83	23	,	,	PUNCT
dpc-1882	83	24	and	and	CCONJ
dpc-1882	83	25	the	the	DET
dpc-1882	83	26	subgroups	subgroup	NOUN
dpc-1882	83	27	were	be	AUX
dpc-1882	83	28	re	re	VERB
dpc-1882	83	29	-	-	VERB
dpc-1882	83	30	distributed	distribute	VERB
dpc-1882	83	31	.	.	PUNCT
dpc-1882	84	1	more	more	ADJ
dpc-1882	84	2	in	in	ADP
dpc-1882	84	3	detail	detail	NOUN
dpc-1882	84	4	,	,	PUNCT
dpc-1882	84	5	stage	stage	NOUN
dpc-1882	84	6	iiia	iiia	NOUN
dpc-1882	84	7	now	now	ADV
dpc-1882	84	8	includes	include	VERB
dpc-1882	84	9	t1a	t1a	NOUN
dpc-1882	84	10	-	-	PUNCT
dpc-1882	84	11	b	b	NOUN
dpc-1882	84	12	n1	n1	NOUN
dpc-1882	84	13	-	-	PUNCT
dpc-1882	84	14	2a	2a	NUM
dpc-1882	84	15	and	and	CCONJ
dpc-1882	84	16	t2a	t2a	ADP
dpc-1882	84	17	n1	n1	NOUN
dpc-1882	84	18	-	-	PUNCT
dpc-1882	84	19	2a	2a	NUM
dpc-1882	85	1	[	[	X
dpc-1882	85	2	16	16	NUM
dpc-1882	85	3	]	]	PUNCT
dpc-1882	85	4	.	.	PUNCT
dpc-1882	86	1	in	in	ADP
dpc-1882	86	2	the	the	DET
dpc-1882	86	3	adjuvant	adjuvant	ADJ
dpc-1882	86	4	trials	trial	NOUN
dpc-1882	86	5	,	,	PUNCT
dpc-1882	86	6	only	only	ADV
dpc-1882	86	7	patients	patient	NOUN
dpc-1882	86	8	categorized	categorize	VERB
dpc-1882	86	9	as	as	ADP
dpc-1882	86	10	stage	stage	NOUN
dpc-1882	86	11	iiia	iiia	NOUN
dpc-1882	86	12	with	with	ADP
dpc-1882	86	13	nodal	nodal	NOUN
dpc-1882	86	14	metastases	metastasis	NOUN
dpc-1882	86	15	>	>	X
dpc-1882	86	16	1	1	NUM
dpc-1882	86	17	mm	mm	NOUN
dpc-1882	86	18	(	(	PUNCT
dpc-1882	86	19	checkmate-238	checkmate-238	NOUN
dpc-1882	86	20	did	do	AUX
dpc-1882	86	21	not	not	PART
dpc-1882	86	22	include	include	VERB
dpc-1882	86	23	them	they	PRON
dpc-1882	86	24	)	)	PUNCT
dpc-1882	86	25	,	,	PUNCT
dpc-1882	86	26	were	be	AUX
dpc-1882	86	27	included	include	VERB
dpc-1882	86	28	.	.	PUNCT
dpc-1882	87	1	furthermore	furthermore	ADV
dpc-1882	87	2	,	,	PUNCT
dpc-1882	87	3	patients	patient	NOUN
dpc-1882	87	4	enrolled	enrol	VERB
dpc-1882	87	5	in	in	ADP
dpc-1882	87	6	these	these	DET
dpc-1882	87	7	trials	trial	NOUN
dpc-1882	87	8	with	with	ADP
dpc-1882	87	9	positive	positive	ADJ
dpc-1882	87	10	sln	sln	NOUN
dpc-1882	87	11	have	have	AUX
dpc-1882	87	12	had	have	VERB
dpc-1882	87	13	lymphadenectomy	lymphadenectomy	NOUN
dpc-1882	87	14	,	,	PUNCT
dpc-1882	87	15	indicating	indicate	VERB
dpc-1882	87	16	that	that	SCONJ
dpc-1882	87	17	some	some	PRON
dpc-1882	87	18	of	of	ADP
dpc-1882	87	19	the	the	DET
dpc-1882	87	20	stage	stage	NOUN
dpc-1882	87	21	iiia	iiia	NOUN
dpc-1882	87	22	may	may	AUX
dpc-1882	87	23	be	be	AUX
dpc-1882	87	24	up	up	ADV
dpc-1882	87	25	-	-	PUNCT
dpc-1882	87	26	staged	stage	VERB
dpc-1882	87	27	.	.	PUNCT
dpc-1882	88	1	on	on	ADP
dpc-1882	88	2	the	the	DET
dpc-1882	88	3	other	other	ADJ
dpc-1882	88	4	hand	hand	NOUN
dpc-1882	88	5	,	,	PUNCT
dpc-1882	88	6	in	in	ADP
dpc-1882	88	7	clinical	clinical	ADJ
dpc-1882	88	8	practice	practice	NOUN
dpc-1882	88	9	,	,	PUNCT
dpc-1882	88	10	several	several	ADJ
dpc-1882	88	11	patients	patient	NOUN
dpc-1882	88	12	without	without	ADP
dpc-1882	88	13	nodal	nodal	NOUN
dpc-1882	88	14	dissection	dissection	NOUN
dpc-1882	88	15	could	could	AUX
dpc-1882	88	16	be	be	AUX
dpc-1882	88	17	downgraded	downgrade	VERB
dpc-1882	88	18	to	to	PART
dpc-1882	88	19	iiia	iiia	VERB
dpc-1882	88	20	(	(	PUNCT
dpc-1882	88	21	for	for	ADP
dpc-1882	88	22	example	example	NOUN
dpc-1882	88	23	if	if	SCONJ
dpc-1882	88	24	they	they	PRON
dpc-1882	88	25	have	have	VERB
dpc-1882	88	26	metastatic	metastatic	ADJ
dpc-1882	88	27	non	non	ADJ
dpc-1882	88	28	-	-	ADJ
dpc-1882	88	29	sentinel	sentinel	ADJ
dpc-1882	88	30	lymph	lymph	NOUN
dpc-1882	88	31	nodes	node	NOUN
dpc-1882	88	32	)	)	PUNCT
dpc-1882	88	33	.	.	PUNCT
dpc-1882	89	1	however	however	ADV
dpc-1882	89	2	,	,	PUNCT
dpc-1882	89	3	taking	take	VERB
dpc-1882	89	4	into	into	ADP
dpc-1882	89	5	account	account	NOUN
dpc-1882	89	6	the	the	DET
dpc-1882	89	7	high	high	ADJ
dpc-1882	89	8	melanoma	melanoma	NOUN
dpc-1882	89	9	specific	specific	ADJ
dpc-1882	89	10	survival	survival	NOUN
dpc-1882	89	11	in	in	ADP
dpc-1882	89	12	this	this	DET
dpc-1882	89	13	stage	stage	NOUN
dpc-1882	89	14	(	(	PUNCT
dpc-1882	89	15	80%-93	80%-93	NUM
dpc-1882	89	16	%	%	NOUN
dpc-1882	89	17	)	)	PUNCT
dpc-1882	90	1	[	[	X
dpc-1882	90	2	17	17	NUM
dpc-1882	90	3	]	]	PUNCT
dpc-1882	90	4	,	,	PUNCT
dpc-1882	90	5	and	and	CCONJ
dpc-1882	90	6	the	the	DET
dpc-1882	90	7	risks	risk	NOUN
dpc-1882	90	8	of	of	ADP
dpc-1882	90	9	durable	durable	ADJ
dpc-1882	90	10	and	and	CCONJ
dpc-1882	90	11	serious	serious	ADJ
dpc-1882	90	12	adverse	adverse	ADJ
dpc-1882	90	13	events	event	NOUN
dpc-1882	90	14	,	,	PUNCT
dpc-1882	90	15	adjuvant	adjuvant	ADJ
dpc-1882	90	16	therapy	therapy	NOUN
dpc-1882	90	17	should	should	AUX
dpc-1882	90	18	be	be	AUX
dpc-1882	90	19	carefully	carefully	ADV
dpc-1882	90	20	discussed	discuss	VERB
dpc-1882	90	21	with	with	ADP
dpc-1882	90	22	these	these	DET
dpc-1882	90	23	patients	patient	NOUN
dpc-1882	91	1	[	[	X
dpc-1882	91	2	18	18	NUM
dpc-1882	91	3	]	]	PUNCT
dpc-1882	91	4	.	.	PUNCT
dpc-1882	92	1	finally	finally	ADV
dpc-1882	92	2	,	,	PUNCT
dpc-1882	92	3	an	an	DET
dpc-1882	92	4	unmet	unmet	NOUN
dpc-1882	92	5	need	need	NOUN
dpc-1882	92	6	that	that	PRON
dpc-1882	92	7	originated	originate	VERB
dpc-1882	92	8	from	from	ADP
dpc-1882	92	9	adjuvant	adjuvant	ADJ
dpc-1882	92	10	trials	trial	NOUN
dpc-1882	92	11	is	be	AUX
dpc-1882	92	12	the	the	DET
dpc-1882	92	13	management	management	NOUN
dpc-1882	92	14	of	of	ADP
dpc-1882	92	15	relapses	relapse	NOUN
dpc-1882	92	16	during	during	ADP
dpc-1882	92	17	and	and	CCONJ
dpc-1882	92	18	after	after	ADP
dpc-1882	92	19	treatment	treatment	NOUN
dpc-1882	92	20	.	.	PUNCT
dpc-1882	93	1	there	there	PRON
dpc-1882	93	2	is	be	VERB
dpc-1882	93	3	in	in	ADP
dpc-1882	93	4	fact	fact	NOUN
dpc-1882	93	5	a	a	DET
dpc-1882	93	6	lack	lack	NOUN
dpc-1882	93	7	of	of	ADP
dpc-1882	93	8	prospective	prospective	ADJ
dpc-1882	93	9	randomized	randomized	ADJ
dpc-1882	93	10	studies	study	NOUN
dpc-1882	93	11	investigating	investigate	VERB
dpc-1882	93	12	this	this	DET
dpc-1882	93	13	question	question	NOUN
dpc-1882	93	14	,	,	PUNCT
dpc-1882	93	15	as	as	SCONJ
dpc-1882	93	16	only	only	ADV
dpc-1882	93	17	retrospective	retrospective	ADJ
dpc-1882	93	18	experiences	experience	NOUN
dpc-1882	93	19	are	be	AUX
dpc-1882	93	20	reported	report	VERB
dpc-1882	93	21	.	.	PUNCT
dpc-1882	94	1	what	what	PRON
dpc-1882	94	2	we	we	PRON
dpc-1882	94	3	know	know	VERB
dpc-1882	94	4	is	be	AUX
dpc-1882	94	5	that	that	SCONJ
dpc-1882	94	6	the	the	DET
dpc-1882	94	7	majority	majority	NOUN
dpc-1882	94	8	of	of	ADP
dpc-1882	94	9	recurrences	recurrence	NOUN
dpc-1882	94	10	are	be	AUX
dpc-1882	94	11	with	with	ADP
dpc-1882	94	12	distant	distant	ADJ
dpc-1882	94	13	metastases	metastasis	NOUN
dpc-1882	94	14	(	(	PUNCT
dpc-1882	94	15	including	include	VERB
dpc-1882	94	16	locoregional+distant	locoregional+distant	ADJ
dpc-1882	94	17	metastases	metastasis	NOUN
dpc-1882	94	18	)	)	PUNCT
dpc-1882	94	19	and	and	CCONJ
dpc-1882	94	20	they	they	PRON
dpc-1882	94	21	are	be	AUX
dpc-1882	94	22	mostly	mostly	ADV
dpc-1882	94	23	on	on	ADP
dpc-1882	94	24	-	-	PUNCT
dpc-1882	94	25	treatment	treatment	NOUN
dpc-1882	94	26	during	during	ADP
dpc-1882	94	27	anti	anti	ADJ
dpc-1882	94	28	-	-	ADJ
dpc-1882	94	29	pd-1	pd-1	ADJ
dpc-1882	94	30	therapy	therapy	NOUN
dpc-1882	94	31	[	[	X
dpc-1882	94	32	19	19	NUM
dpc-1882	94	33	]	]	PUNCT
dpc-1882	94	34	and	and	CCONJ
dpc-1882	94	35	after	after	ADP
dpc-1882	94	36	treatment	treatment	NOUN
dpc-1882	94	37	with	with	ADP
dpc-1882	94	38	targeted	target	VERB
dpc-1882	94	39	therapies	therapy	NOUN
dpc-1882	94	40	[	[	X
dpc-1882	94	41	20	20	NUM
dpc-1882	94	42	,	,	PUNCT
dpc-1882	94	43	21	21	NUM
dpc-1882	94	44	]	]	PUNCT
dpc-1882	94	45	.	.	PUNCT
dpc-1882	95	1	this	this	DET
dpc-1882	95	2	observation	observation	NOUN
dpc-1882	95	3	led	lead	VERB
dpc-1882	95	4	to	to	PART
dpc-1882	95	5	support	support	VERB
dpc-1882	95	6	the	the	DET
dpc-1882	95	7	idea	idea	NOUN
dpc-1882	95	8	that	that	SCONJ
dpc-1882	95	9	treatment	treatment	NOUN
dpc-1882	95	10	with	with	ADP
dpc-1882	95	11	brafand	brafand	PROPN
dpc-1882	95	12	mek	mek	PROPN
dpc-1882	95	13	-	-	NOUN
dpc-1882	95	14	inhibitors	inhibitor	NOUN
dpc-1882	95	15	should	should	AUX
dpc-1882	95	16	be	be	AUX
dpc-1882	95	17	prolonged	prolong	VERB
dpc-1882	95	18	to	to	ADP
dpc-1882	95	19	more	more	ADJ
dpc-1882	95	20	than	than	ADP
dpc-1882	95	21	a	a	PRON
dpc-1882	95	22	year	year	NOUN
dpc-1882	95	23	(	(	PUNCT
dpc-1882	95	24	2	2	NUM
dpc-1882	95	25	-	-	SYM
dpc-1882	95	26	3	3	NUM
dpc-1882	95	27	years	year	NOUN
dpc-1882	95	28	?	?	PUNCT
dpc-1882	95	29	)	)	PUNCT
dpc-1882	95	30	to	to	PART
dpc-1882	95	31	improve	improve	VERB
dpc-1882	95	32	its	its	PRON
dpc-1882	95	33	efficacy	efficacy	NOUN
dpc-1882	95	34	.	.	PUNCT
dpc-1882	96	1	however	however	ADV
dpc-1882	96	2	,	,	PUNCT
dpc-1882	96	3	when	when	SCONJ
dpc-1882	96	4	the	the	DET
dpc-1882	96	5	relapse	relapse	NOUN
dpc-1882	96	6	occurs	occur	VERB
dpc-1882	96	7	during	during	ADP
dpc-1882	96	8	adjuvant	adjuvant	ADJ
dpc-1882	96	9	therapy	therapy	NOUN
dpc-1882	96	10	(	(	PUNCT
dpc-1882	96	11	or	or	CCONJ
dpc-1882	96	12	within	within	ADP
dpc-1882	96	13	few	few	ADJ
dpc-1882	96	14	months	month	NOUN
dpc-1882	96	15	from	from	ADP
dpc-1882	96	16	its	its	PRON
dpc-1882	96	17	conclusion	conclusion	NOUN
dpc-1882	96	18	)	)	PUNCT
dpc-1882	96	19	,	,	PUNCT
dpc-1882	96	20	it	it	PRON
dpc-1882	96	21	is	be	AUX
dpc-1882	96	22	good	good	ADJ
dpc-1882	96	23	practice	practice	NOUN
dpc-1882	96	24	to	to	PART
dpc-1882	96	25	switch	switch	VERB
dpc-1882	96	26	to	to	ADP
dpc-1882	96	27	another	another	DET
dpc-1882	96	28	treatment	treatment	NOUN
dpc-1882	96	29	,	,	PUNCT
dpc-1882	96	30	particularly	particularly	ADV
dpc-1882	96	31	in	in	ADP
dpc-1882	96	32	braf	braf	NOUN
dpc-1882	96	33	mutant	mutant	NOUN
dpc-1882	96	34	patients	patient	NOUN
dpc-1882	96	35	(	(	PUNCT
dpc-1882	96	36	ittt	ittt	NOUN
dpc-1882	96	37	and	and	CCONJ
dpc-1882	96	38	ttit	ttit	NUM
dpc-1882	96	39	)	)	PUNCT
dpc-1882	96	40	.	.	PUNCT
dpc-1882	97	1	on	on	ADP
dpc-1882	97	2	the	the	DET
dpc-1882	97	3	contrary	contrary	NOUN
dpc-1882	97	4	,	,	PUNCT
dpc-1882	97	5	a	a	DET
dpc-1882	97	6	rechallenge	rechallenge	NOUN
dpc-1882	97	7	approach	approach	NOUN
dpc-1882	97	8	,	,	PUNCT
dpc-1882	97	9	adopting	adopt	VERB
dpc-1882	97	10	the	the	DET
dpc-1882	97	11	same	same	ADJ
dpc-1882	97	12	drugs	drug	NOUN
dpc-1882	97	13	,	,	PUNCT
dpc-1882	97	14	when	when	SCONJ
dpc-1882	97	15	the	the	DET
dpc-1882	97	16	relapse	relapse	NOUN
dpc-1882	97	17	occurs	occur	VERB
dpc-1882	97	18	off	off	ADP
dpc-1882	97	19	treatment	treatment	NOUN
dpc-1882	97	20	,	,	PUNCT
dpc-1882	97	21	could	could	AUX
dpc-1882	97	22	be	be	AUX
dpc-1882	97	23	a	a	DET
dpc-1882	97	24	good	good	ADJ
dpc-1882	97	25	option	option	NOUN
dpc-1882	97	26	because	because	SCONJ
dpc-1882	97	27	of	of	ADP
dpc-1882	97	28	good	good	ADJ
dpc-1882	97	29	response	response	NOUN
dpc-1882	97	30	rates	rate	NOUN
dpc-1882	97	31	,	,	PUNCT
dpc-1882	97	32	especially	especially	ADV
dpc-1882	97	33	for	for	ADP
dpc-1882	97	34	tt	tt	PROPN
dpc-1882	97	35	.	.	PUNCT
dpc-1882	98	1	nevertheless	nevertheless	ADV
dpc-1882	98	2	,	,	PUNCT
dpc-1882	98	3	data	datum	NOUN
dpc-1882	98	4	from	from	ADP
dpc-1882	98	5	pembrolizumab	pembrolizumab	NOUN
dpc-1882	98	6	rechallenge	rechallenge	NOUN
dpc-1882	98	7	in	in	ADP
dpc-1882	98	8	the	the	DET
dpc-1882	98	9	keynote-054	keynote-054	ADJ
dpc-1882	98	10	study	study	NOUN
dpc-1882	98	11	,	,	PUNCT
dpc-1882	98	12	performed	perform	VERB
dpc-1882	98	13	on	on	ADP
dpc-1882	98	14	patients	patient	NOUN
dpc-1882	98	15	who	who	PRON
dpc-1882	98	16	recurred	recur	VERB
dpc-1882	98	17	after	after	ADP
dpc-1882	98	18	6	6	NUM
dpc-1882	98	19	months	month	NOUN
dpc-1882	98	20	from	from	ADP
dpc-1882	98	21	the	the	DET
dpc-1882	98	22	completion	completion	NOUN
dpc-1882	98	23	of	of	ADP
dpc-1882	98	24	adjuvant	adjuvant	ADJ
dpc-1882	98	25	therapy	therapy	NOUN
dpc-1882	98	26	,	,	PUNCT
dpc-1882	98	27	were	be	AUX
dpc-1882	98	28	very	very	ADV
dpc-1882	98	29	disappointing	disappointing	ADJ
dpc-1882	98	30	[	[	X
dpc-1882	98	31	22	22	NUM
dpc-1882	98	32	]	]	PUNCT
dpc-1882	98	33	.	.	PUNCT
dpc-1882	99	1	furthermore	furthermore	ADV
dpc-1882	99	2	,	,	PUNCT
dpc-1882	99	3	radical	radical	ADJ
dpc-1882	99	4	surgery	surgery	NOUN
dpc-1882	99	5	followed	follow	VERB
dpc-1882	99	6	or	or	CCONJ
dpc-1882	99	7	not	not	PART
dpc-1882	99	8	by	by	ADP
dpc-1882	99	9	systemic	systemic	ADJ
dpc-1882	99	10	adjuvant	adjuvant	ADJ
dpc-1882	99	11	therapy	therapy	NOUN
dpc-1882	99	12	,	,	PUNCT
dpc-1882	99	13	should	should	AUX
dpc-1882	99	14	be	be	AUX
dpc-1882	99	15	done	do	VERB
dpc-1882	99	16	when	when	SCONJ
dpc-1882	99	17	recurrence	recurrence	NOUN
dpc-1882	99	18	is	be	AUX
dpc-1882	99	19	locoregional	locoregional	ADJ
dpc-1882	99	20	and	and	CCONJ
dpc-1882	99	21	when	when	SCONJ
dpc-1882	99	22	radical	radical	ADJ
dpc-1882	99	23	surgery	surgery	NOUN
dpc-1882	99	24	is	be	AUX
dpc-1882	99	25	achievable	achievable	ADJ
dpc-1882	99	26	.	.	PUNCT
dpc-1882	100	1	a	a	DET
dpc-1882	100	2	step	step	NOUN
dpc-1882	100	3	forward	forward	ADV
dpc-1882	100	4	there	there	PRON
dpc-1882	100	5	are	be	VERB
dpc-1882	100	6	several	several	ADJ
dpc-1882	100	7	ongoing	ongoing	ADJ
dpc-1882	100	8	trials	trial	NOUN
dpc-1882	100	9	trying	try	VERB
dpc-1882	100	10	to	to	PART
dpc-1882	100	11	solve	solve	VERB
dpc-1882	100	12	the	the	DET
dpc-1882	100	13	open	open	ADJ
dpc-1882	100	14	questions	question	NOUN
dpc-1882	100	15	for	for	ADP
dpc-1882	100	16	the	the	DET
dpc-1882	100	17	management	management	NOUN
dpc-1882	100	18	of	of	ADP
dpc-1882	100	19	locoregional	locoregional	ADJ
dpc-1882	100	20	melanoma	melanoma	NOUN
dpc-1882	100	21	.	.	PUNCT
dpc-1882	101	1	one	one	NUM
dpc-1882	101	2	of	of	ADP
dpc-1882	101	3	these	these	DET
dpc-1882	101	4	issues	issue	NOUN
dpc-1882	101	5	concerns	concern	NOUN
dpc-1882	101	6	adjuvant	adjuvant	ADJ
dpc-1882	101	7	therapy	therapy	NOUN
dpc-1882	101	8	for	for	ADP
dpc-1882	101	9	melanomas	melanomas	PROPN
dpc-1882	101	10	without	without	ADP
dpc-1882	101	11	involvement	involvement	NOUN
dpc-1882	101	12	of	of	ADP
dpc-1882	101	13	lymph	lymph	NOUN
dpc-1882	101	14	nodes	node	NOUN
dpc-1882	101	15	:	:	PUNCT
dpc-1882	101	16	paradoxically	paradoxically	ADV
dpc-1882	101	17	,	,	PUNCT
dpc-1882	101	18	5	5	NUM
dpc-1882	101	19	-	-	PUNCT
dpc-1882	101	20	year	year	NOUN
dpc-1882	101	21	survival	survival	NOUN
dpc-1882	101	22	of	of	ADP
dpc-1882	101	23	stage	stage	NOUN
dpc-1882	101	24	iib	iib	NOUN
dpc-1882	101	25	(	(	PUNCT
dpc-1882	101	26	87	87	NUM
dpc-1882	101	27	%	%	NOUN
dpc-1882	101	28	)	)	PUNCT
dpc-1882	101	29	and	and	CCONJ
dpc-1882	101	30	iic	iic	PROPN
dpc-1882	101	31	(	(	PUNCT
dpc-1882	101	32	82	82	NUM
dpc-1882	101	33	%	%	NOUN
dpc-1882	101	34	)	)	PUNCT
dpc-1882	101	35	is	be	AUX
dpc-1882	101	36	worse	bad	ADJ
dpc-1882	101	37	than	than	ADP
dpc-1882	101	38	stage	stage	NOUN
dpc-1882	101	39	iiia	iiia	NOUN
dpc-1882	101	40	(	(	PUNCT
dpc-1882	101	41	93	93	NUM
dpc-1882	101	42	%	%	NOUN
dpc-1882	101	43	)	)	PUNCT
dpc-1882	101	44	.	.	PUNCT
dpc-1882	102	1	keynote-716	keynote-716	NOUN
dpc-1882	102	2	and	and	CCONJ
dpc-1882	102	3	checkmate-76k	checkmate-76k	PROPN
dpc-1882	102	4	will	will	AUX
dpc-1882	102	5	compare	compare	VERB
dpc-1882	102	6	the	the	DET
dpc-1882	102	7	efficacy	efficacy	NOUN
dpc-1882	102	8	of	of	ADP
dpc-1882	102	9	pembrolizumab	pembrolizumab	NOUN
dpc-1882	102	10	and	and	CCONJ
dpc-1882	102	11	nivolumab	nivolumab	NOUN
dpc-1882	102	12	,	,	PUNCT
dpc-1882	102	13	respectively	respectively	ADV
dpc-1882	102	14	,	,	PUNCT
dpc-1882	102	15	versus	versus	ADP
dpc-1882	102	16	placebo	placebo	NOUN
dpc-1882	102	17	in	in	ADP
dpc-1882	102	18	these	these	DET
dpc-1882	102	19	patients	patient	NOUN
dpc-1882	102	20	.	.	PUNCT
dpc-1882	103	1	results	result	NOUN
dpc-1882	103	2	are	be	AUX
dpc-1882	103	3	expected	expect	VERB
dpc-1882	103	4	for	for	ADP
dpc-1882	103	5	2023	2023	NUM
dpc-1882	103	6	-	-	SYM
dpc-1882	103	7	24	24	NUM
dpc-1882	103	8	.	.	PUNCT
dpc-1882	104	1	a	a	DET
dpc-1882	104	2	closer	close	ADJ
dpc-1882	104	3	change	change	NOUN
dpc-1882	104	4	in	in	ADP
dpc-1882	104	5	clinical	clinical	ADJ
dpc-1882	104	6	practice	practice	NOUN
dpc-1882	104	7	will	will	AUX
dpc-1882	104	8	probably	probably	ADV
dpc-1882	104	9	come	come	VERB
dpc-1882	104	10	from	from	ADP
dpc-1882	104	11	neoadjuvant	neoadjuvant	ADJ
dpc-1882	104	12	studies	study	NOUN
dpc-1882	104	13	for	for	ADP
dpc-1882	104	14	clinical	clinical	ADJ
dpc-1882	104	15	stage	stage	NOUN
dpc-1882	104	16	iii	iii	NUM
dpc-1882	104	17	melanoma	melanoma	NOUN
dpc-1882	104	18	.	.	PUNCT
dpc-1882	105	1	up	up	ADP
dpc-1882	105	2	to	to	ADP
dpc-1882	105	3	now	now	ADV
dpc-1882	105	4	,	,	PUNCT
dpc-1882	105	5	the	the	DET
dpc-1882	105	6	relapse	relapse	NOUN
dpc-1882	105	7	rate	rate	NOUN
dpc-1882	105	8	for	for	ADP
dpc-1882	105	9	radically	radically	ADV
dpc-1882	105	10	resected	resect	VERB
dpc-1882	105	11	melanoma	melanoma	NOUN
dpc-1882	105	12	with	with	ADP
dpc-1882	105	13	nodal	nodal	NOUN
dpc-1882	105	14	macro	macro	NOUN
dpc-1882	105	15	metastases	metastasis	NOUN
dpc-1882	105	16	was	be	AUX
dpc-1882	105	17	40	40	NUM
dpc-1882	105	18	%	%	NOUN
dpc-1882	105	19	at	at	ADP
dpc-1882	105	20	2	2	NUM
dpc-1882	105	21	years	year	NOUN
dpc-1882	105	22	with	with	ADP
dpc-1882	105	23	immunotherapies	immunotherapy	NOUN
dpc-1882	105	24	and	and	CCONJ
dpc-1882	105	25	40	40	NUM
dpc-1882	105	26	%	%	NOUN
dpc-1882	105	27	at	at	ADP
dpc-1882	105	28	3	3	NUM
dpc-1882	105	29	years	year	NOUN
dpc-1882	105	30	with	with	ADP
dpc-1882	105	31	targeted	target	VERB
dpc-1882	105	32	therapies	therapy	NOUN
dpc-1882	105	33	(	(	PUNCT
dpc-1882	105	34	without	without	ADP
dpc-1882	105	35	considering	consider	VERB
dpc-1882	105	36	15	15	NUM
dpc-1882	105	37	-	-	SYM
dpc-1882	105	38	20	20	NUM
dpc-1882	105	39	%	%	NOUN
dpc-1882	105	40	of	of	ADP
dpc-1882	105	41	patients	patient	NOUN
dpc-1882	105	42	in	in	ADP
dpc-1882	105	43	the	the	DET
dpc-1882	105	44	trials	trial	NOUN
dpc-1882	105	45	recurred	recur	VERB
dpc-1882	105	46	during	during	ADP
dpc-1882	105	47	the	the	DET
dpc-1882	105	48	screening	screening	NOUN
dpc-1882	105	49	period	period	NOUN
dpc-1882	105	50	before	before	ADP
dpc-1882	105	51	the	the	DET
dpc-1882	105	52	start	start	NOUN
dpc-1882	105	53	of	of	ADP
dpc-1882	105	54	adjuvant	adjuvant	ADJ
dpc-1882	105	55	therapy	therapy	NOUN
dpc-1882	105	56	)	)	PUNCT
dpc-1882	106	1	[	[	X
dpc-1882	106	2	23	23	NUM
dpc-1882	106	3	]	]	PUNCT
dpc-1882	106	4	.	.	PUNCT
dpc-1882	107	1	neoadjuvant	neoadjuvant	ADJ
dpc-1882	107	2	therapy	therapy	NOUN
dpc-1882	107	3	could	could	AUX
dpc-1882	107	4	improve	improve	VERB
dpc-1882	107	5	outcome	outcome	NOUN
dpc-1882	107	6	from	from	ADP
dpc-1882	107	7	surgery	surgery	NOUN
dpc-1882	107	8	,	,	PUNCT
dpc-1882	107	9	could	could	AUX
dpc-1882	107	10	personalize	personalize	VERB
dpc-1882	107	11	adjuvant	adjuvant	ADJ
dpc-1882	107	12	treatment	treatment	NOUN
dpc-1882	107	13	based	base	VERB
dpc-1882	107	14	on	on	ADP
dpc-1882	107	15	treatment	treatment	NOUN
dpc-1882	107	16	response	response	NOUN
dpc-1882	107	17	,	,	PUNCT
dpc-1882	107	18	and	and	CCONJ
dpc-1882	107	19	could	could	AUX
dpc-1882	107	20	safely	safely	ADV
dpc-1882	107	21	provide	provide	VERB
dpc-1882	107	22	tissue	tissue	NOUN
dpc-1882	107	23	for	for	ADP
dpc-1882	107	24	analysis	analysis	NOUN
dpc-1882	107	25	of	of	ADP
dpc-1882	107	26	resistance	resistance	NOUN
dpc-1882	107	27	mechanisms	mechanism	NOUN
dpc-1882	107	28	from	from	ADP
dpc-1882	107	29	those	those	PRON
dpc-1882	107	30	who	who	PRON
dpc-1882	107	31	do	do	AUX
dpc-1882	107	32	not	not	PART
dpc-1882	107	33	have	have	VERB
dpc-1882	107	34	a	a	DET
dpc-1882	107	35	pathological	pathological	ADJ
dpc-1882	107	36	response	response	NOUN
dpc-1882	107	37	.	.	PUNCT
dpc-1882	108	1	for	for	ADP
dpc-1882	108	2	this	this	DET
dpc-1882	108	3	reason	reason	NOUN
dpc-1882	108	4	,	,	PUNCT
dpc-1882	108	5	in	in	ADP
dpc-1882	108	6	the	the	DET
dpc-1882	108	7	last	last	ADJ
dpc-1882	108	8	years	year	NOUN
dpc-1882	108	9	several	several	ADJ
dpc-1882	108	10	trials	trial	NOUN
dpc-1882	108	11	have	have	AUX
dpc-1882	108	12	evaluated	evaluate	VERB
dpc-1882	108	13	this	this	DET
dpc-1882	108	14	strategy	strategy	NOUN
dpc-1882	108	15	and	and	CCONJ
dpc-1882	108	16	a	a	DET
dpc-1882	108	17	recent	recent	ADJ
dpc-1882	108	18	pooled	pool	VERB
dpc-1882	108	19	analysis	analysis	NOUN
dpc-1882	108	20	summarized	summarize	VERB
dpc-1882	108	21	the	the	DET
dpc-1882	108	22	results	result	NOUN
dpc-1882	108	23	of	of	ADP
dpc-1882	108	24	6	6	NUM
dpc-1882	108	25	of	of	ADP
dpc-1882	108	26	them	they	PRON
dpc-1882	108	27	(	(	PUNCT
dpc-1882	108	28	2	2	NUM
dpc-1882	108	29	with	with	ADP
dpc-1882	108	30	targeted	target	VERB
dpc-1882	108	31	therapy	therapy	NOUN
dpc-1882	108	32	,	,	PUNCT
dpc-1882	108	33	4	4	NUM
dpc-1882	108	34	with	with	ADP
dpc-1882	108	35	immunotherapy	immunotherapy	NOUN
dpc-1882	108	36	)	)	PUNCT
dpc-1882	109	1	[	[	X
dpc-1882	109	2	19	19	NUM
dpc-1882	109	3	]	]	PUNCT
dpc-1882	109	4	.	.	PUNCT
dpc-1882	110	1	in	in	ADP
dpc-1882	110	2	particular	particular	ADJ
dpc-1882	110	3	,	,	PUNCT
dpc-1882	110	4	pathological	pathological	ADJ
dpc-1882	110	5	complete	complete	ADJ
dpc-1882	110	6	response	response	NOUN
dpc-1882	110	7	(	(	PUNCT
dpc-1882	110	8	pcr	pcr	NOUN
dpc-1882	110	9	)	)	PUNCT
dpc-1882	110	10	was	be	AUX
dpc-1882	110	11	found	find	VERB
dpc-1882	110	12	to	to	PART
dpc-1882	110	13	be	be	AUX
dpc-1882	110	14	a	a	DET
dpc-1882	110	15	good	good	ADJ
dpc-1882	110	16	surrogate	surrogate	NOUN
dpc-1882	110	17	of	of	ADP
dpc-1882	110	18	rfs	rfs	PROPN
dpc-1882	110	19	and	and	CCONJ
dpc-1882	110	20	os	os	NOUN
dpc-1882	110	21	.	.	PUNCT
dpc-1882	111	1	pcr	pcr	ADJ
dpc-1882	111	2	rate	rate	NOUN
dpc-1882	111	3	was	be	AUX
dpc-1882	111	4	39.7	39.7	NUM
dpc-1882	111	5	%	%	NOUN
dpc-1882	111	6	in	in	ADP
dpc-1882	111	7	the	the	DET
dpc-1882	111	8	whole	whole	ADJ
dpc-1882	111	9	cohort	cohort	NOUN
dpc-1882	111	10	:	:	PUNCT
dpc-1882	111	11	worst	bad	ADJ
dpc-1882	111	12	4	4	NUM
dpc-1882	111	13	review	review	NOUN
dpc-1882	111	14	|	|	ADV
dpc-1882	111	15	dermatol	dermatol	ADJ
dpc-1882	111	16	pract	pract	NOUN
dpc-1882	111	17	concept	concept	NOUN
dpc-1882	111	18	.	.	PUNCT
dpc-1882	112	1	2021;11(s1	2021;11(s1	NUM
dpc-1882	112	2	):	):	PUNCT
dpc-1882	112	3	e2021165s	e2021165s	X
dpc-1882	112	4	results	result	NOUN
dpc-1882	112	5	were	be	AUX
dpc-1882	112	6	found	find	VERB
dpc-1882	112	7	for	for	ADP
dpc-1882	112	8	single	single	ADJ
dpc-1882	112	9	agent	agent	NOUN
dpc-1882	112	10	nivolumab	nivolumab	NOUN
dpc-1882	112	11	(	(	PUNCT
dpc-1882	112	12	pcr	pcr	NOUN
dpc-1882	112	13	20	20	NUM
dpc-1882	112	14	%	%	NOUN
dpc-1882	112	15	)	)	PUNCT
dpc-1882	112	16	,	,	PUNCT
dpc-1882	112	17	while	while	SCONJ
dpc-1882	112	18	similar	similar	ADJ
dpc-1882	112	19	outcomes	outcome	NOUN
dpc-1882	112	20	were	be	AUX
dpc-1882	112	21	found	find	VERB
dpc-1882	112	22	for	for	ADP
dpc-1882	112	23	dabrafenib+trametinib	dabrafenib+trametinib	PROPN
dpc-1882	112	24	(	(	PUNCT
dpc-1882	112	25	47	47	NUM
dpc-1882	112	26	%	%	NOUN
dpc-1882	112	27	)	)	PUNCT
dpc-1882	112	28	and	and	CCONJ
dpc-1882	112	29	for	for	ADP
dpc-1882	112	30	nivolumab+ipilimumab	nivolumab+ipilimumab	PROPN
dpc-1882	112	31	(	(	PUNCT
dpc-1882	112	32	42.7	42.7	NUM
dpc-1882	112	33	%	%	NOUN
dpc-1882	112	34	)	)	PUNCT
dpc-1882	112	35	.	.	PUNCT
dpc-1882	113	1	the	the	DET
dpc-1882	113	2	rfs	rfs	PROPN
dpc-1882	113	3	was	be	AUX
dpc-1882	113	4	similar	similar	ADJ
dpc-1882	113	5	between	between	ADP
dpc-1882	113	6	combination	combination	NOUN
dpc-1882	113	7	immunotherapies	immunotherapy	NOUN
dpc-1882	113	8	and	and	CCONJ
dpc-1882	113	9	targeted	target	VERB
dpc-1882	113	10	therapies	therapy	NOUN
dpc-1882	113	11	after	after	ADP
dpc-1882	113	12	1	1	NUM
dpc-1882	113	13	year	year	NOUN
dpc-1882	113	14	(	(	PUNCT
dpc-1882	113	15	84	84	NUM
dpc-1882	113	16	%	%	NOUN
dpc-1882	113	17	vs	vs	ADP
dpc-1882	113	18	75	75	NUM
dpc-1882	113	19	%	%	NOUN
dpc-1882	113	20	)	)	PUNCT
dpc-1882	113	21	while	while	SCONJ
dpc-1882	113	22	a	a	DET
dpc-1882	113	23	significant	significant	ADJ
dpc-1882	113	24	difference	difference	NOUN
dpc-1882	113	25	was	be	AUX
dpc-1882	113	26	seen	see	VERB
dpc-1882	113	27	at	at	ADP
dpc-1882	113	28	2	2	NUM
dpc-1882	113	29	years	year	NOUN
dpc-1882	113	30	(	(	PUNCT
dpc-1882	113	31	80	80	NUM
dpc-1882	113	32	%	%	NOUN
dpc-1882	113	33	vs	vs	ADP
dpc-1882	113	34	47	47	NUM
dpc-1882	113	35	%	%	NOUN
dpc-1882	113	36	)	)	PUNCT
dpc-1882	113	37	.	.	PUNCT
dpc-1882	114	1	furthermore	furthermore	ADV
dpc-1882	114	2	,	,	PUNCT
dpc-1882	114	3	with	with	ADP
dpc-1882	114	4	nivolumab+ipilimumab	nivolumab+ipilimumab	PROPN
dpc-1882	114	5	,	,	PUNCT
dpc-1882	114	6	impressive	impressive	ADJ
dpc-1882	114	7	os	os	NOUN
dpc-1882	114	8	were	be	AUX
dpc-1882	114	9	achieved	achieve	VERB
dpc-1882	114	10	in	in	ADP
dpc-1882	114	11	patients	patient	NOUN
dpc-1882	114	12	who	who	PRON
dpc-1882	114	13	obtained	obtain	VERB
dpc-1882	114	14	a	a	DET
dpc-1882	114	15	pcr	pcr	NOUN
dpc-1882	114	16	,	,	PUNCT
dpc-1882	114	17	or	or	CCONJ
dpc-1882	114	18	a	a	DET
dpc-1882	114	19	near	near	ADJ
dpc-1882	114	20	pcr	pcr	NOUN
dpc-1882	114	21	,	,	PUNCT
dpc-1882	114	22	or	or	CCONJ
dpc-1882	114	23	a	a	DET
dpc-1882	114	24	partial	partial	ADJ
dpc-1882	114	25	response	response	NOUN
dpc-1882	114	26	(	(	PUNCT
dpc-1882	114	27	about	about	ADP
dpc-1882	114	28	2/3	2/3	NUM
dpc-1882	114	29	of	of	ADP
dpc-1882	114	30	patients	patient	NOUN
dpc-1882	114	31	)	)	PUNCT
dpc-1882	114	32	reaching	reach	VERB
dpc-1882	114	33	99	99	NUM
dpc-1882	114	34	%	%	NOUN
dpc-1882	114	35	after	after	ADP
dpc-1882	114	36	2	2	NUM
dpc-1882	114	37	years	year	NOUN
dpc-1882	114	38	.	.	PUNCT
dpc-1882	115	1	despite	despite	SCONJ
dpc-1882	115	2	this	this	DET
dpc-1882	115	3	very	very	ADV
dpc-1882	115	4	promising	promising	ADJ
dpc-1882	115	5	result	result	NOUN
dpc-1882	115	6	,	,	PUNCT
dpc-1882	115	7	larger	large	ADJ
dpc-1882	115	8	studies	study	NOUN
dpc-1882	115	9	are	be	AUX
dpc-1882	115	10	needed	need	VERB
dpc-1882	115	11	to	to	PART
dpc-1882	115	12	confirm	confirm	VERB
dpc-1882	115	13	these	these	DET
dpc-1882	115	14	findings	finding	NOUN
dpc-1882	115	15	and	and	CCONJ
dpc-1882	115	16	to	to	PART
dpc-1882	115	17	clarify	clarify	VERB
dpc-1882	115	18	other	other	ADJ
dpc-1882	115	19	open	open	ADJ
dpc-1882	115	20	questions	question	NOUN
dpc-1882	115	21	such	such	ADJ
dpc-1882	115	22	as	as	ADP
dpc-1882	115	23	understanding	understand	VERB
dpc-1882	115	24	the	the	DET
dpc-1882	115	25	mechanisms	mechanism	NOUN
dpc-1882	115	26	underlying	underlie	VERB
dpc-1882	115	27	the	the	DET
dpc-1882	115	28	relapse	relapse	NOUN
dpc-1882	115	29	in	in	ADP
dpc-1882	115	30	21	21	NUM
dpc-1882	115	31	%	%	NOUN
dpc-1882	115	32	of	of	ADP
dpc-1882	115	33	patients	patient	NOUN
dpc-1882	115	34	with	with	ADP
dpc-1882	115	35	pcr	pcr	PROPN
dpc-1882	115	36	to	to	ADP
dpc-1882	115	37	targeted	target	VERB
dpc-1882	115	38	therapy	therapy	NOUN
dpc-1882	115	39	.	.	PUNCT
dpc-1882	116	1	conclusion	conclusion	VERB
dpc-1882	116	2	the	the	DET
dpc-1882	116	3	efficacy	efficacy	NOUN
dpc-1882	116	4	of	of	ADP
dpc-1882	116	5	immunotherapy	immunotherapy	NOUN
dpc-1882	116	6	and	and	CCONJ
dpc-1882	116	7	targeted	target	VERB
dpc-1882	116	8	therapy	therapy	NOUN
dpc-1882	116	9	as	as	ADP
dpc-1882	116	10	adjuvant	adjuvant	ADJ
dpc-1882	116	11	treatment	treatment	NOUN
dpc-1882	116	12	in	in	ADP
dpc-1882	116	13	stage	stage	NOUN
dpc-1882	116	14	iii	iii	NUM
dpc-1882	116	15	melanoma	melanoma	NOUN
dpc-1882	116	16	is	be	AUX
dpc-1882	116	17	unquestionable	unquestionable	ADJ
dpc-1882	116	18	.	.	PUNCT
dpc-1882	117	1	something	something	PRON
dpc-1882	117	2	could	could	AUX
dpc-1882	117	3	change	change	VERB
dpc-1882	117	4	soon	soon	ADV
dpc-1882	117	5	when	when	SCONJ
dpc-1882	117	6	the	the	DET
dpc-1882	117	7	overall	overall	ADJ
dpc-1882	117	8	survival	survival	NOUN
dpc-1882	117	9	results	result	NOUN
dpc-1882	117	10	will	will	AUX
dpc-1882	117	11	be	be	AUX
dpc-1882	117	12	consolidated	consolidate	VERB
dpc-1882	117	13	and	and	CCONJ
dpc-1882	117	14	when	when	SCONJ
dpc-1882	117	15	data	datum	NOUN
dpc-1882	117	16	on	on	ADP
dpc-1882	117	17	neoadjuvant	neoadjuvant	ADJ
dpc-1882	117	18	therapy	therapy	NOUN
dpc-1882	117	19	will	will	AUX
dpc-1882	117	20	be	be	AUX
dpc-1882	117	21	more	more	ADV
dpc-1882	117	22	consistent	consistent	ADJ
dpc-1882	117	23	.	.	PUNCT
dpc-1882	118	1	to	to	ADP
dpc-1882	118	2	date	date	NOUN
dpc-1882	118	3	,	,	PUNCT
dpc-1882	118	4	there	there	PRON
dpc-1882	118	5	is	be	VERB
dpc-1882	118	6	no	no	DET
dpc-1882	118	7	evidence	evidence	NOUN
dpc-1882	118	8	that	that	SCONJ
dpc-1882	118	9	one	one	NUM
dpc-1882	118	10	type	type	NOUN
dpc-1882	118	11	of	of	ADP
dpc-1882	118	12	treatment	treatment	NOUN
dpc-1882	118	13	among	among	ADP
dpc-1882	118	14	those	those	PRON
dpc-1882	118	15	approved	approve	VERB
dpc-1882	118	16	is	be	AUX
dpc-1882	118	17	more	more	ADV
dpc-1882	118	18	effective	effective	ADJ
dpc-1882	118	19	than	than	ADP
dpc-1882	118	20	another	another	PRON
dpc-1882	118	21	.	.	PUNCT
dpc-1882	119	1	for	for	ADP
dpc-1882	119	2	this	this	DET
dpc-1882	119	3	reason	reason	NOUN
dpc-1882	119	4	,	,	PUNCT
dpc-1882	119	5	personalized	personalized	ADJ
dpc-1882	119	6	treatment	treatment	NOUN
dpc-1882	119	7	must	must	AUX
dpc-1882	119	8	be	be	AUX
dpc-1882	119	9	based	base	VERB
dpc-1882	119	10	on	on	ADP
dpc-1882	119	11	the	the	DET
dpc-1882	119	12	clinical	clinical	ADJ
dpc-1882	119	13	-	-	PUNCT
dpc-1882	119	14	pathological	pathological	ADJ
dpc-1882	119	15	characteristics	characteristic	NOUN
dpc-1882	119	16	of	of	ADP
dpc-1882	119	17	the	the	DET
dpc-1882	119	18	disease	disease	NOUN
dpc-1882	119	19	,	,	PUNCT
dpc-1882	119	20	on	on	ADP
dpc-1882	119	21	patient	patient	ADJ
dpc-1882	119	22	compliance	compliance	NOUN
dpc-1882	119	23	,	,	PUNCT
dpc-1882	119	24	and	and	CCONJ
dpc-1882	119	25	on	on	ADP
dpc-1882	119	26	comorbidities	comorbiditie	NOUN
dpc-1882	119	27	,	,	PUNCT
dpc-1882	119	28	taking	take	VERB
dpc-1882	119	29	into	into	ADP
dpc-1882	119	30	account	account	NOUN
dpc-1882	119	31	the	the	DET
dpc-1882	119	32	side	side	NOUN
dpc-1882	119	33	effects	effect	NOUN
dpc-1882	119	34	of	of	ADP
dpc-1882	119	35	each	each	DET
dpc-1882	119	36	drug	drug	NOUN
dpc-1882	119	37	.	.	PUNCT
dpc-1882	120	1	references	reference	NOUN
dpc-1882	120	2	1	1	NUM
dpc-1882	120	3	.	.	PUNCT
dpc-1882	121	1	paulson	paulson	PROPN
dpc-1882	121	2	kg	kg	PROPN
dpc-1882	121	3	,	,	PUNCT
dpc-1882	121	4	gupta	gupta	PROPN
dpc-1882	121	5	d	d	PROPN
dpc-1882	121	6	,	,	PUNCT
dpc-1882	121	7	kim	kim	PROPN
dpc-1882	121	8	ts	ts	PROPN
dpc-1882	121	9	,	,	PUNCT
dpc-1882	121	10	et	et	PROPN
dpc-1882	121	11	al	al	PROPN
dpc-1882	121	12	.	.	PUNCT
dpc-1882	121	13	age	age	NOUN
dpc-1882	121	14	-	-	PUNCT
dpc-1882	121	15	specific	specific	ADJ
dpc-1882	121	16	incidence	incidence	NOUN
dpc-1882	121	17	of	of	ADP
dpc-1882	121	18	melanoma	melanoma	NOUN
dpc-1882	121	19	in	in	ADP
dpc-1882	121	20	the	the	DET
dpc-1882	121	21	united	united	PROPN
dpc-1882	121	22	states	states	PROPN
dpc-1882	121	23	.	.	PUNCT
dpc-1882	122	1	jama	jama	PROPN
dpc-1882	122	2	dermatol	dermatol	NOUN
dpc-1882	122	3	.	.	PUNCT
dpc-1882	123	1	2020;156(1):5764	2020;156(1):5764	NUM
dpc-1882	123	2	.	.	PUNCT
dpc-1882	124	1	doi:10.1001	doi:10.1001	PROPN
dpc-1882	124	2	/	/	SYM
dpc-1882	124	3	jamadermatol.2019.3353	jamadermatol.2019.3353	PROPN
dpc-1882	124	4	.	.	PROPN
dpc-1882	125	1	pmid:31721989	pmid:31721989	PROPN
dpc-1882	125	2	.	.	PUNCT
dpc-1882	126	1	2	2	X
dpc-1882	126	2	.	.	X
dpc-1882	126	3	giunta	giunta	PROPN
dpc-1882	126	4	ef	ef	PROPN
dpc-1882	126	5	,	,	PUNCT
dpc-1882	126	6	de	de	PROPN
dpc-1882	126	7	falco	falco	PROPN
dpc-1882	126	8	v	v	PROPN
dpc-1882	126	9	,	,	PUNCT
dpc-1882	126	10	napolitano	napolitano	PROPN
dpc-1882	126	11	s	s	PROPN
dpc-1882	126	12	,	,	PUNCT
dpc-1882	126	13	et	et	PROPN
dpc-1882	126	14	al	al	PROPN
dpc-1882	126	15	.	.	PUNCT
dpc-1882	127	1	optimal	optimal	ADJ
dpc-1882	127	2	treatment	treatment	NOUN
dpc-1882	127	3	strategy	strategy	NOUN
dpc-1882	127	4	for	for	ADP
dpc-1882	127	5	metastatic	metastatic	ADJ
dpc-1882	127	6	melanoma	melanoma	NOUN
dpc-1882	127	7	patients	patient	NOUN
dpc-1882	127	8	harboring	harbor	VERB
dpc-1882	127	9	braf	braf	NOUN
dpc-1882	127	10	-	-	PUNCT
dpc-1882	127	11	v600	v600	NUM
dpc-1882	127	12	mutations	mutation	NOUN
dpc-1882	127	13	.	.	PUNCT
dpc-1882	128	1	ther	ther	PROPN
dpc-1882	128	2	adv	adv	PROPN
dpc-1882	128	3	med	med	PROPN
dpc-1882	128	4	oncol	oncol	PROPN
dpc-1882	128	5	.	.	PUNCT
dpc-1882	129	1	2020;12	2020;12	X
dpc-1882	129	2	.	.	PUNCT
dpc-1882	129	3	doi:10.1177/1758835920925219	doi:10.1177/1758835920925219	PROPN
dpc-1882	129	4	.	.	PUNCT
dpc-1882	130	1	pmid	pmid	NOUN
dpc-1882	130	2	:	:	PUNCT
dpc-1882	130	3	32612709	32612709	NUM
dpc-1882	130	4	.	.	PUNCT
dpc-1882	131	1	3	3	X
dpc-1882	131	2	.	.	PUNCT
dpc-1882	131	3	balch	balch	PROPN
dpc-1882	131	4	cm	cm	PROPN
dpc-1882	131	5	,	,	PUNCT
dpc-1882	131	6	gershenwald	gershenwald	PROPN
dpc-1882	131	7	je	je	PROPN
dpc-1882	131	8	,	,	PUNCT
dpc-1882	131	9	soong	soong	PROPN
dpc-1882	131	10	s	s	PROPN
dpc-1882	131	11	-	-	PUNCT
dpc-1882	131	12	j	j	PROPN
dpc-1882	131	13	,	,	PUNCT
dpc-1882	131	14	et	et	PROPN
dpc-1882	131	15	al	al	PROPN
dpc-1882	131	16	.	.	PROPN
dpc-1882	131	17	final	final	ADJ
dpc-1882	131	18	version	version	NOUN
dpc-1882	131	19	of	of	ADP
dpc-1882	131	20	2009	2009	NUM
dpc-1882	131	21	ajcc	ajcc	PROPN
dpc-1882	131	22	melanoma	melanoma	NOUN
dpc-1882	131	23	staging	staging	NOUN
dpc-1882	131	24	and	and	CCONJ
dpc-1882	131	25	classification	classification	NOUN
dpc-1882	131	26	.	.	PUNCT
dpc-1882	132	1	j	j	PROPN
dpc-1882	132	2	clin	clin	PROPN
dpc-1882	132	3	oncol	oncol	PROPN
dpc-1882	132	4	.	.	PUNCT
dpc-1882	133	1	2009;27(36):6199	2009;27(36):6199	NUM
dpc-1882	133	2	-	-	SYM
dpc-1882	133	3	6206	6206	NUM
dpc-1882	133	4	.	.	PUNCT
dpc-1882	134	1	doi:10.1200	doi:10.1200	PROPN
dpc-1882	134	2	/	/	SYM
dpc-1882	134	3	jco.2009.23.4799	jco.2009.23.4799	PROPN
dpc-1882	134	4	.	.	PUNCT
dpc-1882	135	1	pmid	pmid	NOUN
dpc-1882	135	2	:	:	PUNCT
dpc-1882	135	3	19917835	19917835	NUM
dpc-1882	135	4	.	.	PUNCT
dpc-1882	136	1	4	4	X
dpc-1882	136	2	.	.	X
dpc-1882	136	3	ives	ives	PROPN
dpc-1882	136	4	nj	nj	PROPN
dpc-1882	136	5	,	,	PUNCT
dpc-1882	136	6	suciu	suciu	PROPN
dpc-1882	136	7	s	s	PROPN
dpc-1882	136	8	,	,	PUNCT
dpc-1882	136	9	eggermont	eggermont	PROPN
dpc-1882	136	10	amm	amm	PROPN
dpc-1882	136	11	,	,	PUNCT
dpc-1882	136	12	et	et	PROPN
dpc-1882	136	13	al	al	PROPN
dpc-1882	136	14	.	.	PROPN
dpc-1882	137	1	adjuvant	adjuvant	PROPN
dpc-1882	137	2	interferon	interferon	PROPN
dpc-1882	137	3	-	-	PUNCT
dpc-1882	137	4	α	α	NOUN
dpc-1882	137	5	for	for	ADP
dpc-1882	137	6	the	the	DET
dpc-1882	137	7	treatment	treatment	NOUN
dpc-1882	137	8	of	of	ADP
dpc-1882	137	9	high	high	ADJ
dpc-1882	137	10	-	-	PUNCT
dpc-1882	137	11	risk	risk	NOUN
dpc-1882	137	12	melanoma	melanoma	NOUN
dpc-1882	137	13	:	:	PUNCT
dpc-1882	137	14	an	an	DET
dpc-1882	137	15	individual	individual	ADJ
dpc-1882	137	16	patient	patient	NOUN
dpc-1882	137	17	data	datum	NOUN
dpc-1882	137	18	meta	meta	ADJ
dpc-1882	137	19	-	-	PUNCT
dpc-1882	137	20	analysis	analysis	NOUN
dpc-1882	137	21	.	.	PUNCT
dpc-1882	138	1	eur	eur	PROPN
dpc-1882	138	2	j	j	PROPN
dpc-1882	138	3	cancer	cancer	NOUN
dpc-1882	138	4	.	.	PUNCT
dpc-1882	139	1	2017;82:171	2017;82:171	NUM
dpc-1882	139	2	-	-	PUNCT
dpc-1882	139	3	183	183	NUM
dpc-1882	139	4	.	.	PUNCT
dpc-1882	140	1	doi:10.1016	doi:10.1016	PROPN
dpc-1882	140	2	/	/	SYM
dpc-1882	140	3	j.ejca.2017.06.006	j.ejca.2017.06.006	PROPN
dpc-1882	140	4	.	.	PUNCT
dpc-1882	141	1	pmid	pmid	NOUN
dpc-1882	141	2	:	:	PUNCT
dpc-1882	141	3	28692949	28692949	NUM
dpc-1882	141	4	.	.	PUNCT
dpc-1882	142	1	5	5	NUM
dpc-1882	142	2	.	.	X
dpc-1882	142	3	michielin	michielin	PROPN
dpc-1882	142	4	o	o	PROPN
dpc-1882	142	5	,	,	PUNCT
dpc-1882	142	6	van	van	PROPN
dpc-1882	142	7	akkooi	akkooi	PROPN
dpc-1882	142	8	acj	acj	PROPN
dpc-1882	142	9	,	,	PUNCT
dpc-1882	142	10	ascierto	ascierto	PROPN
dpc-1882	142	11	pa	pa	PROPN
dpc-1882	142	12	,	,	PUNCT
dpc-1882	142	13	dummer	dummer	PROPN
dpc-1882	142	14	r	r	PROPN
dpc-1882	142	15	,	,	PUNCT
dpc-1882	142	16	keilholz	keilholz	PROPN
dpc-1882	142	17	u	u	NOUN
dpc-1882	142	18	,	,	PUNCT
dpc-1882	142	19	esmo	esmo	NOUN
dpc-1882	142	20	guidelines	guideline	NOUN
dpc-1882	142	21	committee	committee	NOUN
dpc-1882	142	22	.	.	PUNCT
dpc-1882	143	1	electronic	electronic	ADJ
dpc-1882	143	2	address	address	NOUN
dpc-1882	143	3	:	:	PUNCT
dpc-1882	144	1	clinicalguidelines@esmo.org	clinicalguidelines@esmo.org	X
dpc-1882	144	2	.	.	PUNCT
dpc-1882	144	3	cutaneous	cutaneous	ADJ
dpc-1882	144	4	melanoma	melanoma	NOUN
dpc-1882	144	5	:	:	PUNCT
dpc-1882	144	6	esmo	esmo	VERB
dpc-1882	144	7	clinical	clinical	ADJ
dpc-1882	144	8	practice	practice	NOUN
dpc-1882	144	9	guidelines	guideline	NOUN
dpc-1882	144	10	for	for	ADP
dpc-1882	144	11	diagnosis	diagnosis	NOUN
dpc-1882	144	12	,	,	PUNCT
dpc-1882	144	13	treatment	treatment	NOUN
dpc-1882	144	14	and	and	CCONJ
dpc-1882	144	15	follow	follow	NOUN
dpc-1882	144	16	-	-	PUNCT
dpc-1882	144	17	up†.	up†.	NOUN
dpc-1882	144	18	ann	ann	PROPN
dpc-1882	144	19	oncol	oncol	NOUN
dpc-1882	144	20	.	.	PUNCT
dpc-1882	145	1	2019;30(12):1884	2019;30(12):1884	NUM
dpc-1882	145	2	-	-	SYM
dpc-1882	145	3	1901	1901	NUM
dpc-1882	145	4	.	.	PUNCT
dpc-1882	146	1	doi:10.1093	doi:10.1093	NOUN
dpc-1882	146	2	/	/	SYM
dpc-1882	146	3	annonc	annonc	PROPN
dpc-1882	146	4	/	/	SYM
dpc-1882	146	5	mdz411	mdz411	PROPN
dpc-1882	146	6	.	.	PUNCT
dpc-1882	147	1	pmid	pmid	NOUN
dpc-1882	147	2	:	:	PUNCT
dpc-1882	147	3	31566661	31566661	NUM
dpc-1882	147	4	.	.	X
dpc-1882	148	1	6	6	X
dpc-1882	148	2	.	.	X
dpc-1882	148	3	eggermont	eggermont	PROPN
dpc-1882	148	4	amm	amm	PROPN
dpc-1882	148	5	,	,	PUNCT
dpc-1882	148	6	chiarion	chiarion	NOUN
dpc-1882	148	7	-	-	PUNCT
dpc-1882	148	8	sileni	sileni	NOUN
dpc-1882	148	9	v	v	NOUN
dpc-1882	148	10	,	,	PUNCT
dpc-1882	148	11	grob	grob	PROPN
dpc-1882	148	12	j	j	PROPN
dpc-1882	148	13	-	-	PROPN
dpc-1882	148	14	j	j	PROPN
dpc-1882	148	15	,	,	PUNCT
dpc-1882	148	16	et	et	PROPN
dpc-1882	148	17	al	al	PROPN
dpc-1882	148	18	.	.	PROPN
dpc-1882	148	19	prolonged	prolonged	ADJ
dpc-1882	148	20	survival	survival	NOUN
dpc-1882	148	21	in	in	ADP
dpc-1882	148	22	stage	stage	NOUN
dpc-1882	148	23	iii	iii	NUM
dpc-1882	148	24	melanoma	melanoma	NOUN
dpc-1882	148	25	with	with	ADP
dpc-1882	148	26	ipilimumab	ipilimumab	ADJ
dpc-1882	148	27	adjuvant	adjuvant	NOUN
dpc-1882	148	28	therapy	therapy	NOUN
dpc-1882	148	29	.	.	PUNCT
dpc-1882	149	1	new	new	PROPN
dpc-1882	149	2	england	england	PROPN
dpc-1882	149	3	journal	journal	PROPN
dpc-1882	149	4	of	of	ADP
dpc-1882	149	5	medicine	medicine	NOUN
dpc-1882	149	6	.	.	PUNCT
dpc-1882	150	1	2016;375(19):1845	2016;375(19):1845	PROPN
dpc-1882	150	2	-	-	SYM
dpc-1882	150	3	1855	1855	NUM
dpc-1882	150	4	.	.	PUNCT
dpc-1882	151	1	doi:10.1056	doi:10.1056	PROPN
dpc-1882	151	2	/	/	SYM
dpc-1882	151	3	nejmoa1611299	nejmoa1611299	PROPN
dpc-1882	151	4	.	.	PUNCT
dpc-1882	152	1	pmid	pmid	NOUN
dpc-1882	152	2	:	:	PUNCT
dpc-1882	152	3	27717298	27717298	NUM
dpc-1882	152	4	.	.	PUNCT
dpc-1882	153	1	7	7	X
dpc-1882	153	2	.	.	X
dpc-1882	153	3	weber	weber	PROPN
dpc-1882	153	4	j	j	PROPN
dpc-1882	153	5	,	,	PUNCT
dpc-1882	153	6	mandala	mandala	PROPN
dpc-1882	153	7	m	m	PROPN
dpc-1882	153	8	,	,	PUNCT
dpc-1882	153	9	del	del	PROPN
dpc-1882	153	10	vecchio	vecchio	PROPN
dpc-1882	153	11	m	m	PROPN
dpc-1882	153	12	,	,	PUNCT
dpc-1882	153	13	et	et	PROPN
dpc-1882	153	14	al	al	PROPN
dpc-1882	153	15	.	.	PROPN
dpc-1882	154	1	adjuvant	adjuvant	PROPN
dpc-1882	154	2	nivolumab	nivolumab	ADV
dpc-1882	154	3	versus	versus	ADP
dpc-1882	154	4	ipilimumab	ipilimumab	VERB
dpc-1882	154	5	in	in	ADP
dpc-1882	154	6	resected	resect	VERB
dpc-1882	154	7	stage	stage	NOUN
dpc-1882	154	8	iii	iii	NOUN
dpc-1882	154	9	or	or	CCONJ
dpc-1882	154	10	iv	iv	NUM
dpc-1882	154	11	melanoma	melanoma	NOUN
dpc-1882	154	12	.	.	PUNCT
dpc-1882	155	1	new	new	PROPN
dpc-1882	155	2	england	england	PROPN
dpc-1882	155	3	journal	journal	PROPN
dpc-1882	155	4	of	of	ADP
dpc-1882	155	5	medicine	medicine	NOUN
dpc-1882	155	6	.	.	PUNCT
dpc-1882	156	1	2017;377(19):1824	2017;377(19):1824	NUM
dpc-1882	156	2	-	-	SYM
dpc-1882	156	3	1835	1835	NUM
dpc-1882	156	4	.	.	PUNCT
dpc-1882	157	1	doi:10.1056	doi:10.1056	PROPN
dpc-1882	157	2	/	/	SYM
dpc-1882	157	3	nejmoa1709030	nejmoa1709030	PROPN
dpc-1882	157	4	.	.	PUNCT
dpc-1882	158	1	pmid	pmid	NOUN
dpc-1882	158	2	:	:	PUNCT
dpc-1882	158	3	28891423	28891423	NUM
dpc-1882	158	4	.	.	PUNCT
dpc-1882	159	1	8	8	X
dpc-1882	159	2	.	.	X
dpc-1882	159	3	ascierto	ascierto	PROPN
dpc-1882	159	4	pa	pa	PROPN
dpc-1882	159	5	,	,	PUNCT
dpc-1882	159	6	del	del	PROPN
dpc-1882	159	7	vecchio	vecchio	PROPN
dpc-1882	159	8	m	m	PROPN
dpc-1882	159	9	,	,	PUNCT
dpc-1882	159	10	mandalá	mandalá	PROPN
dpc-1882	159	11	m	m	PROPN
dpc-1882	159	12	,	,	PUNCT
dpc-1882	159	13	et	et	PROPN
dpc-1882	159	14	al	al	PROPN
dpc-1882	159	15	.	.	PROPN
dpc-1882	160	1	adjuvant	adjuvant	PROPN
dpc-1882	160	2	nivolumab	nivolumab	ADV
dpc-1882	160	3	versus	versus	ADP
dpc-1882	160	4	ipilimumab	ipilimumab	VERB
dpc-1882	160	5	in	in	ADP
dpc-1882	160	6	resected	resect	VERB
dpc-1882	160	7	stage	stage	NOUN
dpc-1882	160	8	iiib	iiib	NOUN
dpc-1882	160	9	-	-	PUNCT
dpc-1882	160	10	c	c	NOUN
dpc-1882	160	11	and	and	CCONJ
dpc-1882	160	12	stage	stage	NOUN
dpc-1882	160	13	iv	iv	NUM
dpc-1882	160	14	melanoma	melanoma	NOUN
dpc-1882	160	15	(	(	PUNCT
dpc-1882	160	16	checkmate	checkmate	NOUN
dpc-1882	160	17	238	238	NUM
dpc-1882	160	18	):	):	PUNCT
dpc-1882	160	19	4	4	NUM
dpc-1882	160	20	-	-	PUNCT
dpc-1882	160	21	year	year	NOUN
dpc-1882	160	22	results	result	NOUN
dpc-1882	160	23	from	from	ADP
dpc-1882	160	24	a	a	DET
dpc-1882	160	25	multicentre	multicentre	NOUN
dpc-1882	160	26	,	,	PUNCT
dpc-1882	160	27	double	double	ADJ
dpc-1882	160	28	-	-	PUNCT
dpc-1882	160	29	blind	blind	ADJ
dpc-1882	160	30	,	,	PUNCT
dpc-1882	160	31	randomised	randomise	VERB
dpc-1882	160	32	,	,	PUNCT
dpc-1882	160	33	controlled	control	VERB
dpc-1882	160	34	,	,	PUNCT
dpc-1882	160	35	phase	phase	NOUN
dpc-1882	160	36	3	3	NUM
dpc-1882	160	37	trial	trial	NOUN
dpc-1882	160	38	.	.	PUNCT
dpc-1882	161	1	lancet	lancet	PROPN
dpc-1882	161	2	oncol	oncol	PROPN
dpc-1882	161	3	.	.	PUNCT
dpc-1882	162	1	2020;21(11):1465	2020;21(11):1465	NUM
dpc-1882	162	2	-	-	SYM
dpc-1882	162	3	1477	1477	NUM
dpc-1882	162	4	.	.	PUNCT
dpc-1882	163	1	doi:10.1016	doi:10.1016	PROPN
dpc-1882	163	2	/	/	SYM
dpc-1882	163	3	s1470	s1470	PROPN
dpc-1882	163	4	-	-	PUNCT
dpc-1882	163	5	2045(20)30494	2045(20)30494	NUM
dpc-1882	163	6	-	-	SYM
dpc-1882	163	7	0	0	NUM
dpc-1882	163	8	.	.	NOUN
dpc-1882	163	9	9	9	NUM
dpc-1882	163	10	.	.	X
dpc-1882	163	11	eggermont	eggermont	PROPN
dpc-1882	163	12	amm	amm	PROPN
dpc-1882	163	13	,	,	PUNCT
dpc-1882	163	14	blank	blank	PROPN
dpc-1882	163	15	cu	cu	PROPN
dpc-1882	163	16	,	,	PUNCT
dpc-1882	163	17	mandala	mandala	PROPN
dpc-1882	163	18	m	m	PROPN
dpc-1882	163	19	,	,	PUNCT
dpc-1882	163	20	et	et	PROPN
dpc-1882	163	21	al	al	PROPN
dpc-1882	163	22	.	.	PROPN
dpc-1882	164	1	adjuvant	adjuvant	PROPN
dpc-1882	164	2	pembrolizumab	pembrolizumab	NOUN
dpc-1882	164	3	versus	versus	ADP
dpc-1882	164	4	placebo	placebo	NOUN
dpc-1882	164	5	in	in	ADP
dpc-1882	164	6	resected	resect	VERB
dpc-1882	164	7	stage	stage	NOUN
dpc-1882	164	8	iii	iii	NUM
dpc-1882	164	9	melanoma	melanoma	NOUN
dpc-1882	164	10	.	.	PUNCT
dpc-1882	165	1	new	new	PROPN
dpc-1882	165	2	england	england	PROPN
dpc-1882	165	3	journal	journal	PROPN
dpc-1882	165	4	of	of	ADP
dpc-1882	165	5	medicine	medicine	NOUN
dpc-1882	165	6	.	.	PUNCT
dpc-1882	166	1	2018;378(19):1789	2018;378(19):1789	PROPN
dpc-1882	166	2	-	-	SYM
dpc-1882	166	3	1801	1801	NUM
dpc-1882	166	4	.	.	PUNCT
dpc-1882	167	1	doi:10.1056	doi:10.1056	PROPN
dpc-1882	167	2	/	/	SYM
dpc-1882	167	3	nejmoa1802357	nejmoa1802357	PROPN
dpc-1882	167	4	.	.	PUNCT
dpc-1882	168	1	pmid	pmid	NOUN
dpc-1882	168	2	:	:	PUNCT
dpc-1882	168	3	29658430	29658430	NUM
dpc-1882	168	4	.	.	PUNCT
dpc-1882	169	1	10	10	NUM
dpc-1882	169	2	.	.	X
dpc-1882	170	1	grossmann	grossmann	PROPN
dpc-1882	170	2	kf	kf	PROPN
dpc-1882	170	3	,	,	PUNCT
dpc-1882	170	4	othus	othus	PROPN
dpc-1882	170	5	m	m	PROPN
dpc-1882	170	6	,	,	PUNCT
dpc-1882	170	7	patel	patel	PROPN
dpc-1882	170	8	sp	sp	PROPN
dpc-1882	170	9	,	,	PUNCT
dpc-1882	170	10	et	et	PROPN
dpc-1882	170	11	al	al	PROPN
dpc-1882	170	12	.	.	PROPN
dpc-1882	171	1	final	final	ADJ
dpc-1882	171	2	analysis	analysis	NOUN
dpc-1882	171	3	of	of	ADP
dpc-1882	171	4	overall	overall	ADJ
dpc-1882	171	5	survival	survival	NOUN
dpc-1882	171	6	(	(	PUNCT
dpc-1882	171	7	os	os	NOUN
dpc-1882	171	8	)	)	PUNCT
dpc-1882	171	9	and	and	CCONJ
dpc-1882	171	10	relapse	relapse	NOUN
dpc-1882	171	11	-	-	PUNCT
dpc-1882	171	12	free	free	ADJ
dpc-1882	171	13	-	-	PUNCT
dpc-1882	171	14	survival	survival	NOUN
dpc-1882	171	15	(	(	PUNCT
dpc-1882	171	16	rfs	rfs	PROPN
dpc-1882	171	17	)	)	PUNCT
dpc-1882	171	18	in	in	ADP
dpc-1882	171	19	the	the	DET
dpc-1882	171	20	intergroup	intergroup	NOUN
dpc-1882	171	21	s1404	s1404	PROPN
dpc-1882	171	22	phase	phase	NOUN
dpc-1882	171	23	iii	iii	NUM
dpc-1882	171	24	randomized	randomized	ADJ
dpc-1882	171	25	trial	trial	NOUN
dpc-1882	171	26	comparing	compare	VERB
dpc-1882	171	27	either	either	CCONJ
dpc-1882	171	28	high	high	ADV
dpc-1882	171	29	-	-	PUNCT
dpc-1882	171	30	dose	dose	NOUN
dpc-1882	171	31	interferon	interferon	NOUN
dpc-1882	171	32	(	(	PUNCT
dpc-1882	171	33	hdi	hdi	PROPN
dpc-1882	171	34	)	)	PUNCT
dpc-1882	171	35	or	or	CCONJ
dpc-1882	171	36	ipilimumab	ipilimumab	VERB
dpc-1882	171	37	to	to	PART
dpc-1882	171	38	pembrolizumab	pembrolizumab	NOUN
dpc-1882	171	39	in	in	ADP
dpc-1882	171	40	patients	patient	NOUN
dpc-1882	171	41	with	with	ADP
dpc-1882	171	42	high	high	ADJ
dpc-1882	171	43	-	-	PUNCT
dpc-1882	171	44	risk	risk	NOUN
dpc-1882	171	45	resected	resect	VERB
dpc-1882	171	46	melanoma	melanoma	NOUN
dpc-1882	171	47	.	.	PUNCT
dpc-1882	172	1	jco	jco	PROPN
dpc-1882	172	2	.	.	PUNCT
dpc-1882	173	1	2021;39(15_suppl):9501	2021;39(15_suppl):9501	NUM
dpc-1882	173	2	-	-	SYM
dpc-1882	173	3	9501	9501	NUM
dpc-1882	173	4	.	.	PUNCT
dpc-1882	174	1	doi:10.1200	doi:10.1200	PRON
dpc-1882	174	2	/	/	SYM
dpc-1882	174	3	jco.2021.39.15_suppl.9501	jco.2021.39.15_suppl.9501	PROPN
dpc-1882	174	4	.	.	PUNCT
dpc-1882	175	1	11	11	NUM
dpc-1882	175	2	.	.	PUNCT
dpc-1882	176	1	zimmer	zimmer	PROPN
dpc-1882	176	2	l	l	PROPN
dpc-1882	176	3	,	,	PUNCT
dpc-1882	176	4	livingstone	livingstone	PROPN
dpc-1882	176	5	e	e	PROPN
dpc-1882	176	6	,	,	PUNCT
dpc-1882	176	7	hassel	hassel	PROPN
dpc-1882	176	8	jc	jc	PROPN
dpc-1882	176	9	,	,	PUNCT
dpc-1882	176	10	et	et	PROPN
dpc-1882	176	11	al	al	PROPN
dpc-1882	176	12	.	.	PROPN
dpc-1882	177	1	adjuvant	adjuvant	PROPN
dpc-1882	177	2	nivolumab	nivolumab	NOUN
dpc-1882	177	3	plus	plus	CCONJ
dpc-1882	177	4	ipilimumab	ipilimumab	NOUN
dpc-1882	177	5	or	or	CCONJ
dpc-1882	177	6	nivolumab	nivolumab	ADV
dpc-1882	177	7	monotherapy	monotherapy	NOUN
dpc-1882	177	8	versus	versus	ADP
dpc-1882	177	9	placebo	placebo	NOUN
dpc-1882	177	10	in	in	ADP
dpc-1882	177	11	patients	patient	NOUN
dpc-1882	177	12	with	with	ADP
dpc-1882	177	13	resected	resected	ADJ
dpc-1882	177	14	stage	stage	NOUN
dpc-1882	177	15	iv	iv	NUM
dpc-1882	177	16	melanoma	melanoma	NOUN
dpc-1882	177	17	with	with	ADP
dpc-1882	177	18	no	no	DET
dpc-1882	177	19	evidence	evidence	NOUN
dpc-1882	177	20	of	of	ADP
dpc-1882	177	21	disease	disease	NOUN
dpc-1882	177	22	(	(	PUNCT
dpc-1882	177	23	immuned	immuned	ADJ
dpc-1882	177	24	):	):	PUNCT
dpc-1882	177	25	a	a	DET
dpc-1882	177	26	randomised	randomised	ADJ
dpc-1882	177	27	,	,	PUNCT
dpc-1882	177	28	double	double	ADJ
dpc-1882	177	29	-	-	PUNCT
dpc-1882	177	30	blind	blind	ADJ
dpc-1882	177	31	,	,	PUNCT
dpc-1882	177	32	placebo	placebo	NOUN
dpc-1882	177	33	-	-	PUNCT
dpc-1882	177	34	controlled	control	VERB
dpc-1882	177	35	,	,	PUNCT
dpc-1882	177	36	phase	phase	NOUN
dpc-1882	177	37	2	2	NUM
dpc-1882	177	38	trial	trial	NOUN
dpc-1882	177	39	.	.	PUNCT
dpc-1882	178	1	lancet	lancet	NOUN
dpc-1882	178	2	.	.	PUNCT
dpc-1882	179	1	2020;395(10236):1558	2020;395(10236):1558	NUM
dpc-1882	179	2	-	-	SYM
dpc-1882	179	3	1568	1568	NUM
dpc-1882	179	4	.	.	PUNCT
dpc-1882	180	1	doi:10.1016	doi:10.1016	PROPN
dpc-1882	180	2	/	/	SYM
dpc-1882	180	3	s0140	s0140	PROPN
dpc-1882	180	4	-	-	PUNCT
dpc-1882	180	5	6736(20)30417	6736(20)30417	NUM
dpc-1882	180	6	-	-	SYM
dpc-1882	180	7	7	7	NUM
dpc-1882	180	8	.	.	NOUN
dpc-1882	180	9	12	12	NUM
dpc-1882	180	10	.	.	PUNCT
dpc-1882	181	1	long	long	ADJ
dpc-1882	181	2	gv	gv	ADP
dpc-1882	181	3	,	,	PUNCT
dpc-1882	181	4	schadendorf	schadendorf	PROPN
dpc-1882	181	5	d	d	PROPN
dpc-1882	181	6	,	,	PUNCT
dpc-1882	181	7	vecchio	vecchio	PROPN
dpc-1882	181	8	md	md	PROPN
dpc-1882	181	9	,	,	PUNCT
dpc-1882	181	10	et	et	PROPN
dpc-1882	181	11	al	al	PROPN
dpc-1882	181	12	.	.	PUNCT
dpc-1882	182	1	abstract	abstract	PROPN
dpc-1882	182	2	ct004	ct004	PROPN
dpc-1882	182	3	:	:	PUNCT
dpc-1882	182	4	adjuvant	adjuvant	ADJ
dpc-1882	182	5	therapy	therapy	NOUN
dpc-1882	182	6	with	with	ADP
dpc-1882	182	7	nivolumab	nivolumab	NOUN
dpc-1882	182	8	(	(	PUNCT
dpc-1882	182	9	nivo	nivo	PROPN
dpc-1882	182	10	)	)	PUNCT
dpc-1882	182	11	combined	combine	VERB
dpc-1882	182	12	with	with	ADP
dpc-1882	182	13	ipilimumab	ipilimumab	NOUN
dpc-1882	182	14	(	(	PUNCT
dpc-1882	182	15	ipi	ipi	PROPN
dpc-1882	182	16	)	)	PUNCT
dpc-1882	182	17	vs	vs	ADP
dpc-1882	182	18	nivo	nivo	NOUN
dpc-1882	182	19	alone	alone	ADV
dpc-1882	182	20	in	in	ADP
dpc-1882	182	21	patients	patient	NOUN
dpc-1882	182	22	(	(	PUNCT
dpc-1882	182	23	pts	pt	NOUN
dpc-1882	182	24	)	)	PUNCT
dpc-1882	182	25	with	with	ADP
dpc-1882	182	26	resected	resect	VERB
dpc-1882	182	27	stage	stage	NOUN
dpc-1882	182	28	iiib	iiib	NOUN
dpc-1882	182	29	-	-	PUNCT
dpc-1882	182	30	d	d	NOUN
dpc-1882	182	31	/	/	SYM
dpc-1882	182	32	iv	iv	NUM
dpc-1882	182	33	melanoma	melanoma	NOUN
dpc-1882	182	34	(	(	PUNCT
dpc-1882	182	35	checkmate	checkmate	NOUN
dpc-1882	182	36	915	915	NUM
dpc-1882	182	37	)	)	PUNCT
dpc-1882	182	38	.	.	PUNCT
dpc-1882	183	1	cancer	cancer	NOUN
dpc-1882	183	2	res	re	NOUN
dpc-1882	183	3	.	.	PUNCT
dpc-1882	183	4	2021;81(13	2021;81(13	NUM
dpc-1882	183	5	supplement):ct004	supplement):ct004	NOUN
dpc-1882	183	6	-	-	PUNCT
dpc-1882	183	7	ct004	ct004	NOUN
dpc-1882	183	8	.	.	PUNCT
dpc-1882	183	9	doi:10.1158/1538	doi:10.1158/1538	NOUN
dpc-1882	183	10	-	-	PUNCT
dpc-1882	183	11	7445.am2021ct004	7445.am2021ct004	NOUN
dpc-1882	183	12	.	.	NOUN
dpc-1882	184	1	13	13	NUM
dpc-1882	184	2	.	.	PUNCT
dpc-1882	185	1	long	long	ADJ
dpc-1882	185	2	gv	gv	VERB
dpc-1882	185	3	,	,	PUNCT
dpc-1882	185	4	hauschild	hauschild	VERB
dpc-1882	185	5	a	a	PRON
dpc-1882	185	6	,	,	PUNCT
dpc-1882	185	7	santinami	santinami	NOUN
dpc-1882	185	8	m	m	PROPN
dpc-1882	185	9	,	,	PUNCT
dpc-1882	185	10	et	et	PROPN
dpc-1882	185	11	al	al	PROPN
dpc-1882	185	12	.	.	PROPN
dpc-1882	186	1	adjuvant	adjuvant	PROPN
dpc-1882	186	2	dabrafenib	dabrafenib	NOUN
dpc-1882	186	3	plus	plus	CCONJ
dpc-1882	186	4	trametinib	trametinib	NOUN
dpc-1882	186	5	in	in	ADP
dpc-1882	186	6	stage	stage	NOUN
dpc-1882	186	7	iii	iii	NUM
dpc-1882	186	8	braf	braf	NOUN
dpc-1882	186	9	-	-	PUNCT
dpc-1882	186	10	mutated	mutate	VERB
dpc-1882	186	11	melanoma	melanoma	NOUN
dpc-1882	186	12	.	.	PUNCT
dpc-1882	187	1	new	new	PROPN
dpc-1882	187	2	england	england	PROPN
dpc-1882	187	3	journal	journal	PROPN
dpc-1882	187	4	of	of	ADP
dpc-1882	187	5	medicine	medicine	NOUN
dpc-1882	187	6	.	.	PUNCT
dpc-1882	188	1	2017;377(19):1813	2017;377(19):1813	NUM
dpc-1882	188	2	-	-	SYM
dpc-1882	188	3	1823	1823	NUM
dpc-1882	188	4	.	.	PUNCT
dpc-1882	189	1	doi:10.1056	doi:10.1056	PROPN
dpc-1882	189	2	/	/	SYM
dpc-1882	189	3	nejmoa1708539	nejmoa1708539	PROPN
dpc-1882	189	4	.	.	PUNCT
dpc-1882	190	1	pmid:28891408	pmid:28891408	ADJ
dpc-1882	190	2	.	.	PUNCT
dpc-1882	191	1	14	14	NUM
dpc-1882	191	2	.	.	PUNCT
dpc-1882	192	1	faries	farie	NOUN
dpc-1882	192	2	mb	mb	ADP
dpc-1882	192	3	,	,	PUNCT
dpc-1882	192	4	thompson	thompson	PROPN
dpc-1882	192	5	jf	jf	PROPN
dpc-1882	192	6	,	,	PUNCT
dpc-1882	192	7	cochran	cochran	PROPN
dpc-1882	192	8	aj	aj	PROPN
dpc-1882	192	9	,	,	PUNCT
dpc-1882	192	10	et	et	PROPN
dpc-1882	192	11	al	al	PROPN
dpc-1882	192	12	.	.	PUNCT
dpc-1882	192	13	completion	completion	NOUN
dpc-1882	192	14	dissection	dissection	NOUN
dpc-1882	192	15	or	or	CCONJ
dpc-1882	192	16	observation	observation	NOUN
dpc-1882	192	17	for	for	ADP
dpc-1882	192	18	sentinel	sentinel	ADJ
dpc-1882	192	19	-	-	PUNCT
dpc-1882	192	20	node	node	ADJ
dpc-1882	192	21	metastasis	metastasis	NOUN
dpc-1882	192	22	in	in	ADP
dpc-1882	192	23	melanoma	melanoma	NOUN
dpc-1882	192	24	.	.	PUNCT
dpc-1882	193	1	n	n	PRON
dpc-1882	193	2	engl	engl	PROPN
dpc-1882	193	3	j	j	PROPN
dpc-1882	193	4	med	med	PROPN
dpc-1882	193	5	.	.	PUNCT
dpc-1882	194	1	2017;376(23):2211	2017;376(23):2211	NUM
dpc-1882	194	2	-	-	SYM
dpc-1882	194	3	2222	2222	NUM
dpc-1882	194	4	.	.	PUNCT
dpc-1882	194	5	doi:10.1056	doi:10.1056	PROPN
dpc-1882	194	6	/	/	SYM
dpc-1882	194	7	nejmoa1613210	nejmoa1613210	PROPN
dpc-1882	194	8	.	.	PUNCT
dpc-1882	195	1	pmid	pmid	NOUN
dpc-1882	195	2	:	:	PUNCT
dpc-1882	195	3	28591523	28591523	NUM
dpc-1882	195	4	.	.	PUNCT
dpc-1882	196	1	15	15	NUM
dpc-1882	196	2	.	.	PUNCT
dpc-1882	196	3	leiter	leiter	PROPN
dpc-1882	196	4	u	u	PROPN
dpc-1882	196	5	,	,	PUNCT
dpc-1882	196	6	stadler	stadler	NOUN
dpc-1882	196	7	r	r	NOUN
dpc-1882	196	8	,	,	PUNCT
dpc-1882	196	9	mauch	mauch	PROPN
dpc-1882	196	10	c	c	X
dpc-1882	196	11	,	,	PUNCT
dpc-1882	196	12	et	et	PROPN
dpc-1882	196	13	al	al	PROPN
dpc-1882	196	14	.	.	PROPN
dpc-1882	196	15	final	final	ADJ
dpc-1882	196	16	analysis	analysis	NOUN
dpc-1882	196	17	of	of	ADP
dpc-1882	196	18	decog	decog	VERB
dpc-1882	196	19	-	-	PUNCT
dpc-1882	196	20	slt	slt	NOUN
dpc-1882	196	21	trial	trial	NOUN
dpc-1882	196	22	:	:	PUNCT
dpc-1882	196	23	no	no	DET
dpc-1882	196	24	survival	survival	NOUN
dpc-1882	196	25	benefit	benefit	VERB
dpc-1882	196	26	for	for	ADP
dpc-1882	196	27	complete	complete	ADJ
dpc-1882	196	28	lymph	lymph	NOUN
dpc-1882	196	29	node	node	NOUN
dpc-1882	196	30	dissection	dissection	NOUN
dpc-1882	196	31	in	in	ADP
dpc-1882	196	32	patients	patient	NOUN
dpc-1882	196	33	with	with	ADP
dpc-1882	196	34	melanoma	melanoma	NOUN
dpc-1882	196	35	with	with	ADP
dpc-1882	196	36	positive	positive	ADJ
dpc-1882	196	37	sentinel	sentinel	NOUN
dpc-1882	196	38	node	node	NOUN
dpc-1882	196	39	.	.	PUNCT
dpc-1882	197	1	j	j	PROPN
dpc-1882	197	2	clin	clin	PROPN
dpc-1882	197	3	oncol	oncol	PROPN
dpc-1882	197	4	.	.	PUNCT
dpc-1882	198	1	2019;37(32):3000	2019;37(32):3000	NUM
dpc-1882	198	2	-	-	SYM
dpc-1882	198	3	3008	3008	NUM
dpc-1882	198	4	.	.	PUNCT
dpc-1882	199	1	doi:10.1200	doi:10.1200	PROPN
dpc-1882	199	2	/	/	SYM
dpc-1882	199	3	jco.18.02306	jco.18.02306	NOUN
dpc-1882	199	4	.	.	PUNCT
dpc-1882	200	1	pmid	pmid	NOUN
dpc-1882	200	2	:	:	PUNCT
dpc-1882	200	3	31557067	31557067	NUM
dpc-1882	200	4	.	.	PUNCT
dpc-1882	201	1	16	16	NUM
dpc-1882	201	2	.	.	PUNCT
dpc-1882	202	1	gershenwald	gershenwald	PROPN
dpc-1882	202	2	je	je	PROPN
dpc-1882	202	3	,	,	PUNCT
dpc-1882	202	4	scolyer	scolyer	PROPN
dpc-1882	202	5	ra	ra	PROPN
dpc-1882	202	6	,	,	PUNCT
dpc-1882	202	7	hess	hess	PROPN
dpc-1882	202	8	kr	kr	PROPN
dpc-1882	202	9	,	,	PUNCT
dpc-1882	202	10	et	et	PROPN
dpc-1882	202	11	al	al	PROPN
dpc-1882	202	12	.	.	PUNCT
dpc-1882	202	13	melanoma	melanoma	PROPN
dpc-1882	202	14	staging	staging	NOUN
dpc-1882	202	15	:	:	PUNCT
dpc-1882	202	16	evidence	evidence	NOUN
dpc-1882	202	17	-	-	PUNCT
dpc-1882	202	18	based	base	VERB
dpc-1882	202	19	changes	change	NOUN
dpc-1882	202	20	in	in	ADP
dpc-1882	202	21	the	the	DET
dpc-1882	202	22	american	american	PROPN
dpc-1882	202	23	joint	joint	PROPN
dpc-1882	202	24	committee	committee	PROPN
dpc-1882	202	25	on	on	ADP
dpc-1882	202	26	cancer	cancer	NOUN
dpc-1882	202	27	eighth	eighth	PROPN
dpc-1882	202	28	edition	edition	NOUN
dpc-1882	202	29	cancer	cancer	NOUN
dpc-1882	202	30	staging	staging	NOUN
dpc-1882	202	31	manual	manual	NOUN
dpc-1882	202	32	.	.	PUNCT
dpc-1882	203	1	ca	can	AUX
dpc-1882	203	2	:	:	PUNCT
dpc-1882	203	3	a	a	DET
dpc-1882	203	4	cancer	cancer	NOUN
dpc-1882	203	5	journal	journal	NOUN
dpc-1882	203	6	for	for	ADP
dpc-1882	203	7	clinicians	clinician	NOUN
dpc-1882	203	8	.	.	PUNCT
dpc-1882	204	1	2017;67(6):472	2017;67(6):472	NUM
dpc-1882	204	2	-	-	SYM
dpc-1882	204	3	492	492	NUM
dpc-1882	204	4	.	.	PUNCT
dpc-1882	205	1	doi:10.3322	doi:10.3322	NOUN
dpc-1882	205	2	/	/	SYM
dpc-1882	205	3	caac.21409	caac.21409	PROPN
dpc-1882	205	4	.	.	PUNCT
dpc-1882	206	1	pmid	pmid	NOUN
dpc-1882	206	2	:	:	PUNCT
dpc-1882	206	3	29028110	29028110	NUM
dpc-1882	206	4	.	.	PUNCT
dpc-1882	207	1	17	17	NUM
dpc-1882	207	2	.	.	PUNCT
dpc-1882	208	1	garbe	garbe	PROPN
dpc-1882	208	2	c	c	PROPN
dpc-1882	208	3	,	,	PUNCT
dpc-1882	208	4	keim	keim	PROPN
dpc-1882	208	5	u	u	PROPN
dpc-1882	208	6	,	,	PUNCT
dpc-1882	208	7	suciu	suciu	PROPN
dpc-1882	208	8	s	s	PROPN
dpc-1882	208	9	,	,	PUNCT
dpc-1882	208	10	et	et	PROPN
dpc-1882	208	11	al	al	PROPN
dpc-1882	208	12	.	.	PUNCT
dpc-1882	209	1	prognosis	prognosis	NOUN
dpc-1882	209	2	of	of	ADP
dpc-1882	209	3	patients	patient	NOUN
dpc-1882	209	4	with	with	ADP
dpc-1882	209	5	stage	stage	NOUN
dpc-1882	209	6	iii	iii	NUM
dpc-1882	209	7	melanoma	melanoma	NOUN
dpc-1882	209	8	according	accord	VERB
dpc-1882	209	9	to	to	ADP
dpc-1882	209	10	american	american	ADJ
dpc-1882	209	11	joint	joint	PROPN
dpc-1882	209	12	committee	committee	PROPN
dpc-1882	209	13	on	on	ADP
dpc-1882	209	14	cancer	cancer	NOUN
dpc-1882	209	15	version	version	NOUN
dpc-1882	209	16	8	8	NUM
dpc-1882	209	17	:	:	PUNCT
dpc-1882	209	18	a	a	DET
dpc-1882	209	19	reassessment	reassessment	NOUN
dpc-1882	209	20	on	on	ADP
dpc-1882	209	21	the	the	DET
dpc-1882	209	22	basis	basis	NOUN
dpc-1882	209	23	of	of	ADP
dpc-1882	209	24	3	3	NUM
dpc-1882	209	25	independent	independent	ADJ
dpc-1882	209	26	stage	stage	NOUN
dpc-1882	209	27	iii	iii	NUM
dpc-1882	209	28	melanoma	melanoma	PROPN
dpc-1882	209	29	cohorts	cohort	NOUN
dpc-1882	209	30	.	.	PUNCT
dpc-1882	210	1	j	j	PROPN
dpc-1882	210	2	clin	clin	PROPN
dpc-1882	210	3	oncol	oncol	PROPN
dpc-1882	210	4	.	.	PUNCT
dpc-1882	211	1	2020;38(22):2543	2020;38(22):2543	NOUN
dpc-1882	211	2	-	-	SYM
dpc-1882	211	3	2551	2551	NUM
dpc-1882	211	4	.	.	PUNCT
dpc-1882	212	1	doi:10.1200	doi:10.1200	PROPN
dpc-1882	212	2	/	/	SYM
dpc-1882	212	3	jco.19.03034	jco.19.03034	PROPN
dpc-1882	212	4	.	.	PUNCT
dpc-1882	213	1	pmid	pmid	NOUN
dpc-1882	213	2	:	:	PUNCT
dpc-1882	213	3	32530760	32530760	NUM
dpc-1882	213	4	.	.	PUNCT
dpc-1882	214	1	18	18	NUM
dpc-1882	214	2	.	.	PUNCT
dpc-1882	215	1	michielin	michielin	PROPN
dpc-1882	215	2	o	o	PROPN
dpc-1882	215	3	,	,	PUNCT
dpc-1882	215	4	van	van	PROPN
dpc-1882	215	5	akkooi	akkooi	PROPN
dpc-1882	215	6	a	a	PRON
dpc-1882	215	7	,	,	PUNCT
dpc-1882	215	8	lorigan	lorigan	VERB
dpc-1882	215	9	p	p	X
dpc-1882	215	10	,	,	PUNCT
dpc-1882	215	11	et	et	PROPN
dpc-1882	215	12	al	al	PROPN
dpc-1882	215	13	.	.	PROPN
dpc-1882	216	1	esmo	esmo	PROPN
dpc-1882	216	2	consensus	consensus	NOUN
dpc-1882	216	3	conference	conference	NOUN
dpc-1882	216	4	recommendations	recommendation	NOUN
dpc-1882	216	5	on	on	ADP
dpc-1882	216	6	the	the	DET
dpc-1882	216	7	management	management	NOUN
dpc-1882	216	8	of	of	ADP
dpc-1882	216	9	locoregional	locoregional	ADJ
dpc-1882	216	10	melanoma	melanoma	NOUN
dpc-1882	216	11	:	:	PUNCT
dpc-1882	216	12	under	under	ADP
dpc-1882	216	13	the	the	DET
dpc-1882	216	14	auspices	auspex	NOUN
dpc-1882	216	15	of	of	ADP
dpc-1882	216	16	the	the	DET
dpc-1882	216	17	esmo	esmo	NOUN
dpc-1882	216	18	guidelines	guideline	NOUN
dpc-1882	216	19	committee	committee	NOUN
dpc-1882	216	20	.	.	PUNCT
dpc-1882	217	1	ann	ann	PROPN
dpc-1882	217	2	oncol	oncol	PROPN
dpc-1882	217	3	.	.	PUNCT
dpc-1882	218	1	2020;31(11):1449	2020;31(11):1449	X
dpc-1882	218	2	-	-	SYM
dpc-1882	218	3	1461	1461	NUM
dpc-1882	218	4	.	.	PUNCT
dpc-1882	218	5	doi:10.1016	doi:10.1016	PROPN
dpc-1882	218	6	/	/	SYM
dpc-1882	218	7	j.	j.	PROPN
dpc-1882	218	8	annonc.2020.07.005	annonc.2020.07.005	PROPN
dpc-1882	218	9	.	.	PUNCT
dpc-1882	219	1	pmid	pmid	NOUN
dpc-1882	219	2	:	:	PUNCT
dpc-1882	219	3	32763452	32763452	NUM
dpc-1882	219	4	.	.	PUNCT
dpc-1882	220	1	review	review	NOUN
dpc-1882	220	2	|	|	ADV
dpc-1882	220	3	dermatol	dermatol	ADJ
dpc-1882	220	4	pract	pract	NOUN
dpc-1882	220	5	concept	concept	NOUN
dpc-1882	220	6	.	.	PUNCT
dpc-1882	221	1	2021;11(s1	2021;11(s1	NUM
dpc-1882	221	2	):	):	PUNCT
dpc-1882	221	3	e2021165s	e2021165s	X
dpc-1882	221	4	5	5	NUM
dpc-1882	221	5	19	19	NUM
dpc-1882	221	6	.	.	PUNCT
dpc-1882	222	1	owen	owen	PROPN
dpc-1882	222	2	cn	cn	PROPN
dpc-1882	222	3	,	,	PUNCT
dpc-1882	222	4	shoushtari	shoushtari	PROPN
dpc-1882	222	5	an	an	PROPN
dpc-1882	222	6	,	,	PUNCT
dpc-1882	222	7	chauhan	chauhan	PROPN
dpc-1882	222	8	d	d	PROPN
dpc-1882	222	9	,	,	PUNCT
dpc-1882	222	10	et	et	PROPN
dpc-1882	222	11	al	al	PROPN
dpc-1882	222	12	.	.	PUNCT
dpc-1882	222	13	management	management	NOUN
dpc-1882	222	14	of	of	ADP
dpc-1882	222	15	early	early	ADJ
dpc-1882	222	16	melanoma	melanoma	NOUN
dpc-1882	222	17	recurrence	recurrence	NOUN
dpc-1882	222	18	despite	despite	SCONJ
dpc-1882	222	19	adjuvant	adjuvant	ADJ
dpc-1882	222	20	anti	anti	ADJ
dpc-1882	222	21	-	-	ADJ
dpc-1882	222	22	pd-1	pd-1	ADJ
dpc-1882	222	23	antibody	antibody	NOUN
dpc-1882	222	24	therapy	therapy	NOUN
dpc-1882	222	25	.	.	PUNCT
dpc-1882	223	1	ann	ann	PROPN
dpc-1882	223	2	oncol	oncol	PROPN
dpc-1882	223	3	.	.	PUNCT
dpc-1882	224	1	2020;31(8):1075	2020;31(8):1075	NUM
dpc-1882	224	2	-	-	SYM
dpc-1882	224	3	1082	1082	NUM
dpc-1882	224	4	.	.	PUNCT
dpc-1882	225	1	doi:10.1016	doi:10.1016	PROPN
dpc-1882	225	2	/	/	SYM
dpc-1882	225	3	j.	j.	PROPN
dpc-1882	225	4	annonc.2020.04.471	annonc.2020.04.471	PROPN
dpc-1882	225	5	.	.	PUNCT
dpc-1882	226	1	pmid	pmid	NOUN
dpc-1882	226	2	:	:	PUNCT
dpc-1882	226	3	32387454	32387454	NUM
dpc-1882	226	4	.	.	PUNCT
dpc-1882	227	1	20	20	NUM
dpc-1882	227	2	.	.	PUNCT
dpc-1882	228	1	bhave	bhave	PROPN
dpc-1882	228	2	p	p	X
dpc-1882	228	3	,	,	PUNCT
dpc-1882	228	4	pallan	pallan	PROPN
dpc-1882	228	5	l	l	NOUN
dpc-1882	228	6	,	,	PUNCT
dpc-1882	228	7	atkinson	atkinson	PROPN
dpc-1882	228	8	v	v	PROPN
dpc-1882	228	9	,	,	PUNCT
dpc-1882	228	10	et	et	PROPN
dpc-1882	228	11	al	al	PROPN
dpc-1882	228	12	.	.	PUNCT
dpc-1882	229	1	melanoma	melanoma	PROPN
dpc-1882	229	2	recurrence	recurrence	NOUN
dpc-1882	229	3	after	after	ADP
dpc-1882	229	4	adjuvant	adjuvant	ADJ
dpc-1882	229	5	targeted	target	VERB
dpc-1882	229	6	therapy	therapy	NOUN
dpc-1882	229	7	:	:	PUNCT
dpc-1882	229	8	a	a	DET
dpc-1882	229	9	multicenter	multicenter	ADJ
dpc-1882	229	10	analysis	analysis	NOUN
dpc-1882	229	11	.	.	PUNCT
dpc-1882	230	1	jco	jco	PROPN
dpc-1882	230	2	.	.	PUNCT
dpc-1882	231	1	2020;38(15_suppl):10016	2020;38(15_suppl):10016	NUM
dpc-1882	231	2	-	-	SYM
dpc-1882	231	3	10016	10016	NUM
dpc-1882	231	4	.	.	PUNCT
dpc-1882	232	1	doi:10.1200/	doi:10.1200/	NUM
dpc-1882	232	2	jco.2020.38.15_suppl.10016	jco.2020.38.15_suppl.10016	PROPN
dpc-1882	232	3	.	.	PROPN
dpc-1882	232	4	21	21	NUM
dpc-1882	232	5	.	.	PUNCT
dpc-1882	233	1	bhave	bhave	PROPN
dpc-1882	233	2	p	p	X
dpc-1882	233	3	,	,	PUNCT
dpc-1882	233	4	pallan	pallan	PROPN
dpc-1882	233	5	l	l	NOUN
dpc-1882	233	6	,	,	PUNCT
dpc-1882	233	7	long	long	ADV
dpc-1882	233	8	gv	gv	ADP
dpc-1882	233	9	,	,	PUNCT
dpc-1882	233	10	et	et	PROPN
dpc-1882	233	11	al	al	PROPN
dpc-1882	233	12	.	.	PUNCT
dpc-1882	233	13	melanoma	melanoma	PROPN
dpc-1882	233	14	recurrence	recurrence	NOUN
dpc-1882	233	15	patterns	pattern	NOUN
dpc-1882	233	16	and	and	CCONJ
dpc-1882	233	17	management	management	NOUN
dpc-1882	233	18	after	after	ADP
dpc-1882	233	19	adjuvant	adjuvant	ADJ
dpc-1882	233	20	targeted	target	VERB
dpc-1882	233	21	therapy	therapy	NOUN
dpc-1882	233	22	:	:	PUNCT
dpc-1882	233	23	a	a	DET
dpc-1882	233	24	multicentre	multicentre	NOUN
dpc-1882	233	25	analysis	analysis	NOUN
dpc-1882	233	26	.	.	PUNCT
dpc-1882	234	1	british	british	ADJ
dpc-1882	234	2	journal	journal	PROPN
dpc-1882	234	3	of	of	ADP
dpc-1882	234	4	cancer	cancer	NOUN
dpc-1882	234	5	.	.	PUNCT
dpc-1882	235	1	2021;124(3):574	2021;124(3):574	ADJ
dpc-1882	235	2	-	-	SYM
dpc-1882	235	3	580	580	NUM
dpc-1882	235	4	.	.	PUNCT
dpc-1882	236	1	doi:10.1038	doi:10.1038	NOUN
dpc-1882	236	2	/	/	SYM
dpc-1882	236	3	s41416	s41416	ADP
dpc-1882	236	4	-	-	PUNCT
dpc-1882	236	5	020	020	NUM
dpc-1882	236	6	-	-	PUNCT
dpc-1882	236	7	01121	01121	NUM
dpc-1882	236	8	-	-	PUNCT
dpc-1882	236	9	y.	y.	NOUN
dpc-1882	236	10	pmid	pmid	PROPN
dpc-1882	236	11	:	:	PUNCT
dpc-1882	236	12	33087895	33087895	NUM
dpc-1882	236	13	.	.	PUNCT
dpc-1882	237	1	22	22	NUM
dpc-1882	237	2	.	.	X
dpc-1882	238	1	crossover	crossover	VERB
dpc-1882	238	2	and	and	CCONJ
dpc-1882	238	3	rechallenge	rechallenge	VERB
dpc-1882	238	4	with	with	ADP
dpc-1882	238	5	pembrolizumab	pembrolizumab	NOUN
dpc-1882	238	6	in	in	ADP
dpc-1882	238	7	recurrent	recurrent	ADJ
dpc-1882	238	8	patients	patient	NOUN
dpc-1882	238	9	from	from	ADP
dpc-1882	238	10	the	the	DET
dpc-1882	238	11	eortc	eortc	ADJ
dpc-1882	238	12	1325	1325	NUM
dpc-1882	238	13	-	-	PUNCT
dpc-1882	238	14	mg	mg	ADP
dpc-1882	238	15	/	/	SYM
dpc-1882	238	16	keynote-054	keynote-054	NOUN
dpc-1882	238	17	phase	phase	NOUN
dpc-1882	238	18	3	3	NUM
dpc-1882	238	19	trial	trial	NOUN
dpc-1882	238	20	,	,	PUNCT
dpc-1882	238	21	pembrolizumab	pembrolizumab	NOUN
dpc-1882	238	22	versus	versus	ADP
dpc-1882	238	23	placebo	placebo	NOUN
dpc-1882	238	24	after	after	ADP
dpc-1882	238	25	complete	complete	ADJ
dpc-1882	238	26	resection	resection	NOUN
dpc-1882	238	27	of	of	ADP
dpc-1882	238	28	high	high	ADJ
dpc-1882	238	29	-	-	PUNCT
dpc-1882	238	30	risk	risk	NOUN
dpc-1882	238	31	stage	stage	NOUN
dpc-1882	238	32	iii	iii	NUM
dpc-1882	238	33	melanoma	melanoma	NOUN
dpc-1882	238	34	.	.	PUNCT
dpc-1882	239	1	journal	journal	PROPN
dpc-1882	239	2	of	of	ADP
dpc-1882	239	3	clinical	clinical	ADJ
dpc-1882	239	4	oncology	oncology	NOUN
dpc-1882	239	5	.	.	PUNCT
dpc-1882	240	1	accessed	access	VERB
dpc-1882	240	2	july	july	PROPN
dpc-1882	240	3	13	13	NUM
dpc-1882	240	4	,	,	PUNCT
dpc-1882	240	5	2021	2021	NUM
dpc-1882	240	6	.	.	PUNCT
dpc-1882	241	1	https://ascopubs.org/doi/abs/10.1200/	https://ascopubs.org/doi/abs/10.1200/	VERB
dpc-1882	241	2	jco.2021.39.15_suppl.9500	jco.2021.39.15_suppl.9500	NOUN
dpc-1882	241	3	23	23	NUM
dpc-1882	241	4	.	.	PUNCT
dpc-1882	242	1	menzies	menzies	PROPN
dpc-1882	242	2	am	be	AUX
dpc-1882	242	3	,	,	PUNCT
dpc-1882	242	4	amaria	amaria	PROPN
dpc-1882	242	5	rn	rn	PROPN
dpc-1882	242	6	,	,	PUNCT
dpc-1882	242	7	rozeman	rozeman	PROPN
dpc-1882	242	8	ea	ea	PROPN
dpc-1882	242	9	,	,	PUNCT
dpc-1882	242	10	et	et	PROPN
dpc-1882	242	11	al	al	PROPN
dpc-1882	242	12	.	.	PUNCT
dpc-1882	243	1	pathological	pathological	ADJ
dpc-1882	243	2	response	response	NOUN
dpc-1882	243	3	and	and	CCONJ
dpc-1882	243	4	survival	survival	NOUN
dpc-1882	243	5	with	with	ADP
dpc-1882	243	6	neoadjuvant	neoadjuvant	ADJ
dpc-1882	243	7	therapy	therapy	NOUN
dpc-1882	243	8	in	in	ADP
dpc-1882	243	9	melanoma	melanoma	NOUN
dpc-1882	243	10	:	:	PUNCT
dpc-1882	243	11	a	a	DET
dpc-1882	243	12	pooled	pool	VERB
dpc-1882	243	13	analysis	analysis	NOUN
dpc-1882	243	14	from	from	ADP
dpc-1882	243	15	the	the	DET
dpc-1882	243	16	international	international	ADJ
dpc-1882	243	17	neoadjuvant	neoadjuvant	ADJ
dpc-1882	243	18	melanoma	melanoma	PROPN
dpc-1882	243	19	consortium	consortium	NOUN
dpc-1882	243	20	(	(	PUNCT
dpc-1882	243	21	inmc	inmc	ADJ
dpc-1882	243	22	)	)	PUNCT
dpc-1882	243	23	.	.	PUNCT
dpc-1882	244	1	nature	nature	NOUN
dpc-1882	244	2	medicine	medicine	NOUN
dpc-1882	244	3	.	.	PUNCT
dpc-1882	245	1	2021;27(2):301	2021;27(2):301	NUM
dpc-1882	245	2	-	-	SYM
dpc-1882	245	3	309	309	NUM
dpc-1882	245	4	.	.	PUNCT
dpc-1882	246	1	doi:10.1038	doi:10.1038	NOUN
dpc-1882	246	2	/	/	SYM
dpc-1882	246	3	s41591	s41591	NOUN
dpc-1882	246	4	-	-	PUNCT
dpc-1882	246	5	020	020	NUM
dpc-1882	246	6	-	-	PUNCT
dpc-1882	246	7	01188	01188	NUM
dpc-1882	246	8	-	-	SYM
dpc-1882	246	9	3	3	NUM
dpc-1882	246	10	.	.	PUNCT
dpc-1882	246	11	pmid	pmid	NOUN
dpc-1882	246	12	:	:	PUNCT
dpc-1882	246	13	33558722	33558722	NUM
dpc-1882	246	14	.	.	PUNCT
dpc-1882	247	1	1	1	NUM
dpc-1882	247	2	-	-	PUNCT
dpc-1882	247	3	indice	indice	NOUN
dpc-1882	247	4	5	5	NUM
dpc-1882	247	5	-	-	SYM
dpc-1882	247	6	1882	1882	NUM